GenCore version 5.1.4_p5_4578

OM nucleic - nucleic search, using sw model

Run on: May 22, 2003, 23:14:34 ; Search time 187 Seconds
(without alignments)
228.813 Million cell updates/sec

Title: US-09-925-548-6
Perfect score: 19
Sequence: 1 gggaaggaggatgaaccce 19

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1000 summaries

Database : N_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA2001A.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA2001B.DAT:*
24: /SIDS2/gcgdata/geneseq/geneseqn-[illegible]/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	19	100.0	1789	20	AAZ33623	Human breast tumou
c	2	19	100.0	1786	18	AAT71716	Human integrin-lin
c	3	19	100.0	1789	22	AAF69274	Human integrin-lin
c	4	19	100.0	1789	24	ABK84315	Human cDNA differe
c	5	17	89.5	7191	22	AAK79657	Human immune/haema
	6	16.4	86.3	414	23	ABK41695	cDNA encoding nove
	7	16.4	86.3	1049	23	ABK42256	Genomic sequence #
	8	16.4	86.3	2134	22	AAS07195	DNA encoding zebra
	9	16.4	86.3	14180	19	AAV05159	Mouse butyrophilin
	10	16	84.2	631	20	AAV84692	Rice [illegible]
	11	16	84.2	22916	22	AAK65305	Human [illegible]
c	12	15.8	83.2	365	24	ABN23166	Human [illegible]
	13	15.8	83.2	482	22	AAI85685	Human [illegible]
	14	15.8	83.2	489	22	AAK88550	Human [illegible]
c	15	15.8	83.2	607	24	ABQ54458	Human [illegible]
c	16	15.8	83.2	609	22	ABA07480	Human [illegible]
c	17	15.8	83.2	609	22	AAL00402	Human [illegible]
	18	15.8	83.2	[illegible]	23	AAS60239	DNA [illegible]
c	19	15.8	83.2	[illegible]	2	AAX26301	cDNA [illegible]
c	20	15.8	83.2	1610	21	AAH99943	EBBG-S[illegible]
	21	15.8	83.2	2520	24	ABL60541	Human [illegible]
c	22	15.8	83.2	3200	20	AAZ22260	Nucleic [illegible]
c	23	15.8	83.2	4651	15	AAQ72413	Human [illegible]
c	24	15.8	83.2	4823	23	AAS92612	DNA [illegible]
c	25	15.8	83.2	5775	20	AAZ08539	Human [illegible]
	26	15.8	83.2	72215	22	AAK86832	Human [illegible]
c	27	15.8	83.2	227576	21	ABK83497	Human [illegible]
	28	15.4	81.1	269	24	ABL72171	[illegible]
	29	15.4	81.1	290	24	ABL73524	[illegible]
c	30	15.4	81.1	329	24	ABQ86127	Arabidopsis [illegible]
	31	15.4	81.1	689	22	AAS41142	cDNA [illegible]
	32	15.4	81.1	689	23	ABK43826	DNA [illegible]
	33	15.4	81.1	1647	22	AAF74281	[illegible]
	34	15.4	81.1	1647	22	AAF74282	[illegible]
c	35	15.4	81.1	2260	19	AAV41995	Human [illegible]
c	36	15.4	81.1	2532	23	ABK43569	DNA [illegible]
	37	15.4	81.1	2763	22	AAH16500	Human cDNA [illegible]
	38	15.4	81.1	3565	23	AAS89550	DNA [illegible]
c	39	15.4	81.1	8354	23	ABL02613	Drosophila [illegible]
	40	15.4	81.1	12351	22	AAS41943	Genomic [illegible] #
	41	15.4	81.1	[illegible]	22	AAS41942	Genomic [illegible] #
	42	15.4	81.1	12412	22	AAS41941	Genomic [illegible] #
	43	15.4	81.1	[illegible]	23	ABL02618	Drosophila [illegible]
	44	15.4	81.1	[illegible]	22	[illegible]	Human [illegible]
	45	15.4	81.1	[illegible]	22	[illegible]	Human [illegible]
	46	15.4	81.1	[illegible]	22	[illegible]86604	Human [illegible]
	47	15.4	81.1	[illegible]	22	[illegible]90152	Human [illegible]
	48	15.4	81.1	[illegible]	22	[illegible]39915	Genomic [illegible] #
	49	15.4	81.1	[illegible]	22	[illegible]39916	Genomic [illegible] #
	50	15.4	81.1	[illegible]	22	AAL06415	Human [illegible]
	51	15.4	81.1	31718	22	AAL06416	Human [illegible]
c	52	15.4	81.1	[illegible]	22	[illegible]73104	Human [illegible]
c	53	15.4	81.1	[illegible]	22	[illegible]120	Human immune/haema
	54	15.4	81.1	[illegible]	22	[illegible]87442	Human immune/haema
	55	15.4	81.1	[illegible]	22	[illegible]	Human immune/haema
c	56	15.4	81.1	[illegible]	22	[illegible]7573	Human immune/haema
c	57	15.4	81.1	[illegible]	22	[illegible]87592	Human immune/haema
	58	15.4	81.1	[illegible]	22	AAK90359	Human [illegible]
	59	15.4	81.1	[illegible]	22	[illegible]90360	Human [illegible]
	60	15.4	81.1	[illegible]	24	[illegible]	Human [illegible]
	61	15.4	81.1	129722	24	[illegible]117	Human [illegible]
	62	15	78.9	[illegible]	22	[illegible]84	[illegible]
	63	15	78.9	[illegible]	22	AAF69285	[illegible]
	64	15	78.9	444	22	ABA07567	Human [illegible]
	65	15	78.9	444	22	AAL00616	Human [illegible]
	66	15	78.9	467	21	AAZ36298	Nucleic [illegible]
	67	15	78.9	518	22	AAH19345	Human cDNA [illegible]
c	68	15	78.9	957	22	AAI97733	Human [illegible]
c	69	15	78.9	2040	22	AAH15625	Human cDNA [illegible]
	70	15	78.9	5928	21	ABL34087	Human [illegible]
	71	15	78.9	19175	23	ABL02108	Drosophila [illegible]
	72	14.8	77.9	214	24	ABL53036	Rat [illegible]
	73	14.8	77.9	221	24	ABL38471	Human [illegible]
c	74	14.8	77.9	298	20	AAZ12843	Human [illegible]
	75	14.8	77.9	310	22	ABA13098	Human [illegible]
	76	14.8	77.9	354	21	AAC10189	Human [illegible]
	77	14.8	77.9	446	24	ABN75972	Human [illegible] cDNA
c	78	14.8	77.9	450	24	ABL93339	Arabidopsis [illegible]
	79	14.8	77.9	451	23	AAH88508	CNS [illegible]
	80	14.8	77.9	464	21	AAC38293	Zea mays DNA [illegible]
c	81	14.8	77.9	474	22	ABA41677	Human [illegible]
c	82	14.8	77.9	474	22	ABA54134	Human [illegible]

c 83	14.8	77.9	474	22	ABA23880	Probe #[illegible]
c 84	14.8	77.9	474	22	AAK02403	Human brain expres
c 85	14.8	77.9	474	22	AAK27849	Human bone marrow
c 86	14.8	77.9	474	22	AAI12426	Probe #2359 for ge
c 87	14.8	77.9	474	22	AAI33785	Probe #[illegible] used
c 88	14.8	77.9	474	22	AAI02340	Probe #2331 used
c 89	14.8	77.9	474	24	ABS02302	Human genome deriv
90	14.8	77.9	480	23	AAH88514	[illegible] relat
c 91	14.8	77.9	503	23	AAS94232	DNA encoding novel
92	14.8	77.9	555	9	AAN80997	Sequence of cloned
93	14.8	77.9	632	21	AAC56528	Eucalyptus grandis
94	14.8	77.9	823	22	AAH04164	Human cDNA clone (
c 95	14.8	77.9	1127	21	AAC51253	Arabidopsis thalia
c 96	14.8	77.9	1129	21	AAC41095	Arabidopsis thalia
97	14.8	77.9	1160	23	ABL06161	Drosophila melanog
c 98	14.8	77.9	1191	23	AAS83724	DNA encoding novel
99	14.8	77.9	1291	21	AAA57479	DNA encoding rat a
100	14.8	77.9	1296	24	ABK73629	Bacillus lichenifo
101	14.8	77.9	1381	20	AAV84482	Human secreted pro
102	14.8	77.9	1381	22	ABA83265	Human secreted pro
103	14.8	77.9	1545	22	AAH15478	Human cDNA sequenc
104	14.8	77.9	1550	24	AAH77217	Human serine threo
c 105	14.8	77.9	1699	23	AAS70606	DNA encoding novel
106	14.8	77.9	1790	22	AAH14119	Human cDNA sequenc
107	14.8	77.9	1929	22	AAH16554	Human cDNA sequenc
c 108	14.8	77.9	1947	23	AAS83725	DNA encoding novel
109	14.8	77.9	2050	23	ABV23489	Human prostate exp
110	14.8	77.9	2050	23	ABV29347	Human prostate exp
c 111	14.8	77.9	2064	21	AAA27001	Human Zwnt1 gene.
112	14.8	77.9	2096	22	AAD05091	Human secreted pro
113	14.8	77.9	2148	24	AAL39641	Human secreted pro
114	14.8	77.9	2156	24	ABL64092	Breast cancer rela
c 115	14.8	77.9	2210	21	AAC78148	Human cancer assoc
c 116	14.8	77.9	2210	22	AAH33281	Human colon cancer
117	14.8	77.9	2211	22	AAI60447	Human polynucleoti
118	14.8	77.9	2248	21	AAC98097	Human colon cancer
c 119	14.8	77.9	2294	20	AAX36[illegible]	[illegible] specific [illegible]
c 120	14.8	77.9	2325	22	AAH18637	Human cDNA sequenc
121	14.8	77.9	2482	22	AAI58661	Human polynucleoti
122	14.8	77.9	2541	23	AAS86279	DNA encoding novel
123	14.8	77.9	2730	23	AAS86706	DNA encoding novel
c 124	14.8	77.9	2806	24	ABN95742	Gene #[illegible] used to
c 125	14.8	77.9	2806	24	ABL92098	Human Tumour Endot
c 126	14.8	77.9	2806	24	ABL63091	Breast cancer rela
c 127	14.8	77.9	2806	24	ABL68515	Kidney cancer rela
128	14.8	77.9	2875	22	AAS41903	Genomic sequence #
129	14.8	77.9	3145	21	AAC59241	Human secreted pro
130	14.8	77.9	3207	21	AAC76851	Human [illegible]
131	14.8	77.9	3239	23	ABL06160	Drosophila melanog
132	14.8	77.9	3287	24	AAS99902	Polynucleotide enc
133	14.8	77.9	3345	24	ABN59766	Novel human coding
134	14.8	77.9	3593	22	AAD02774	Murine B7 4 protei
135	14.8	77.9	3593	22	AAD02709	Murine B7 4 protei
136	14.8	77.9	3891	23	AAS94276	DNA encoding novel
137	14.8	77.9	4097	22	AAS41904	Genomic sequence #
138	14.8	77.9	4497	24	ABK46170	cDNA encoding colo
139	14.8	77.9	6545	17	AAI27537	Maltose binding pr
140	14.8	77.9	7828	22	AAK77366	Human immune/haema
141	14.8	77.9	10543	23	ABL06498	Drosophila melanog
142	14.8	77.9	12724	22	AAK88955	Human digestive sy
c 143	14.8	77.9	14484	22	ABA07276	Human pancreatic c
c 144	14.8	77.9	14484	22	AAK89915	Human digestive sy
c 145	14.8	77.9	14495	22	ABA07272	Human pancreatic c
c 146	14.8	77.9	14495	22	AAK89917	Human digestive sy
c 147	14.8	77.9	14674	22	AAS46248	DNA encoding novel
c 148	14.8	77.9	15723	22	AAK81373	Human immune/haema
c 149	14.8	77.9	23394	22	AAK77173	Human immune/haema
c 150	14.8	77.9	25701	22	AAL07078	Human reproductive
c 151	14.8	77.9	25758	22	AAL07077	Human reproductive
152	14.8	77.9	27695	22	AAK77367	Human immune/haema
153	14.8	77.9	143899	24	AAL38336	Genomic sequence e
c 154	14.8	77.9	1503900	22	AAK95240	Human neuregulin I
c 155	14.8	77.9	1503901	22	AAK96733	Human neuregulin I

156	14.4	75.8	242	22	AAK[illegible]	Human [illegible]
157	14.4	75.8	242	22	AAK[illegible]	Human [illegible]
158	14.4	75.8	242	22	AAK[illegible]	Human [illegible]
159	14.4	75.8	242	22	AAK[illegible]	Human [illegible]
160	14.4	75.8	243	22	AAK[illegible]	Human [illegible]
161	14.4	75.8	244	22	AA[illegible]	Human [illegible]
162	14.4	75.8	281	24	ABL[illegible]	[illegible]
163	14.4	75.8	[illegible]	24	ABL[illegible]	Human [illegible]
c 164	14.4	75.8	308	21	AAB[illegible]	Human [illegible]
165	14.4	75.8	[illegible]	22	AAK[illegible]	Human [illegible]
166	14.4	75.8	[illegible]	21	AAC[illegible]	[illegible]
c 167	14.4	75.8	[illegible]	21	AAC[illegible]	Human [illegible]
168	14.4	75.8	[illegible]	21	AAC[illegible]	[illegible]
c 169	14.4	75.8	[illegible]	21	AAC[illegible]	[illegible]
c 170	14.4	75.8	[illegible]	23	ABV[illegible]	Human prostate exp
171	14.4	75.8	[illegible]	22	AAH12148	Human cDNA [illegible]
172	14.4	75.8	[illegible]	24	ABL[illegible]	[illegible]
173	14.4	75.8	[illegible]	23	ABV[illegible]	Human prostate exp
c 174	14.4	75.8	676	21	AAF[illegible]14	Aspergillus [illegible]
c 175	14.4	75.8	[illegible]	22	AAK[illegible]	Human cDNA [illegible]
c 176	14.4	75.8	769	22	AAK[illegible]	Human cDNA [illegible]
177	14.4	75.8	800	20	AA[illegible]	Human [illegible]
178	14.4	75.8	1056	17	AA[illegible]	Human [illegible]
c 179	14.4	75.8	[illegible]	21	AAC[illegible]	Zea mays cDNA fragm
180	14.4	75.8	[illegible]	22	AAK[illegible]	Human [illegible]
181	14.4	75.8	[illegible]	22	AAK71[illegible]	Human immune/haema
182	14.4	75.8	[illegible]	22	AAK84[illegible]	Human immune/haema
c 183	14.4	75.8	1183	20	AAZ3[illegible]	Human [illegible]
c 184	14.4	75.8	1377	23	AAS74[illegible]	DNA encoding novel
c 185	14.4	75.8	1443	23	ABL2[illegible]	Drosophila melanog
186	14.4	75.8	[illegible]	23	AAS65[illegible]	DNA encoding novel
c 187	14.4	75.8	[illegible]	22	AAK[illegible]	Human [illegible]
c 188	14.4	75.8	[illegible]	22	AAF[illegible]	Human [illegible]
c 189	14.4	75.8	[illegible]	22	AAH[illegible]	Human cDNA sequenc
c 190	14.4	75.8	1818	20	AAV84[illegible]	Human secreted pro
c 191	14.4	75.8	[illegible]	22	ABA8[illegible]	Human secreted pro
192	14.4	75.8	[illegible]	[illegible]	AAV0[illegible]	[illegible]
c 193	14.4	75.8	[illegible]	22	AAC[illegible]	Human [illegible]
c 194	14.4	75.8	[illegible]	22	AAS2[illegible]	DNA encoding novel
c 195	14.4	75.8	[illegible]	22	AAS23204	DNA encoding novel
c 196	14.4	75.8	[illegible]	[illegible]	AAE[illegible]	[illegible]
197	14.4	75.8	[illegible]	24	ABK70[illegible]	Human [illegible]
c 198	14.4	75.8	[illegible]	23	ABL2[illegible]	Drosophila melanog
199	14.4	75.8	3045	24	AAS94[illegible]	Human cDNA [illegible]
200	14.4	75.8	[illegible]	20	AAV[illegible]	Human [illegible] cDNA
201	14.4	75.8	[illegible]	21	AAC[illegible]	Human [illegible]
202	14.4	75.8	[illegible]	[illegible]	AAV[illegible]	[illegible]
203	14.4	75.8	[illegible]	[illegible]	AAV[illegible]	[illegible]
c 204	14.4	75.8	[illegible]	23	ABL2[illegible]	Drosophila melanog
c 205	14.4	75.8	[illegible]	22	AAF[illegible]	Human [illegible]
c 206	14.4	75.8	[illegible]	20	AA[illegible]	Human [illegible]
c 207	14.4	75.8	[illegible]	22	AAF[illegible]	Human [illegible]
c 208	14.4	75.8	[illegible]	21	AA[illegible]	Human [illegible]
c 209	14.4	75.8	[illegible]	23	ABL24[illegible]	Drosophila melanog
210	14.4	75.8	[illegible]	[illegible]	AAX[illegible]	[illegible]
211	14.4	75.8	[illegible]	22	AAF[illegible]	[illegible]
c 212	14.4	75.8	[illegible]	23	ABL[illegible]	Drosophila melanog
c 213	14.4	75.8	[illegible]	23	ABL[illegible]	Drosophila melanog
c 214	14.4	75.8	[illegible]	23	ABL[illegible]	Drosophila melanog
c 215	14.4	75.8	[illegible]	23	AA[illegible]	Drosophila melanog
216	14.4	75.8	[illegible]	23	ABL[illegible]	Drosophila melanog
217	14.4	75.8	[illegible]	22	AA[illegible]	Human cDNA [illegible]
c 218	14.4	75.8	[illegible]	24	ABK41[illegible]	[illegible]
219	14.4	75.8	[illegible]	21	AB[illegible]	Human [illegible]
220	14.4	75.8	[illegible]	22	ABA1[illegible]	Human [illegible]
221	14.4	75.8	[illegible]	23	ABL[illegible]	Drosophila melanog
c 222	14.4	75.8	[illegible]	24	ABK[illegible]	Human [illegible]
223	14.4	75.8	44117	24	ABK84[illegible]	Human cDNA [illegible]
224	14.4	75.8	[illegible]	21	AB[illegible]	[illegible]
225	14.4	75.8	[illegible]	21	AB[illegible]	[illegible]
c 226	14.4	75.8	14[illegible]	21	AAF[illegible]	Human [illegible]
c 227	14.4	75.8	14[illegible]	21	AAF[illegible]	Human [illegible]
c 228	14.4	75.8	14[illegible]	21	AAA3[illegible]	Human [illegible]

c	229	14.4	75.8	143058	21	AAA35168
c	230	14.4	75.8	142869	24	ABL68134
c	231	14.4	75.8	149412	21	AAA35151
c	232	14.4	75.8	152740	21	AAF21274
	233	14.2	74.7	45	22	AAD17287
	234	14.2	74.7	51	22	AAB90503
	235	14.2	74.7	100	22	ABA47722
	236	14.2	74.7	180	22	ABA65617
	237	14.2	74.7	180	22	ABA42704
	238	14.2	74.7	180	22	AAK14020
	239	14.2	74.7	180	22	AAK39767
	240	14.2	74.7	180	22	AA120573
	241	14.2	74.7	180	22	AA145783
	242	14.2	74.7	180	22	AA106272
	243	14.2	74.7	180	24	ABS13861
	244	14.2	74.7	180	24	ABL76074
	245	14.2	74.7	196	24	ABL71775
c	246	14.2	74.7	200	24	ABL86329
	247	14.2	74.7	259	22	ABA50859
	248	14.2	74.7	259	22	ABA68832
	249	14.2	74.7	259	22	ABA35783
	250	14.2	74.7	259	22	AAK17168
	251	14.2	74.7	259	22	AAK42952
	252	14.2	74.7	259	22	AA123716
	253	14.2	74.7	259	22	AA149020
	254	14.2	74.7	259	22	AA109334
	255	14.2	74.7	259	24	ABS17014
c	256	14.2	74.7	292	23	ABV33861
c	257	14.2	74.7	301	22	AAS35233
	258	14.2	74.7	336	22	AAF67501
c	259	14.2	74.7	347	24	ABN21198
	260	14.2	74.7	348	24	ABN89990
c	261	14.2	74.7	354	22	AAF73518
	262	14.2	74.7	371	22	AA192651
c	263	14.2	74.7	378	24	ABN78951
	264	14.2	74.7	398	24	ABB62380
	265	14.2	74.7	403	22	ABA42593
	266	14.2	74.7	403	22	ABA53023
	267	14.2	74.7	404	22	ABA22797
	268	14.2	74.7	405	22	AAK01271
	269	14.2	74.7	405	22	AAK26732
	270	14.2	74.7	405	22	AA111358
	271	14.2	74.7	405	22	AA132627
	272	14.2	74.7	405	22	AA101274
	273	14.2	74.7	405	24	ABS01326
	274	14.2	74.7	406	22	ABA45740
	275	14.2	74.7	406	22	ABA56249
	276	14.2	74.7	406	22	ABA27887
	277	14.2	74.7	406	22	AAK03432
	278	14.2	74.7	406	22	AAK23927
	279	14.2	74.7	406	22	AA114517
	280	14.2	74.7	406	22	AA135892
	281	14.2	74.7	406	22	AA104343
	282	14.2	74.7	406	24	ABS04495
	283	14.2	74.7	416	23	ABV10946
c	284	14.2	74.7	424	24	ABL78854
	285	14.2	74.7	425	24	ABN22774
	286	14.2	74.7	438	23	ABV32096
	287	14.2	74.7	438	23	ABV41084
	288	14.2	74.7	442	24	AAD24776
	289	14.2	74.7	443	24	ABL38099
	290	14.2	74.7	447	22	ABA08973
c	291	14.2	74.7	447	23	ABV30228
c	292	14.2	74.7	460	22	AAH36357
c	293	14.2	74.7	465	23	ABV16099
c	294	14.2	74.7	467	24	ABN73004
c	295	14.2	74.7	468	24	ABN73026
c	296	14.2	74.7	470	24	ABN73003
c	297	14.2	74.7	472	19	AAV52944
c	298	14.2	74.7	484	23	ABV12216
	299	14.2	74.7	487	22	ABA57962
	300	14.2	74.7	487	22	ABA27272
	301	14.2	74.7	487	22	AAK06065

Human adenosine re
ovary cancer relat
Human adenosine re
Human low adenosin
Human prostate spe
Human clone cq4392
Human breast cell
Human foetal liver
Probe #11170 for q
Human brain expres
Human bone marrow
Probe #10506 for q
Probe #14469 used
Probe #6263 used t
Human genome-deriv
Corn tassel-derive
Corn tassel-derive
Human ovarian cane
Human breast cell
Human foetal liver
Probe #14249 for q
Human brain expres
Human bone marrow
Probe #13649 for q
Probe #17715 used
Probe #9425 used t
Human genome-deriv
Human prostate exp
Human cardiovascul
Novel human polynu
Human ORFX polynuc
Arabidopsis thalia
Lung carcinoma cDN
Human polynucleoti
Human ORF3898 cDNA
Rat sequence ditte
Human breast cell
Human foetal liver
Probe #1263 for qe
Human brain expres
Human bone marrow
Probe #1291 for qe
Probe #1313 used t
Probe #1265 used t
Human genome-deriv
Human breast cell
Human foetal liver
Probe #4353 for qe
Human brain expres
Human bone marrow
Probe #4450 for qe
Probe #4578 used t
Probe #4334 used t
Human genome-deriv
Human prostate exp
Human ovarian cane
Human ORFX polynuc
Human prostate exp
Human prostate exp
Human nestin gene
Human colon tumour
Human dJ1042K10.5
Human prostate exp
Human colon cancer
Human prostate exp
cDNA sequence 1043
cDNA sequence PB t
cDNA sequence 1043
CEA transcriptiona
Human prostate exp
Human foetal liver
Probe #5748 for qe
Human brain expres

	302	14.2	74.7	487	22	AAK41714
	303	14.2	74.7	487	22	AA147590
	304	14.2	74.7	522	24	ABS00470
c	305	14.2	74.7	492	23	ABV15897
	306	14.2	74.7	497	23	AAC46012
	307	14.2	74.7	498	24	ABL81551
	308	14.2	74.7	527	22	ABA70600
	309	14.2	74.7	527	22	ABA37180
	310	14.2	74.7	527	22	AAK18845
	311	14.2	74.7	527	22	AAK41767
	312	14.2	74.7	527	22	AA155764
	313	14.2	74.7	527	24	ABS13026
	314	14.2	74.7	529	22	AAB05542
	315	14.2	74.7	529	23	AAS84716
c	316	14.2	74.7	529	23	AAS84992
c	317	14.2	74.7	546	22	AAB11733
c	318	14.2	74.7	547	20	AAX97863
c	319	14.2	74.7	547	23	ABV50655
	320	14.2	74.7	552	24	ABK62884
	321	14.2	74.7	578	23	AAS91464
	322	14.2	74.7	594	24	ABK71427
c	323	14.2	74.7	602	22	AAS06081
c	324	14.2	74.7	638	20	AAX97816
	325	14.2	74.7	658	23	AAF12421
c	326	14.2	74.7	758	23	AAS64884
	327	14.2	74.7	811	24	ABL86142
	328	14.2	74.7	926	22	AAS22749
c	329	14.2	74.7	1008	21	AAF12944
	330	14.2	74.7	1149	22	AAF27751
	331	14.2	74.7	1193	22	AAS22515
c	332	14.2	74.7	1231	22	AAF32670
	333	14.2	74.7	1352	24	ABN67512
c	334	14.2	74.7	1454	20	AAL26537
c	335	14.2	74.7	1506	22	AAB70651
c	336	14.2	74.7	1544	19	AAV59603
c	337	14.2	74.7	1618	22	AAF31119
	338	14.2	74.7	1619	20	AAL20647
c	339	14.2	74.7	1622	21	AA077041
c	340	14.2	74.7	1645	24	AAS18000
c	341	14.2	74.7	1647	14	AAQ52272
c	342	14.2	74.7	1667	19	AA191036
c	343	14.2	74.7	1668	20	AAA12759
c	344	14.2	74.7	1668	24	ABK14554
	345	14.2	74.7	1675	19	AAV84129
	346	14.2	74.7	1675	24	AAS15547
c	347	14.2	74.7	1714	21	AAC38765
c	348	14.2	74.7	1714	21	AAC38825
	349	14.2	74.7	1755	18	AA167246
c	350	14.2	74.7	1811	23	AAA12271
	351	14.2	74.7	1852	23	AAA99106
c	352	14.2	74.7	1853	24	ABL05421
c	353	14.2	74.7	1864	22	AAL05502
	354	14.2	74.7	2129	15	AAQ03872
c	355	14.2	74.7	2172	22	AAB15166
c	356	14.2	74.7	2222	21	AAF18508
c	357	14.2	74.7	2222	24	ABL96449
c	358	14.2	74.7	2223	22	AAS33341
c	359	14.2	74.7	2241	24	ABL60659
c	360	14.2	74.7	2281	24	ABL07254
c	361	14.2	74.7	2286	21	ABL72651
	362	14.2	74.7	2343	24	ABK83864
	363	14.2	74.7	2349	22	ABA62500
	364	14.2	74.7	2352	22	AAY08823
	365	14.2	74.7	2363	22	AAS30718
	366	14.2	74.7	2500	24	AAH41703
c	367	14.2	74.7	2532	24	ABN67108
c	368	14.2	74.7	2532	24	ABL01409
c	369	14.2	74.7	2532	24	ABL01488
c	370	14.2	74.7	2532	24	ABL05222
c	371	14.2	74.7	2532	24	ABL08084
c	372	14.2	74.7	2532	24	ABL08128
	373	14.2	74.7	2533	21	AAX82951
c	374	14.2	74.7	2571	24	AAF18055

	475	14.2	74.7	2682	21	AAX82962
c	476	14.2	74.7	2712	24	ABN72976
	477	14.2	74.7	2908	22	AA168822
	478	14.2	74.7	2988	23	AR129735
	479	14.2	74.7	3127	21	AAC51379
	480	14.2	74.7	3166	24	AR869413
c	481	14.2	74.7	3319	17	AA143076
	482	14.2	74.7	3319	19	AAV33412
	483	14.2	74.7	3363	21	AR126225
c	484	14.2	74.7	3429	23	AAS83939
	485	14.2	74.7	3429	23	AAS84714
	486	14.2	74.7	3447	17	AA168711
c	487	14.2	74.7	3447	24	AR199713
	488	14.2	74.7	3727	24	AR883214
	489	14.2	74.7	3734	22	AAS83201
	490	14.2	74.7	3936	24	AR884592
c	491	14.2	74.7	4064	21	AAZ92403
c	492	14.2	74.7	4068	22	AAF54866
c	493	14.2	74.7	4083	21	AAZ91910
c	494	14.2	74.7	4157	22	AAH57457
	495	14.2	74.7	4222	23	AA?1886
	496	14.2	74.7	4458	23	AAS88267
	497	14.2	74.7	4479	24	ABN81598
	498	14.2	74.7	4526	23	AR125526
c	499	14.2	74.7	4670	21	AAA09691
	500	14.2	74.7	4699	22	AAB76213
c	501	14.2	74.7	4903	22	AA342088
	502	14.2	74.7	5036	24	ABN81597
	503	14.2	74.7	5131	24	AR884535
c	504	14.2	74.7	5199	21	AAA59024
	505	14.2	74.7	5402	23	AR129734
c	506	14.2	74.7	5546	23	AAS82952
	507	14.2	74.7	5567	21	AAZ93522
c	508	14.2	74.7	5597	22	AAB98721
c	509	14.2	74.7	5602	22	AAK94869
	510	14.2	74.7	5602	22	AAK91418
	511	14.2	74.7	5602	22	AAS82140
	512	14.2	74.7	5602	24	ABN90495
	513	14.2	74.7	6519	17	AA147401
	514	14.2	74.7	6610	22	ABA06837
	515	14.2	74.7	6610	22	ABA06836
	516	14.2	74.7	6610	22	AAS29013
	517	14.2	74.7	6610	22	AAS29014
	518	14.2	74.7	6610	22	AAS26967
	519	14.2	74.7	6610	22	AAS26968
	520	14.2	74.7	6616	22	AAK51911
	521	14.2	74.7	6775	22	AAK52895
	522	14.2	74.7	7210	22	AAS42084
c	523	14.2	74.7	7784	23	AAS74636
	524	14.2	74.7	8284	23	AAS86535
c	525	14.2	74.7	8286	22	AAK79585
	526	14.2	74.7	9516	22	AAK73555
c	527	14.2	74.7	9516	22	AAK81494
c	528	14.2	74.7	10622	24	ABN73037
c	529	14.2	74.7	11288	16	AAQ90512
	530	14.2	74.7	11288	23	AAS14778
	531	14.2	74.7	11373	24	AR884113
c	532	14.2	74.7	11808	19	AAV33433
c	533	14.2	74.7	11869	22	AAS46792
c	534	14.2	74.7	11994	17	AA143075
	535	14.2	74.7	13192	22	AAK73556
	536	14.2	74.7	13192	22	AAK81496
	537	14.2	74.7	13660	22	AA199126
	538	14.2	74.7	13660	22	AAK67907
	539	14.2	74.7	13660	22	AAK81002
c	540	14.2	74.7	13660	22	AA163476
	541	14.2	74.7	14216	22	AAK79151
	542	14.2	74.7	14216	22	AAK79153
	543	14.2	74.7	14379	22	AAK79152
c	544	14.2	74.7	14556	16	AAQ90511
c	545	14.2	74.7	15056	19	AAV62963
c	546	14.2	74.7	15056	21	AAA49651
c	547	14.2	74.7	15056	21	AA299933
c	548	14.2	74.7	15056	21	AAB45...
c	549	14.2	74.7	15056	21	AAE92...
	550	14.2	74.7	15056	21	AAK45...
c	551	14.2	74.7	15056	21	AAK45...
c	552	14.2	74.7	15056	21	AAK45...
	553	14.2	74.7	15056	21	AAK45...
	554	14.2	74.7	15056	21	AAK45...
	555	14.2	74.7	15056	21	AAK45...
	556	14.2	74.7	15056	21	AAK45...
	557	14.2	74.7	15056	21	AAK45...
	558	14.2	74.7	15056	21	AAK45...
	559	14.2	74.7	15056	21	AAK45...
	560	14.2	74.7	15056	21	AAK45...
	561	14.2	74.7	15056	21	AAK45...
	562	14.2	74.7	15056	21	AAK45...
	563	14.2	74.7	15056	21	AAK45...
	564	14.2	74.7	15056	21	AAK45...
	565	14.2	74.7	15056	21	AAK45...
	566	14.2	74.7	15056	21	AAK45...
	567	14.2	74.7	15056	21	AAK45...
	568	14.2	74.7	15056	21	AAK45...
	569	14.2	74.7	15056	21	AAK45...
	570	14.2	74.7	15056	21	AAK45...
	571	14.2	74.7	15056	21	AAK45...
	572	14.2	74.7	15056	21	AAK45...
	573	14.2	74.7	15056	21	AAK45...
	574	14.2	74.7	15056	21	AAK45...
	575	14.2	74.7	15056	21	AAK45...
	576	14.2	74.7	15056	21	AAK45...
	577	14.2	74.7	15056	21	AAK45...
	578	14.2	74.7	15056	21	AAK45...
	579	14.2	74.7	15056	21	AAK45...
	580	14.2	74.7	15056	21	AAK45...
	581	14.2	74.7	15056	21	AAK45...
	582	14.2	74.7	15056	21	AAK45...
	583	14.2	74.7	15056	21	AAK45...
	584	14.2	74.7	15056	21	AAK45...
	585	14.2	74.7	15056	21	AAK45...
	586	14.2	74.7	15056	21	AAK45...
	587	14.2	74.7	15056	21	AAK45...
	588	14.2	74.7	15056	21	AAK45...
	589	14.2	74.7	15056	21	AAK45...
	590	14.2	74.7	15056	21	AAK45...
	591	14.2	74.7	15056	21	AAK45...
	592	14.2	74.7	15056	21	AAK45...
	593	14.2	74.7	15056	21	AAK45...
	594	14.2	74.7	15056	21	AAK45...
	595	14.2	74.7	15056	21	AAK45...
	596	14.2	74.7	15056	21	AAK45...
	597	14.2	74.7	15056	21	AAK45...
	598	14.2	74.7	15056	21	AAK45...
	599	14.2	74.7	15056	21	AAK45...
	600	14.2	74.7	15056	21	AAK45...
	601	14.2	74.7	15056	21	AAK45...
	602	14.2	74.7	15056	21	AAK45...
	603	14.2	74.7	15056	21	AAK45...
	604	14.2	74.7	15056	21	AAK45...
	605	14.2	74.7	15056	21	AAK45...
	606	14.2	74.7	15056	21	AAK45...
	607	14.2	74.7	15056	21	AAK45...
	608	14.2	74.7	15056	21	AAK45...
	609	14.2	74.7	15056	21	AAK45...
	610	14.2	74.7	15056	21	AAK45...
	611	14.2	74.7	15056	21	AAK45...
	612	14.2	74.7	15056	21	AAK45...
	613	14.2	74.7	15056	21	AAK45...
	614	14.2	74.7	15056	21	AAK45...
	615	14.2	74.7	15056	21	AAK45...
	616	14.2	74.7	15056	21	AAK45...
	617	14.2	74.7	15056	21	AAK45...
	618	14.2	74.7	15056	21	AAK45...
	619	14.2	74.7	15056	21	AAK45...
	620	14.2	74.7	15056	21	AAK45...

c 521	14	73.7	1587	22	AAS21476	Human cDNA sequenc
c 522	14	73.7	1587	22	AAF44229	Human PRO1181 (UNQ
c 523	14	73.7	1587	21	ABF[illegible]	cDNA encoding huma
c 524	14	73.7	1600	21	AAA12386	Human PRV-1 DNA.
c 525	14	73.7	1600	22	AAF61560	Human PRV 1 encodi
c 526	14	73.7	1612	24	ABA97156	Human granulocyte
c 527	14	73.7	1613	21	AAZ98146	Human signal pepti
528	14	73.7	1689	22	AAH23117	osteoarthritis tis
c 529	14	73.7	1733	20	AAV81394	Human tumour antig
c 530	14	73.7	1740	22	AAH16997	Human cDNA sequenc
c 531	14	73.7	2029	20	AAZ09492	Human heart tissue
c 532	14	73.7	2229	23	AAS69702	DNA encoding novel
533	14	73.7	2334	23	ABL13039	Drosophila melanog
534	14	73.7	2418	23	ABL20866	Drosophila melanog
535	14	73.7	2789	23	ABL19652	Drosophila melanog
536	14	73.7	3079	23	ABL08820	Drosophila melanog
537	14	73.7	4497	23	ABL13038	Drosophila melanog
c 538	14	73.7	4751	20	AAZ09496	Human heart tissue
c 539	14	73.7	4751	24	AAD29757	Human hyperpolaris
540	14	73.7	4798	21	AAC74503	Human ORFX ORF58 p
541	14	73.7	4846	23	ABL10620	Drosophila melanog
542	14	73.7	4852	23	ABL10600	Drosophila melanog
543	14	73.7	4993	21	AAC75872	Human ORFX ORF1427
c 544	14	73.7	5065	22	AAH48730	Human HCN4 cDNA.
545	14	73.7	5340	24	ABL32234	Human immune syste
c 546	14	73.7	5499	22	ABA09157	Human cation chann
547	14	73.7	6197	24	ABL33710	Human immune syste
548	14	73.7	6788	24	ABK83506	Human cDNA differe
549	14	73.7	6794	21	AAZ45567	cDNA sequence of h
550	14	73.7	7920	20	AAV08864	Grapevine leafroll
c 551	14	73.7	8856	23	ABL18068	Drosophila melanog
c 552	14	73.7	11870	22	AAL07328	Human reproductive
c 553	14	73.7	11870	22	AAL07329	Human reproductive
554	14	73.7	11870	22	AAK82242	Human immune/haema
555	14	73.7	11870	22	AAK82243	Human immune/haema
556	14	73.7	11870	22	AAK84752	Human immune/haema
557	14	73.7	11870	22	AAK84753	Human immune/haema
558	14	73.7	15500	20	AAV08874	Grapevine leafroll
559	14	73.7	32195	22	AAL04180	Human reproductive
560	14	73.7	134499	21	AAF22286	BAC containing rep
c 561	13.8	72.6	60	24	ABN37896	Human spliced tran
c 562	13.8	72.6	60	24	ABN48894	Human spliced tran
563	13.8	72.6	197	22	ABA49671	Human breast cell
564	13.8	72.6	197	22	ABA67574	Human foetal liver
565	13.8	72.6	197	22	ABA34651	Probe #13117 for g
566	13.8	72.6	197	22	AAK15066	Human brain expres
567	13.8	72.6	197	22	AAK41742	Human bone marrow
568	13.8	72.6	197	22	AAI22409	Probe #12431 for g
569	13.8	72.6	197	22	AAI47790	Probe #16476 used
570	13.8	72.6	197	22	AAI08184	Probe #8175 used t
571	13.8	72.6	197	24	ABS15751	Human genome-deriv
572	13.8	72.6	208	22	ABA71192	Human foetal liver
573	13.8	72.6	208	22	AAK19490	Human brain expres
574	13.8	72.6	208	22	AAK45481	Human bone marrow
575	13.8	72.6	208	22	AAI51436	Probe #20112 used
576	13.8	72.6	208	24	ABS19749	Human genome-deriv
c 577	13.8	72.6	209	21	AAA44394	Human secreted exp
c 578	13.8	72.6	222	24	ABN24223	Human ORFX polynuc
c 579	13.8	72.6	226	20	AAV87335	EST clone BT139.
580	13.8	72.6	233	18	AAV75598	Staphylococcus aur
581	13.8	72.6	241	24	ABL84337	Human ovarian canc
c 582	13.8	72.6	262	21	AAA41366	Human secreted exp
583	13.8	72.6	267	24	ABK39650	cDNA encoding lung
c 584	13.8	72.6	271	21	AAA44295	Human secreted exp
585	13.8	72.6	289	21	AAA87390	Rat hepatocyte car
c 586	13.8	72.6	294	24	ABK74707	Bacillus lichenifo
587	13.8	72.6	300	20	AAZ14316	Human gene express
588	13.8	72.6	326	24	ABN93969	Gene #467 used to
589	13.8	72.6	334	22	AAI11847	Human breast cance
c 590	13.8	72.6	335	20	AAX40592	Human secreted pro
c 591	13.8	72.6	344	14	AAQ59664	Human brain Expres
c 592	13.8	72.6	353	21	AAA98243	Human retrovirus L
593	13.8	72.6	358	24	ABK62615	Rat sequence diffe
c 594	13.8	72.6	378	22	AAI80292	Human [illegible]
595	13.8	72.6	378	22	AAH12431	Human cDNA [illegible]
c 596	13.8	72.6	397	21	AAA98220	Human [illegible]
c 597	13.8	72.6	404	24	ABN94162	Gene #[illegible]
598	13.8	72.6	406	24	ABK64278	Human [illegible]
599	13.8	72.6	406	24	ABL69684	Prostate [illegible]
c 600	13.8	72.6	407	23	ABV04879	Human [illegible]
c 601	13.8	72.6	411	[illegible]	ABV13375	Human [illegible]
c 602	13.8	72.6	417	21	AAS90043	Hy[illegible]
c 603	13.8	72.6	417	23	ABV14048	Human [illegible]
604	13.8	72.6	[illegible]	[illegible]	ABV55102	Human [illegible]
605	13.8	72.6	437	21	ABK76310	Ba[illegible]
606	13.8	72.6	437	24	ABN60879	Human [illegible]
c 607	13.8	72.6	440	23	ABV35154	Human [illegible]
c 608	13.8	72.6	440	23	ABV43936	Human [illegible]
c 609	13.8	72.6	443	22	AAI79959	Human [illegible]
c 610	13.8	72.6	446	23	ABV35683	Human [illegible]
c 611	13.8	72.6	448	22	AAK05836	Human [illegible]
c 612	13.8	72.6	448	22	AAK31467	Human [illegible]
c 613	13.8	72.6	448	22	AAI37353	Probe #[illegible]
c 614	13.8	72.6	448	24	ABS06[illegible]	Human [illegible]
615	13.8	72.6	461	21	AAC47[illegible]	Ar[illegible]
616	13.8	72.6	462	22	ABA14520	Human [illegible]
617	13.8	72.6	462	22	ABA54962	Human [illegible]
618	13.8	72.6	462	22	ABA24726	Probe #[illegible]
619	13.8	72.6	462	22	AAK03233	Human [illegible]
620	13.8	72.6	462	22	AAK20687	Human [illegible]
621	13.8	72.6	462	22	AAI13263	Probe #[illegible]
622	13.8	72.6	462	22	AAI34616	Probe #[illegible]
623	13.8	72.6	462	22	AAI03168	Probe #[illegible]
624	13.8	72.6	462	24	ABS03198	Human [illegible]
625	13.8	72.6	465	21	AAC39305	Arabidopsis [illegible]
c 626	13.8	72.6	466	22	AAK30625	Human [illegible]
c 627	13.8	72.6	467	21	AAZ42340	Human [illegible]
c 628	13.8	72.6	472	24	ABL53350	Arabidopsis [illegible]
c 629	13.8	72.6	476	24	ABL67297	Thyroid [illegible]
630	13.8	72.6	482	21	AAC03911	Human [illegible]
631	13.8	72.6	482	[illegible]	ABV23052	Human [illegible]
632	13.8	72.6	482	23	ABV23418	Human [illegible]
633	13.8	72.6	482	23	ABV28888	Human [illegible]
634	13.8	72.6	482	23	ABV29275	Human [illegible]
c 635	13.8	72.6	483	22	ABA24518	Probe #[illegible]
c 636	13.8	72.6	483	22	AAK03026	Human [illegible]
c 637	13.8	72.6	483	22	AAK28473	Human [illegible]
c 638	13.8	72.6	483	22	AAI13049	Probe #[illegible]
c 639	13.8	72.6	483	22	AAI34396	Probe #[illegible]
c 640	13.8	72.6	483	24	ABS02986	Human [illegible]
c 641	13.8	72.6	489	22	ABA57732	Human [illegible]
c 642	13.8	72.6	489	22	ABA27118	Probe #[illegible]
c 643	13.8	72.6	489	22	AAK05796	Human [illegible]
c 644	13.8	72.6	489	22	AAK31425	Human [illegible]
c 645	13.8	72.6	489	22	AAI15621	Probe #[illegible]
c 646	13.8	72.6	489	22	AAI37512	Probe #[illegible]
c 647	13.8	72.6	489	24	ABS06174	Human [illegible]
c 648	13.8	72.6	491	22	ABA58760	Human [illegible]
c 649	13.8	72.6	491	22	ABA27708	Probe #[illegible]
c 650	13.8	72.6	491	22	AAK06902	Human [illegible]
c 651	13.8	72.6	491	22	AAK32627	Human [illegible]
c 652	13.8	72.6	491	22	AAI16152	Probe #[illegible]
c 653	13.8	72.6	491	22	AAI38445	Probe #[illegible]
c 654	13.8	72.6	491	24	ABS07418	Human [illegible]
c 655	13.8	72.6	494	22	ABA44594	Human [illegible]
c 656	13.8	72.6	494	22	ABA52018	Human [illegible]
c 657	13.8	72.6	494	22	ABA55043	Human [illegible]
c 658	13.8	72.6	494	22	ABA21832	Probe #[illegible]
c 659	13.8	72.6	494	22	ABA24801	Probe #[illegible]
c 660	13.8	72.6	494	22	AAK00303	Human [illegible]
c 661	13.8	72.6	494	22	AAK03311	Human [illegible]
c 662	13.8	72.6	494	22	AAK25744	Human [illegible]
c 663	13.8	72.6	494	22	AAK28761	Human [illegible]
c 664	13.8	72.6	494	22	AAI10373	Probe #[illegible]
c 665	13.8	72.6	494	22	AAI13345	Probe #[illegible]
c 666	13.8	72.6	494	22	AAI31626	Probe #[illegible]

	667	18.8	72.6	494	22	AAI41699
c	668	18.8	72.6	494	22	AAI30808
c	669	18.8	72.6	494	22	AAI04244
c	670	18.8	72.6	494	24	ABS00623
c	671	18.8	72.6	494	24	ABS03281
	672	18.8	72.6	498	21	AAA41442
	673	18.8	72.6	499	22	ABA58694
	674	18.8	72.6	499	22	AAK60822
	675	18.8	72.6	499	22	AAK32547
	676	18.8	72.6	499	22	AAI48373
	677	18.8	72.6	499	24	ABS07337
c	678	18.8	72.6	500	24	ABN15787
	679	18.8	72.6	501	21	AAC41010
	680	18.8	72.6	502	24	AEL78424
	681	18.8	72.6	508	22	AAH98095
c	682	18.8	72.6	509	23	ABV87258
	683	18.8	72.6	512	23	AAC58303
	684	18.8	72.6	517	22	AAK88943
	685	18.8	72.6	517	22	AAI17619
c	686	18.8	72.6	518	22	ABA61373
c	687	18.8	72.6	518	22	ABA29162
c	688	18.8	72.6	518	22	AAK09672
c	689	18.8	72.6	518	22	AAK35564
c	690	18.8	72.6	518	22	AAI41279
c	691	18.8	72.6	518	24	ABS09884
	692	18.8	72.6	521	24	ABK76188
	693	18.8	72.6	526	23	AAV87282
c	694	18.8	72.6	550	22	AAS05533
	695	18.8	72.6	552	22	AAH36251
c	696	18.8	72.6	574	22	AAK62147
	697	18.8	72.6	590	21	AAF09178
	698	18.8	72.6	604	23	ABV47502
c	699	18.8	72.6	607	22	AAK60856
c	700	18.8	72.6	624	21	AAZ60150
c	701	18.8	72.6	642	22	AAK62146
	702	18.8	72.6	643	21	AAF11257
	703	18.8	72.6	648	24	AAL37814
c	704	18.8	72.6	673	22	AAH64776
	705	18.8	72.6	676	21	AAF14103
	706	18.8	72.6	684	20	AAX29295
c	707	18.8	72.6	685	21	AAA26488
	708	18.8	72.6	691	22	AAF22960
	709	18.8	72.6	692	24	ABL55110
	710	18.8	72.6	697	21	AAF13225
c	711	18.8	72.6	710	22	AAL04661
c	712	18.8	72.6	710	23	ABL07568
	713	18.8	72.6	720	23	AAS05437
c	714	18.8	72.6	730	22	AAL05224
	715	18.8	72.6	731	22	AAH98785
	716	18.8	72.6	742	22	AAI60759
	717	18.8	72.6	745	22	ABA89512
	718	18.8	72.6	742	20	AAZ07142
	719	18.8	72.6	749	19	AAV69617
c	720	18.8	72.6	757	21	AAC46581
	721	18.8	72.6	764	22	AAF22701
	722	18.8	72.6	769	22	AAI58973
	723	18.8	72.6	774	24	ABK63439
	724	18.8	72.6	776	24	ABK65758
	725	18.8	72.6	784	23	AAS70850
	726	18.8	72.6	787	22	AAF22703
c	727	18.8	72.6	789	21	AAO48708
c	728	18.8	72.6	795	21	AAC62959
	729	18.8	72.6	810	22	AAI96309
c	730	18.8	72.6	812	22	AAI02639
c	731	18.8	72.6	821	23	ABL10585
	732	18.8	72.6	900	24	ABK14771
	733	18.8	72.6	911	24	ABN90676
	734	18.8	72.6	918	23	AAS92132
c	735	18.8	72.6	922	24	ABE67087
	736	18.8	72.6	927	22	AAL15692
c	737	18.8	72.6	948	22	AAS26182
	738	18.8	72.6	965	18	AAN01629
c	739	18.8	72.6	968	21	AAA98219

	740	18.8	72.6	968	21	AAA79164
	741	18.8	72.6	973	24	ABN71167
	742	18.8	72.6	984	21	AAZ99431
	743	18.8	72.6	1008	21	ABK09624
c	744	18.8	72.6	1150	24	AAC06290
c	745	18.8	72.6	1171	21	AAT [illegible]
	746	18.8	72.6	1179	20	AAZ99417
c	747	18.8	72.6	1230	20	AAX01827
c	748	18.8	72.6	1240	21	AAL [illegible]
	749	18.8	72.6	1241	21	AAT [illegible]
	750	18.8	72.6	1243	21	AAU [illegible]
c	751	18.8	72.6	1260	19	AAQ [illegible]
c	752	18.8	72.6	1263	20	AAV [illegible]
	753	18.8	72.6	1277	21	AAL [illegible]
c	754	18.8	72.6	1280	21	AAT [illegible]
c	755	18.8	72.6	1311	20	AAQ [illegible]
c	756	18.8	72.6	1311	21	AAL [illegible]
c	757	18.8	72.6	1311	21	AAA [illegible]
c	758	18.8	72.6	1322	23	ABV [illegible]
c	759	18.8	72.6	1322	23	ABV [illegible]
c	760	18.8	72.6	1341	21	AAC [illegible]
	761	18.8	72.6	1351	21	AAT [illegible]
	762	18.8	72.6	1351	24	ABK [illegible]
	763	18.8	72.6	1351	21	AAC [illegible]
	764	18.8	72.6	1360	20	AAC [illegible]
c	765	18.8	72.6	1411	22	AAC [illegible]
	766	18.8	72.6	1415	20	AAE [illegible]
c	767	18.8	72.6	1424	20	AAT [illegible]
	768	18.8	72.6	1425	20	AAX [illegible]
	769	18.8	72.6	1426	21	ABK [illegible]
	770	18.8	72.6	1427	20	AAB [illegible]
	771	18.8	72.6	1432	20	AAC [illegible]
	772	18.8	72.6	1436	21	AAC [illegible]
	773	18.8	72.6	1445	20	AAE [illegible]
c	774	18.8	72.6	1461	20	ABA [illegible]
c	775	18.8	72.6	1462	22	AAE [illegible]
c	776	18.8	72.6	1462	22	AAH [illegible]
	777	18.8	72.6	1470	19	AAC [illegible]
	778	18.8	72.6	1472	20	AAI [illegible]
c	779	18.8	72.6	1473	21	AAI [illegible]
	780	18.8	72.6	1479	23	AAZ [illegible]
c	781	18.8	72.6	1484	20	AAC [illegible]
	782	18.8	72.6	1492	22	AAP [illegible]
	783	18.8	72.6	1495	22	AAS [illegible]
	784	18.8	72.6	1500	20	AAI [illegible]
	785	18.8	72.6	1502	20	AAC [illegible]
	786	18.8	72.6	1508	22	AAH [illegible]
	787	18.8	72.6	1509	20	AAH [illegible]
	788	18.8	72.6	1511	20	AAZ [illegible]
	789	18.8	72.6	1512	21	AAA [illegible]
	790	18.8	72.6	1520	20	AAE [illegible]
	791	18.8	72.6	1525	20	AAC [illegible]
	792	18.8	72.6	1528	21	ABK [illegible]
	793	18.8	72.6	1528	24	ABN [illegible]
c	794	18.8	72.6	1530	21	AAE [illegible]
	795	18.8	72.6	1531	20	AAC [illegible]
c	796	18.8	72.6	1535	19	AAC [illegible]
c	797	18.8	72.6	1535	20	AAV [illegible]
	798	18.8	72.6	1541	21	AAT [illegible]
c	799	18.8	72.6	1548	22	AAC [illegible]
c	800	18.8	72.6	1548	22	AAC [illegible]
c	801	18.8	72.6	1548	22	AAK [illegible]
c	802	18.8	72.6	1548	22	AAE [illegible]
	803	18.8	72.6	1549	24	AAI [illegible]
	804	18.8	72.6	1553	21	AAJ [illegible]
c	805	18.8	72.6	1554	21	ABC [illegible]
	806	18.8	72.6	1554	21	ABC [illegible]
	807	18.8	72.6	1561	20	AAV [illegible]
	808	18.8	72.6	1565	20	AAK [illegible]
c	809	18.8	72.6	1566	21	ABK [illegible]
	810	18.8	72.6	1580	20	AAC [illegible]
	811	18.8	72.6	1581	22	AAC [illegible]
	812	18.8	72.6	1588	21	AAJ [illegible]

813	13.8	72.6	2387	22	[illegible]	Human polynucleoti
814	13.8	72.6	2388	23	ABL30221	Drosophila melanog
815	13.8	72.6	2396	21	AAC46033	Arabidopsis thalia
816	13.8	72.6	2401	21	AAC40442	Arabidopsis thalia
817	13.8	72.6	2402	24	AAS62613	cDNA sequence #400
c 818	13.8	72.6	2414	22	AAS63903	Human prostate cDN
c 819	13.8	72.6	2414	22	AAH93810	Human prostate-spe
c 820	13.8	72.6	2414	22	AAH85124	Human prostate-spe
c 821	13.8	72.6	2414	24	ABL55274	Human P775P splice
c 822	13.8	72.6	2470	24	ABL59505	Human dihydroxyace
823	13.8	72.6	2481	20	AAX90448	Human secreted pro
824	13.8	72.6	2481	22	AAS59277	Human cDNA encodin
825	13.8	72.6	2481	24	ABA90946	Human polynucleoti
826	13.8	72.6	2489	23	ABL05928	Drosophila melanog
827	13.8	72.6	2501	20	AAX29622	Nucleotide sequenc
828	13.8	72.6	2532	22	AAI58996	Human polynucleoti
829	13.8	72.6	2541	21	AAC42943	Arabidopsis thalia
830	13.8	72.6	2543	21	AAC76644	Human ORFX ORF2199
831	13.8	72.6	2606	19	AAV18077	Human adenomatous
832	13.8	72.6	2640	19	AAV35790	Mouse trident tran
833	13.8	72.6	2652	20	AAX23386	Human Delta7-stero
834	13.8	72.6	2652	20	AAX23387	Human Delta7-stero
c 835	13.8	72.6	2682	22	AAI60782	Human polynucleoti
c 836	13.8	72.6	2745	23	AAS83219	DNA encoding novel
c 837	13.8	72.6	2774	22	AAH16729	Human cDNA sequenc
838	13.8	72.6	2963	23	ABL30247	Drosophila melanog
839	13.8	72.6	2875	22	ABL29675	Drosophila melanog
840	13.8	72.6	2988	19	[illegible]	Human calcium chan
841	13.8	72.6	3013	23	ABL16302	Drosophila melanog
c 842	13.8	72.6	3058	22	AAK83876	Human immune/haema
843	13.8	72.6	3079	23	ABL15656	Drosophila melanog
c 844	13.8	72.6	3090	24	AAH99946	Murine WT1 cDNA en
845	13.8	72.6	3167	23	ABL03175	Drosophila melanog
846	13.8	72.6	3336	14	AAQ64652	Human Mannose-Bind
c 847	13.8	72.6	3406	23	ABL04749	Drosophila melanog
848	13.8	72.6	3435	24	ABK63573	Rat sequence diffe
849	13.8	72.6	3441	19	AAV37493	Rat hepatocyte nuc
c 850	13.8	72.6	3514	19	AAV70359	Human ehb10 encodi
851	13.8	72.6	3592	14	AAQ53529	Human Mannose-Bind
852	13.8	72.6	3605	20	AAZ07143	Human mannan-bindi
853	13.8	72.6	3605	24	ABN97219	Gene #3708 used to
c 854	13.8	72.6	3708	13	AAQ23963	Probe BtY2. Bos t
855	13.8	72.6	3730	22	AAI59396	Human polynucleoti
856	13.8	72.6	3778	24	ABK84653	Human cDNA differe
857	13.8	72.6	3783	22	AAI61182	Human polynucleoti
c 858	13.8	72.6	3824	22	AAH18219	Human cDNA sequenc
859	13.8	72.6	3832	21	ABL41120	Breast cancer rela
860	13.8	72.6	3833	24	ABL69525	Prostate cancer re
861	13.8	72.6	3851	23	AAS86411	DNA encoding novel
c 862	13.8	72.6	3878	22	AAH76167	Human drug metabol
863	13.8	72.6	3878	21	ABK95071	cDNA encoding Aspe
864	13.8	72.6	3879	23	AAS86413	DNA encoding novel
865	13.8	72.6	3966	23	ABV21862	Human prostate exp
866	13.8	72.6	3966	23	ABV25182	Human prostate exp
867	13.8	72.6	3966	23	ABV27690	Human prostate exp
868	13.8	72.6	3997	22	AAK94864	Human full-length
869	13.8	72.6	4040	24	ABL61904	Colon adenocarcino
870	13.8	72.6	4040	24	ABL65211	Lung cancer relate
c 871	13.8	72.6	4067	15	AAQ63192	Human adeno-associ
872	13.8	72.6	4159	23	ABL16300	Drosophila melanog
873	13.8	72.6	4241	21	AAC77313	Human ORFX ORF2868
874	13.8	72.6	4294	23	ABV21071	Human prostate exp
875	13.8	72.6	4294	23	ABV26914	Human prostate exp
876	13.8	72.6	4345	23	ABL04746	Drosophila melanog
c 877	13.8	72.6	4490	22	AAH02953	Human shear stress
c 878	13.8	72.6	4635	23	ABL30220	Drosophila melanog
879	13.8	72.6	4991	23	AAS75353	DNA encoding novel
c 880	13.8	72.6	4998	23	ABL29974	Drosophila melanog
881	13.8	72.6	5153	16	AAT05116	STLVpan-p 5' regio
882	13.8	72.6	5258	23	ABL30246	Drosophila melanog
c 883	13.8	72.6	5481	22	AAK76925	Human immune/haema
884	13.8	72.6	5496	23	ABL21796	Drosophila melanog
c 885	13.8	72.6	5509	22	AAK76924	Human immune/haema

886	13.8	72.6	5785	23	ABL04748	[illegible]
887	13.8	72.6	[illegible]	2[illegible]	AAX20?74	[illegible]
888	13.8	72.6	6002	23	AAS84616	DNA [illegible]
889	13.8	72.6	6027	22	AAI58624	Human [illegible]
c 890	13.8	72.6	6035	22	AAS39977	[illegible]
c 891	13.8	72.6	6035	22	AAK90669	Human [illegible]
c 892	13.8	72.6	6035	22	AAS32217	Human [illegible]
c 893	13.8	72.6	6045	22	AAH18244	Human [illegible]
c 894	13.8	72.6	6138	23	ABL03174	[illegible]
895	13.8	72.6	6202	16	AAQ68161	[illegible]
896	13.8	72.6	6282	19	AAV59040	A. thaliana [illegible]
897	13.8	72.6	6566	23	AAS79147	DNA [illegible]
c 898	13.8	72.6	6637	22	AAI87199	Human [illegible]
c 899	13.8	72.6	6656	24	ABK51005	Human [illegible]
c 900	13.8	72.6	6716	24	ABL68111	Ovary cancer [illegible]
c 901	13.8	72.6	6716	21	ABK35498	Human [illegible]
c 902	13.8	72.6	6747	13	AAQ24508	[illegible]
903	13.8	72.6	7193	24	ABK92260	Prostate [illegible]
c 904	13.8	72.6	7510	21	ABI04094	Human [illegible]
c 905	13.8	72.6	7577	19	AAV52179	Strept[illegible]
906	13.8	72.6	7635	14	AAQ37811	Sequence [illegible]
907	13.8	72.6	7635	16	AAQ84653	Human [illegible]
908	13.8	72.6	7635	16	AAQ84654	Human [illegible]
909	13.8	72.6	7635	19	AAV42679	DNA [illegible]
910	13.8	72.6	7635	19	AAV42697	DNA [illegible]
911	13.8	72.6	7635	21	AAA71697	Human [illegible]
c 912	13.8	72.6	7885	21	ABL75808	Lung [illegible]
913	13.8	72.6	7984	23	ABV22768	Human [illegible]
914	13.8	72.6	7984	23	ABV22922	Human [illegible]
915	13.8	72.6	7984	23	ABV23025	Human [illegible]
916	13.8	72.6	7984	23	ABV25?09	Human [illegible]
917	13.8	72.6	7984	23	ABV28594	Human [illegible]
918	13.8	72.6	7984	23	ABV28753	Human [illegible]
919	13.8	72.6	7984	23	ABV28861	Human [illegible]
920	13.8	72.6	8268	22	AAS28434	Genomic [illegible] #
921	13.8	72.6	8272	22	AAS28433	Genomic [illegible] #
c 922	13.8	72.6	8895	22	AAS32714	Human [illegible] DNA
923	13.8	72.6	8895	22	AAK91538	Human [illegible]
924	13.8	72.6	8895	22	AAI57795	Human [illegible]
c 925	13.8	72.6	8896	22	AAS32712	Human [illegible] DNA
926	13.8	72.6	8896	22	AAK91537	Human [illegible]
927	13.8	72.6	8896	22	AAI57794	Human [illegible]
928	13.8	72.6	9350	22	AAK89656	Human [illegible]
929	13.8	72.6	9505	22	AAK89657	Human [illegible]
930	13.8	72.6	9732	23	AAS79[illegible]	DNA [illegible]
931	13.8	72.6	9997	18	AAI97925	Compo[illegible]
932	13.8	72.6	[illegible]	1[illegible]	AAV[illegible]	Mouse [illegible]
c 933	13.8	72.6	[illegible]	22	AAK6[illegible]	Human [illegible]
934	13.8	72.6	10318	20	AAS23436	Human [illegible]
935	13.8	72.6	10318	22	ABA08654	Human [illegible]
936	13.8	72.6	[illegible]	22	ABA08714	Human [illegible]
c 937	13.8	72.6	[illegible]	21	AAS91971	DNA [illegible]
938	13.8	72.6	10966	15	AAQ67401	[illegible]
939	13.8	72.6	10966	18	AAI97924	Compo[illegible]
940	13.8	72.6	10966	15	AAV05828	Human [illegible]
941	13.8	72.6	11827	22	AAK85942	Human [illegible]
c 942	13.8	72.6	11888	22	AAL07198	Human [illegible]
c 943	13.8	72.6	11967	15	AAQ45339	cDNA [illegible]
944	13.8	72.6	11987	22	AAL07284	Human [illegible]
945	13.8	72.6	11987	23	ABL98830	Human [illegible]
c 946	13.8	72.6	12042	23	AAS76999	DNA [illegible]
947	13.8	72.6	12575	22	AAL07283	Human [illegible]
948	13.8	72.6	12575	23	ABL98824	Human [illegible]
c 949	13.8	72.6	14255	14	AAQ43526	ALL [illegible] DNA
c 950	13.8	72.6	14255	16	AAQ75181	ALL [illegible]
c 951	13.8	72.6	14255	19	AAV20477	Human ALL [illegible]
c 952	13.8	72.6	14255	24	ABL67248	[illegible]
953	13.8	72.6	14918	22	AAS26792	Human [illegible]
c 954	13.8	72.6	15088	23	ABL27868	Drosophila [illegible]
955	13.8	72.6	[illegible]	13	AAQ25975	MH [illegible]
c 956	13.8	72.6	[illegible]	22	AAK68321	Human [illegible]
957	13.8	72.6	[illegible]	22	AAL04753	Human [illegible]
958	13.8	72.6	18408	22	AAL04751	Human [illegible]

960	13.8	72.6	18408	23	ABL97656	Human testicular [illegible]
961	13.8	72.6	18408	23	ABL97657	Human testicular a
c 962	13.8	72.6	1612	14	AAQ[illegible]	[illegible]
963	13.8	72.6	19861	22	AAK71206	Human immune/haema
964	13.8	72.6	20097	22	AAS32695	Human genomic DNA
c 965	13.8	72.6	20097	22	AAS42142	[illegible] sequence #
c 966	13.8	72.6	21234	24	AAD32039	Human kinase prote
967	13.8	72.6	21340	23	ABL12524	Drosophila melanog
c 968	13.8	72.6	21429	22	AAF[illegible]2	[illegible] cDNA comp
c 969	13.8	72.6	22916	22	AAK65305	Human immune/haema
970	13.8	72.6	23670	24	ABA97077	Tomato Hero gene c
c 971	13.8	72.6	24533	22	AAS27685	DNA encoding novel
c 972	13.8	72.6	26555	22	AAK68372	Human immune/haema
c 973	13.8	72.6	26555	22	AAK68605	Human immune/haema
c 974	13.8	72.6	26555	22	AAI62833	Human genomic DNA
975	13.8	72.6	32150	22	AAS32454	Human genomic DNA
976	13.8	72.6	32153	22	AAL62[illegible]	Human musculoskele
977	13.8	72.6	32153	22	AAD16[illegible]	Human novel protei
978	13.8	72.6	37590	22	AAS12439	DNA encoding [illegible]
979	13.8	72.6	50000	21	AAA96365	Polymorphic repeat
980	13.8	72.6	90164	23	ABL12462	Drosophila melanog
c 981	13.8	72.6	112460	24	ABK83567	Human cDNA differe
982	13.8	72.6	135385	24	ABK84795	Human cDNA differe
c 983	13.8	72.6	149480	24	ABL61947	[illegible]
c 984	13.8	72.6	149480	24	ABL61948	[illegible]
c 985	13.8	72.6	149480	24	ABL68365	Kidney cancer rela
c 986	13.8	72.6	291143	24	ABK83568	Human DNA differen
c 987	13.8	72.6	273254	21	AAC81914	[illegible] plasmid
988	13.8	72.6	1230025	20	AAX91990	Nucleotide sequenc
989	13.4	70.5	50	22	AAL29[illegible]	Human SNP oligonuc
990	13.4	70.5	103	24	ABK88534	Human [illegible]
c 991	13.4	70.5	122	23	AAS58855	cDNA #1551 encodin
c 992	13.4	70.5	157	21	AAC[illegible]	Human secreted pro
c 993	13.4	70.5	182	22	AAK54592	Human haematologic
c 994	13.4	70.5	182	22	AAK54739	Human haematologic
c 995	13.4	70.5	185	21	AAC30638	Human secreted pro
996	13.4	70.5	188	22	AAS37414	Novel human diagno
c 997	13.4	70.5	196	21	ABN81056	Shrimp polynucleot
c 998	13.4	70.5	196	21	ABN81062	Shrimp polynucleot
c 999	13.4	70.5	207	22	ABA48566	Human breast cell
c 1000	13.4	70.5	207	22	ABA66481	Human foetal liver
c 1000	13.4	70.5	207	22	ABA33542	[illegible] #1,008 for q

ALIGNMENTS

```
RESULT 1
AAZ33623/c
ID   AAZ33623 standard; cDNA; 1780 BP.
XX
AC   AAZ33623;
XX
DT   [illegible] DEC 1999  (first entry)
XX
DE   Human breast tumour-associated EST 13.
XX
KW   Expressed sequence tag; EST; human; breast; [illegible] gene therapy;
KW   treatment; tumour; cytostatic; medicament; ss.
XX
OS   Homo sapiens.
XX
PN   DE[illegible] A1.
XX
PD   [illegible] 1999.
XX
PF   [illegible] MAR 1998;   98DE-1010839.
XX
PR   [illegible] MAR 1998;   98DE-1010[illegible].
XX
PA   (META-) METAGEN GES GENOMFORSCHUNG MBH.
XX
PI   Specht T, Hinzmann B, Schmitt A, Pilarsky C, [illegible]
```

```
XX
DR   WPI; 1999-[illegible]/[illegible]
XX
PT   Human nucleic acid sequences and protein products from tumorous breast
PT   tissue, useful for breast cancer therapy
XX
PS   Claim [illegible]; [illegible]pp; German.
XX
CC   This invention describes novel human nucleic acid sequences from tumorous
CC   breast tissue which have [illegible] activity. The nucleic acid sequences
CC   can be used to produce and isolate full length gene sequences [illegible]
CC   be used to express proteins, which can be used as tools to find [illegible]
CC   activity against breast cancer. The sequences can be used in sense or
CC   antisense form. They are especially useful for medicaments [illegible]
CC   therapy to treat breast cancer. AAZ[illegible] represents [illegible]
CC   sequence tags described in the method of the invention.
XX
SQ   Sequence 1780 BP; [illegible] A; [illegible] C; [illegible] G; [illegible] T; [illegible] other;

  Query Match             [illegible]
  Best Local Similarity   [illegible]; Pred. No. [illegible];
  Matches   [illegible]; Conservative   [illegible]; Mismatches   [illegible]; Indels   [illegible]; Gaps   [illegible];

Qy          1 [illegible]
Db         85 [illegible]


RESULT 2
AAT[illegible]/c
ID   AAT[illegible] standard; cDNA; [illegible] BP.
XX
AC   AAT[illegible];
XX
DT   29-SEP-1997  (first entry)
XX
DE   Human integrin linked kinase (ILK) cDNA.
XX
KW   Integrin linked kinase; ILK; serine/threonine kinase; cell [illegible]
KW   cell adhesion; cell migration; [illegible]; inhibitor;
KW   gene therapy; diagnosis; cancer; leukaemia; tumour; inflammation;
KW   arthritis; osteoporosis; cardiovascular disease; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             [illegible]
FT                   /*tag= a
FT   polyA_signal    [illegible]
FT                   /*tag= b
XX
PN   WO97[illegible] A1.
XX
PD   03-JUL-1997.
XX
PF   19-NOV-1996;   96WO-CA00[illegible].
XX
PR   21-DEC-1995;   [illegible]
XX
PA   (DEDH/) DEDHAR S.
PA   (HANN/) HANNIGAN G.
XX
PI   Dedhar S, Hannigan G;
XX
DR   WPI; 1997-[illegible]/[illegible].
DR   P-PSDB; AAW[illegible].
XX
PT   New isolated integrin linked serine/threonine kinase [illegible]
PT   derived products to modulate cell growth, adhesion, migration [illegible]
PT   [illegible] for treating cancer or inflammation
XX
PS   Claim [illegible]; [illegible]pp; English.
XX
```

```
XX   cDNA clone Plac5 (AAI71716) codes for a serine/threonine kinase
XX   (AAK18211) which is an integrin-linked kinase, designated ILK,
XX   that can be used to modulate cell growth, adhesion, migration and
XX   invasion.  It was isolated from a human placental cDNA library
XX   using a partial cDNA, BIT-9, that had been obtd. in a two-hybrid
XX   screen using a bait plasmid expressing the integrin beta-1 subunit
XX   cytoplasmic domain.  The ILK chromosomal locus has been mapped to
XX   11p15, a region implicated in a subset of breast carcinomas,
XX   inherited cardiac arrythmia and long QT syndrome.  ILK nucleic
XX   acids (including antisense) can be used in gene therapy to inhibit
XX   ILK expression for the treatment of e.g. cancer, leukaemia, solid
XX   tumours, chronic inflammatory disease, arthritis, osteoporosis and
XX   cardiovascular disease, and can also be used as diagnostics to
XX   screen biopsy samples.
XX
SQ   Sequence 1786 BP; 444 A; 487 C; 479 G; 377 T; 0 other;

  Query Match             100.0%;  Score 19;  DB 18;  Length 1786;
  Best Local Similarity   100.0%;  Prod. No. 13;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 GGGAAGGAGGATGAACCCC 19
           |||||||||||||||||||
Db     95 GGGAAGGAGGATGAACCCC 77


RESULT 3
AAP69274/c
ID   AAP69274 standard; DNA; 1790 BP.
XX
AC   AAP69274;
XX
DT   18-APR-2001  (first entry)
XX
DE   Human integrin-linked kinase DNA.
XX
KW   Antisense; integrin-linked kinase; ILK; infection; tumour;
KW   inflammation; ds.
XX
OS   Homo sapiens.
XX
PN   US6177274-B1.
XX
PD   23-JAN-2001.
XX
PF   26-OCT-1999;  99US-0428219.
XX
PR   26-OCT-1999;  99US-0428219.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF;  Cowsert LM;
XX
DR   WPI; 2001-137069/14.
XX
PT   Novel antisense compounds capable of modulating expression of human
PT   integrin-linked kinase, useful for diagnosis, prophylaxis and treatment
PT   of diseases, e.g. tumors, associated with expression of the kinase
XX
PS   Example 13; Column 47-50; 40pp; English.
XX
CC   The present invention relates to an antisense compound 8 to
CC   30 bases in length targeted to the 5' untranslated (UTR) region,
CC   the coding region or the 3' UTR region human Integrin-linked
CC   kinase (hILK). The antisense oligonucleotides are useful for
CC   inhibiting the expression of human hILK in human cells or tissues,
CC   in vitro. The oligonucleotides can be utilized for diagnostics,
CC   therapeutics for the treatment of diseases associated with
CC   the expression of hILK, prophylaxis e.g. to prevent or delay infection,
CC   inflammation or tumor formation and as research reagent.
XX
SQ   Sequence 1789 BP; 443 A; 488 C; 480 G; 378 T; 0 other;

  Query Match             100.0%;  Score 19;  DB 22;  Length 1790;
  Best Local Similarity   100.0%;  Prod. No. 13;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 GGGAAGGAGGATGAACCCC 19
           |||||||||||||||||||
Db     95 GGGAAGGAGGATGAACCCC 77


RESULT 4
ABK84315/c
ID   ABK84315 standard; cDNA; 1790 BP.
XX
AC   ABK84315;
XX
DT   14-AUG-2002  (first entry)
XX
DE   Human cDNA differentially expressed in granulocytic cells #999.
XX
KW   Human; ss; granulocytic cell; DNA chip; bacterial infection;
KW   viral infection; parasitic infection; protozoal infection;
KW   fungal infection; sterile inflammatory disease; psoriasis;
KW   rheumatoid arthritis; glomerulonephritis; asthma; thrombosis;
KW   cardiac reperfusion injury; renal reperfusion injury; ARDS;
KW   adult respiratory distress syndrome; inflammatory bowel disease;
KW   Crohn's disease; ulcerative colitis; periodontal disease;
KW   granulocyte activation; chronic inflammation; allergy.
XX
OS   Homo sapiens.
XX
PN   WO200229019-A2.
XX
PD   11-APR-2002.
XX
PF   03-OCT-2001;  2001WO-US030821.
XX
PR   03-OCT-2000;  2000US-237809P.
XX
PA   (GENE ) GENE LOGIC INC.
XX
PI   Boazel Barclay Y;  Weissman SM;  Yamada S;  Vockley J;
XX
DR   WPI; 2002-435628/46.
XX
PT   Detecting granulocyte activation by detecting differential expression
PT   of genes associated with granulocyte activation, which serves as
PT   diagnostic markers that is useful for monitoring disease status and
PT   drug toxicity
XX
PS   Claim 1; SEQ ID NO 999; 114pp; English.
XX
CC   The invention relates to detecting (M1) granulocyte (GC) activation
CC   (GCA), by detecting the level of expression of gene(s) (Gs) associated
CC   DNA chip analysis as given in the specification, and comparing
CC   the expression level to an expression level in an unactivated
CC   GC, where differential expression of Gs is indicative of GCA.
CC   Also included are modulating (M2) GCA by contacting GC with an agent
CC   that alters the expression of at least one gene in Gs; (3) screening
CC   for an agent capable of modulating GCA or an inflammation (e.g.
CC   chronic) in a tissue, an allergic response in a subject, exposure
CC   subject to a pathogen or sterile inflammatory disease using the
CC   gene expression profile; (4) detecting (M4) an inflammation (e.g.
CC   chronic) in a tissue, an allergic response in a subject, exposure
CC   subject to a pathogen or sterile inflammatory disease, by detecting the
CC   level of expression in a sample of the tissue of gene(s) from Gs, where
CC   the level of expression of the gene is indicative of inflammation;
CC   (4) treating (M5) an inflammation, (especially chronic) or in a tissue,
CC   an allergic response in a subject, exposure of a subject to a pathogen
CC   or sterile inflammatory disease, by contacting a tissue having
CC   inflammation with an agent that modulates the expression of gene(s)
CC   from Gs in the tissue. M1 is useful for detecting GCA; M2 is useful for
CC   modulating GA; M3 is useful for screening an agent capable of modulating
CC   GCA preferably in an inflammation in a tissue; M1 is useful for
```

```
CC   detecting an inflammation (especially chronic) in a tissue, an allergic
CC   response in a subject, exposure of a subject to a pathogen or sterile
CC   inflammatory disease (e.g. psoriasis, rheumatoid arthritis,
CC   glomerulonephritis, asthma, thrombosis, cardiac reperfusion injury, renal
CC   reperfusion injury, ARDS, adult respiratory distress syndrome,
CC   inflammatory bowel disease, Crohn's disease, ulcerative colitis,
CC   periodontal disease; also bacterial infection, viral infection,
CC   parasitic infection, protozoal infection, fungal infection and HIV is
CC   useful for treating one of the above conditions. The present
CC   sequence represents a gene differentially expressed in granulocytes.
CC   Note: The sequence data for this patent did not form part
CC   of the printed specification, but was obtained in electronic
CC   format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 1789 BP; 443 A; 488 C; 480 G; 378 T; 0 other;

  Query Match             100.0%;  Score 19;  DB 24;  Length [illegible];
  Best Local Similarity   100.0%;  Pred. No. 14;
  Matches   19;  Conservative    0;  Mismatches    [illegible];  Indels    [illegible];  Gaps    [illegible];

Qy          1 [illegible]GGAAGGAGGATGAACCCC 19
              |||||||||||||||||||
Db         [illegible] [illegible]GGAAGGAGGATGAACCCC [illegible]


RESULT [illegible]
AAK[illegible]
ID   AAK[illegible] standard; DNA; [illegible] BP.
XX
AC   AAK[illegible];
XX
DT   07-NOV-2001  (first entry)
XX
DE   Human immune/haematopoietic antigen genomic sequence SEQ ID NO:34469.
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW   cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS   Homo sapiens.
XX
PN   WO[illegible]A2.
XX
PD   [illegible]-AUG-2001.
XX
PF   1[illegible]-JAN-2001; 2001WO-US01354.
XX
PR   [illegible]-JAN-2000; 2000US-0179065.
PR   [illegible]-FEB-2000; 2000US-018[illegible].
PR   24-FEB-2000; 2000US-0184664.
PR   [illegible]-MAR-2000; 2000US-018[illegible].
PR   1[illegible]-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   [illegible]-MAY-2000; 2000US-0205515.
PR   [illegible]-JUN-2000; 2000US-020946[illegible].
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218[illegible].
PR   [illegible]-JUL-2000; 2000US-0220[illegible].
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-022526[illegible].
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-[illegible].
PR   14-AUG-2000; 2000US-[illegible].
PR   14-AUG-2000; 2000US-[illegible].
PR   14-AUG-2000; 2000US-[illegible].
PR   18-AUG-2000; 2000US-[illegible].
PR   22-AUG-2000; 2000US-[illegible].
PR   22-AUG-2000; 2000US-[illegible].
PR   22-AUG-2000; 2000US-[illegible].
PR   23-AUG-2000; 2000US-[illegible].
PR   30-AUG-2000; 2000US-[illegible].
PR   01-SEP-2000; 2000US-[illegible].
PR   01-SEP-2000; 2000US-[illegible].
PR   01-SEP-2000; 2000US-[illegible].
PR   01-SEP-2000; 2000US-[illegible].
PR   05-SEP-2000; 2000US-[illegible].
PR   05-SEP-2000; 2000US-[illegible].
PR   06-SEP-2000; 2000US-[illegible].
PR   06-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   12-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   21-SEP-2000; 2000US-[illegible].
PR   21-SEP-2000; 2000US-[illegible].
PR   25-SEP-2000; 2000US-[illegible].
PR   25-SEP-2000; 2000US-[illegible].
PR   26-SEP-2000; 2000US-[illegible].
PR   27-SEP-2000; 2000US-[illegible].
PR   27-SEP-2000; 2000US-[illegible].
PR   29-SEP-2000; 2000US-[illegible].
PR   29-SEP-2000; 2000US-[illegible].
PR   29-SEP-2000; 2000US-[illegible].
PR   29-SEP-2000; 2000US-[illegible].
PR   29-SEP-2000; 2000US-[illegible].
PR   02-OCT-2000; 2000US-[illegible].
PR   02-OCT-2000; 2000US-[illegible].
PR   02-OCT-2000; 2000US-[illegible].
PR   02-OCT-2000; 2000US-[illegible].
PR   02-OCT-2000; 2000US-[illegible].
PR   13-OCT-2000; 2000US-[illegible].
PR   13-OCT-2000; 2000US-[illegible].
PR   20-OCT-2000; 2000US-[illegible].
PR   20-OCT-2000; 2000US-[illegible].
PR   20-OCT-2000; 2000US-[illegible].
PR   20-OCT-2000; 2000US-[illegible].
PR   20-OCT-2000; 2000US-[illegible].
PR   20-OCT-2000; 2000US-[illegible].
PR   20-OCT-2000; 2000US-[illegible].
PR   20-OCT-2000; 2000US-[illegible].
PR   01-NOV-2000; 2000US-[illegible].
PR   08-NOV-2000; 2000US-[illegible].
PR   08-NOV-2000; 2000US-[illegible].
PR   08-NOV-2000; 2000US-[illegible].
PR   08-NOV-2000; 2000US-[illegible].
PR   08-NOV-2000; 2000US-[illegible].
PR   08-NOV-2000; 2000US-[illegible].
PR   08-NOV-2000; 2000US-[illegible].
PR   08-NOV-2000; 2000US-[illegible].
PR   08-NOV-2000; 2000US-[illegible].
PR   08-NOV-2000; 2000US-[illegible].
PR   08-NOV-2000; 2000US-[illegible].
```

PR 08-NOV-2000; 2000US-0246542.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 05-DEC-2000; 2000US-0250361.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254047.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis
XX
PS Disclosure; SEQ ID NO 3446; 307pp; English.
XX
CC AAK64521 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM84921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK82764 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 7191 BP; 2042 A; 1680 C; 1614 G; 1856 T; 0 other;

Query Match 89.5%; Score 17; DB 22; Length 7191;
Best Local Similarity 100.0%; Pred. No. 1.3e-02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GGAAGCAGGAGCAAGGT 18
||||||||||||||||||
Db 2727 GGAAGCAGGAGCAAGGT 2767

RESULT 6
AAK41695
ID AAK41695 standard; cDNA; 111 BP.
XX
AC AAK41695;
XX
DT 21-MAY-2002 (first entry)
XX
DE cDNA encoding novel human connective tissue related polypeptide SEQ
XX
KW Human; connective tissue related disorder; cancer; gene therapy;
KW cytostatic gene; SS.
XX
OS Homo sapiens.
XX
RN [2]
XX
RD 02-AUG-2001.
XX
RF 17-JAN-2001; 2001WO-US01422.
XX
PR 31-JAN-2000; 2000US-0179005.
PR 04-FEB-2000; 2000US-0180029.
PR 24-FEB-2000; 2000US-0184661.
PR 02-MAR-2000; 2000US-0186553.
PR 16-MAR-2000; 2000US-0189821.
PR 17-MAR-2000; 2000US-0190078.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215155.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217490.
PR 14-JUL-2000; 2000US-0218293.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224619.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225269.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226274.
PR 22-AUG-2000; 2000US-0226581.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227605.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229515.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.

PR 0[illegible] SEP 2000; 2000US-0231244.
PR 08 SEP 2000; 2000US-0231413.
PR 08 SEP 2000; 2000US-0231414.
PR [illegible] SEP 2000; 2000US-0232080.
PR [illegible] SEP 2000; 2000US-0232081.
PR 12 SEP 2000; 2000US-0231968.
PR 14 SEP 2000; 2000US-0232397.
PR 14 SEP 2000; 2000US-0232398.
PR 14 SEP 2000; 2000US-0232399.
PR 14 SEP 2000; 2000US-0232400.
PR 14 SEP 2000; 2000US-0232401.
PR 14 SEP 2000; 2000US-0233063.
PR 14 SEP 2000; 2000US-0233064.
PR 14 SEP 2000; 2000US-0233065.
PR 21 SEP 2000; 2000US-0234223.
PR 21 SEP 2000; 2000US-0234274.
PR 25 SEP 2000; 2000US-0234997.
PR 25 SEP 2000; 2000US-0234998.
PR 26 SEP 2000; 2000US-0235484.
PR 27 SEP 2000; 2000US-0235834.
PR 27 SEP 2000; 2000US-0235836.
PR 29 SEP 2000; 2000US-0236327.
PR 29 SEP 2000; 2000US-0236367.
PR 29 SEP 2000; 2000US-0236368.
PR 29 SEP 2000; 2000US-0236369.
PR 29 SEP 2000; 2000US-0236370.
PR 02 OCT 2000; 2000US-0236802.
PR 02 OCT 2000; 2000US-0237037.
PR 02 OCT 2000; 2000US-0237038.
PR 02 OCT 2000; 2000US-0237039.
PR 02 OCT 2000; 2000US-0237040.
PR 13 OCT 2000; 2000US-0239935.
PR 13 OCT 2000; 2000US-0239937.
PR 20 OCT 2000; 2000US-0240960.
PR 20 OCT 2000; 2000US-0241221.
PR 20 OCT 2000; 2000US-0241785.
PR 20 OCT 2000; 2000US-0241786.
PR 20 OCT 2000; 2000US-0241787.
PR 20 OCT 2000; 2000US-0241808.
PR 20 OCT 2000; 2000US-0241809.
PR 20 OCT 2000; 2000US-0241826.
PR 01 NOV 2000; 2000US-0244617.
PR 08 NOV 2000; 2000US-0246474.
PR 08 NOV 2000; 2000US-0246475.
PR 08 NOV 2000; 2000US-0246476.
PR 08 NOV 2000; 2000US-0246477.
PR 08 NOV 2000; 2000US-0246478.
PR 08 NOV 2000; 2000US-0246523.
PR 08 NOV 2000; 2000US-0246524.
PR 08 NOV 2000; 2000US-0246525.
PR 08 NOV 2000; 2000US-0246526.
PR 08 NOV 2000; 2000US-0246527.
PR 08 NOV 2000; 2000US-0246528.
PR 08 NOV 2000; 2000US-0246532.
PR 08 NOV 2000; 2000US-0246609.
PR 08 NOV 2000; 2000US-0246610.
PR 08 NOV 2000; 2000US-0246611.
PR 08 NOV 2000; 2000US-0246613.
PR 17 NOV 2000; 2000US-0249207.
PR 17 NOV 2000; 2000US-0249208.
PR 17 NOV 2000; 2000US-0249209.
PR 17 NOV 2000; 2000US-0249210.
PR 17 NOV 2000; 2000US-0249211.
PR 17 NOV 2000; 2000US-0249212.
PR 17 NOV 2000; 2000US-0249213.
PR 17 NOV 2000; 2000US-0249214.
PR 17 NOV 2000; 2000US-0249215.
PR 17 NOV 2000; 2000US-0249216.
PR 17 NOV 2000; 2000US-0249217.
PR 17 NOV 2000; 2000US-0249218.
PR 17 NOV 2000; 2000US-0249244.
PR 17 NOV 2000; 2000US-0249245.
PR 17 NOV 2000; 2000US-0249264.
PR 17 NOV 2000; 2000US-[illegible].
PR 17 NOV 2000; 2000US-[illegible].
PR 17 NOV 2000; 2000US-[illegible].
PR 17 NOV 2000; 2000US-[illegible].
PR 01 DEC 2000; 2000US-[illegible].
PR 01 DEC 2000; 2000US-[illegible].
PR 0[illegible] DEC 2000; 2000US-[illegible].
PR 05 DEC 2000; 2000US-[illegible].
PR 05 DEC 2000; 2000US-[illegible].
PR 06 DEC 2000; 2000US-[illegible].
PR 08 DEC 2000; 2000US-[illegible].
PR 08 DEC 2000; 2000US-[illegible].
PR 08 DEC 2000; 2000US-[illegible].
PR 08 DEC 2000; 2000US-[illegible].
PR 08 DEC 2000; 2000US-[illegible].
PR 11 DEC 2000; 2000US-[illegible].
PR 05 JAN 2001; 2001US-[illegible].
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, [illegible]
XX
DR WPI; [illegible]
DR P-PSDB; AAB[illegible]
XX
PT Nucleic acid encoding novel connective tissue associated [illegible]
PT used in diagnosis, prevention, treatment or amelioration [illegible]
PT such as cancer [illegible]
XX
PS Claim [illegible]; SEQ ID NO [illegible]; English.
XX
CC The present invention relates to the [illegible]
CC tissue related polypeptides (AA[illegible]) and the [illegible]
CC (cDNA and genomic) sequences encoding them. The sequences [illegible]
CC invention are useful in the diagnosis, treatment, prevention [illegible]
CC prognosis of diseases associated with connective tissue(s), [illegible]
CC cancer. The polynucleotide sequences of the invention are [illegible]
CC in gene therapy. ABK41613-ABK12101 represent cDNA sequences [illegible]
CC the novel human connective tissue related polypeptides.
CC Note: The sequence data for this patent did not form part of the [illegible]
CC specification, but was obtained in electronic format directly [illegible]
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence [illegible] BP; [illegible] other;

Query Match [illegible]; Score [illegible]; DB [illegible]; Length [illegible];
Best Local Similarity [illegible]; Pred. No. [illegible];
Matches [illegible]; Conservative [illegible]; Mismatches [illegible]; Indels [illegible]; Gaps [illegible];

Qy [illegible] GGAAGGAGGATGAAC[illegible]
Db [illegible] GGAAGGAGGATGAA[illegible]

RESULT 7
ABK4[illegible]
ID ABK1[illegible] standard; DNA; [illegible] BP.
XX
AC ABK1[illegible];
XX
DT 21 MAY 2002 (first entry)
XX
DE Genomic sequence #[illegible] encoding novel human connective tissue [illegible]
XX
KW Human; [illegible]
KW cytostatic; gene; [illegible]
XX
OS Homo sapiens.
XX
PN WO200[illegible]-A1.
XX
PD [illegible] AUG 200[illegible].
XX

PR 27-JAN-2001; 2001WO-US01422.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 17-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 10-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 13-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226808.
PR 22-AUG-2000; 2000US-0227182.
PR 25-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230427.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 06-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.

PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236862.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0238645.
PR 13-OCT-2000; 2000US-0238647.
PR 20-OCT-2000; 2000US-0240660.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241829.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246615.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249301.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250491.
PR 05-DEC-2000; 2000US-0251040.
PR 05-DEC-2000; 2000US-0251088.
PR 05-DEC-2000; 2000US-0251219.
PR 06-DEC-2000; 2000US-0251477.
PR 08-DEC-2000; 2000US-0251865.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251885.
PR 08-DEC-2000; 2000US-0251899.
PR 11-DEC-2000; 2000US-0254057.
PR 05-JAN-2001; 2001US-0259078.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA; Barash SC; Ruben SM;
XX
DR WPI; 2001-565100/63.
XX
PT Nucleic acid encoding novel connective tissue associated protein-like

```
PT   used in diagnosing, preventing, treating or ameliorating a disorder
PT   such as cancer or rheumatoid arthritis
XX
PS   Disclosure; SEQ ID No 1143; 673pp; English.
XX
CC   The present invention relates to the isolation of novel human connective
CC   tissue related polypeptides (AAU86435-AAU8[illegible]) and the polynucleotide
CC   (cDNA and genomic) sequences encoding them. The sequences of the
CC   invention are useful in the diagnosis, treatment, prevention and/or
CC   prognosis of diseases associated with connective tissue(s), including
CC   cancer. The polynucleotide sequences of the invention are also useful
CC   in gene therapy. ABK42102-ABK43116 represent genomic sequences encoding
CC   the novel human connective tissue related polypeptides.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 1049 BP; 305 A; 201 C; 231 G; 312 T; 0 other;

  Query Match             86.9%;  Score 16.4;  DB [illegible];  Length [illegible];
  Best Local Similarity   94.4%;  Pred. No. [illegible];
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 GGGAAGGAGGATGAACCC 18
              || |||||||||||||||
Db        239 GGCAAGGAGGATGAACCC 256


RESULT 8
AAS07195
ID   AAS07195 standard; cDNA; 2134 BP.
XX
AC   AAS07195;
XX
DT   23-OCT-2001  (first entry)
XX
DE   DNA encoding zebra 2, beta-carotene dioxygenase (beta diox II).
XX
KW   Beta carotene dioxygenase; beta diox II; zebra 2; beta carotene;
KW   lycopene; beta apocarotenal; beta ionone; apolycopenal; grain seed; corn;
KW   oil seed; palm; chick-pea; diagnostic; therapeutic; ribozyme; zebrafish;
KW   retinoid/vitamin A deficiency; beta diox II; transgenic; nutrition;
KW   carotene/retinoid pathway; vitamin A aldehyde; retinoic acid; ss.
XX
OS   Brachydanio rerio.
XX
FH   Key             Location/Qualifiers
FT   CDS             29..1678
FT                   /*tag=  a
FT                   /product= "Zebra 2"
FT                   /note= "Beta-carotene dioxygenase (beta diox II)"
XX
PN   WO200118163-A2.
XX
PD   15-MAR-2001.
XX
PF   27-SEP-2000; 2000WO-EP13273.
XX
PR   21-SEP-1999;   99EP-0120605.
PR   2-MAR-2000; 2000EP-0104822.
XX
PA   (GREE-) GREENOVATION PFLANZENBIOTECHNOLOGIE GMBH.
XX
PI   Von Lintig J,  Vogt K;
XX
DR   WPI; 2001-425657/45.
DR   P-PSDB; AAU04293.
XX
PT   Novel isolated mouse, human, zebrafish beta carotene dioxygenase
PT   (beta diox II) protein that cleaves beta-carotene and lycopene to yield
PT   beta apocarotenal and beta ionone, and apolycopenals, respectively
XX
PS   Claim 8; Page 106-109; 116pp; English.
XX
CC   The sequence represents the coding sequence of zebra 2, beta carotene
CC   dioxygenase (beta diox II). Beta diox specifically cleaves beta carotene
CC   and lycopene to form beta apocarotenal and beta ionone, and
CC   apolycopenals, respectively. The DNA is useful for transforming [illegible]
CC   seeds, e.g. corn; oil seeds, e.g. Brassica seeds; edible seeds [illegible]
CC   edible seeds or seeds with edible parts e.g. chick peas; potatoes,
CC   carrots, sweet potatoes, sugar beets, tomato. The polypeptide is useful
CC   for diagnostic and/or therapeutic purposes and for preparation of [illegible]
CC   ribozyme type therapeutic agents and for detecting and [illegible]
CC   endogenous beta diox II. The beta diox II specific antisense
CC   oligonucleotides derived from the DNA sequence are useful for [illegible]
CC   response studies in relevant models of retinoid/vitamin A deficiency
CC   during any stage of an organism's development. The [illegible]
CC   useful as probes and as a guideline to define new PCR (polymerase chain
CC   reaction) primers for the cloning of substantially homologous DNA
CC   sequences from other sources. The nucleic acids are also useful for
CC   determining the presence or quantity of beta diox II nucleic acid and
CC   determining presence and amount of beta diox II. The polypeptide is
CC   useful for increasing or decreasing the amount of beta [illegible]
CC   a cell or tissue which can modify the level of vitamin A and other
CC   retinoids. Antibodies are useful for studying beta diox II [illegible]
CC   screening of an expression library to identify [illegible]
CC   beta diox II or the structure of functional domains. The [illegible]
CC   fungi, yeast, insect, animal or plant cells, seeds, tissues [illegible]
CC   organisms have improved nutritional quality or physiological [illegible]
CC   and accumulate important metabolites of carotene/retinoid pathway such
CC   as vitamin A aldehyde and retinoic acid, beta carotene or [illegible]
CC   carotene from the medium. Expression systems encoding beta [illegible]
CC   useful in the study of beta diox II activity. Identification of DNA
CC   encoding beta diox I and II allows the physiological characterisation of
CC   mammalian carotene/retinoid metabolism. Vitamin A [illegible]
CC   microorganisms can be achieved by transforming the [illegible]
CC   with the cDNA..
XX
SQ   Sequence 2134 BP; 627 A; 419 C; 411 G; [illegible] T; 0 other;

  Query Match             86.9%;  Score 16.4;  DB 22;  Length 2134;
  Best Local Similarity   94.4%;  Pred. No. [illegible];
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 GGGAAGGAGGATGAACCC 18
              || |||||||||||||||
Db       1187 GGCAAGGAGGATGAACCC [illegible]


RESULT 9
AAV05199
ID   AAV05199 standard; DNA; [illegible] BP.
XX
AC   AAV05199;
XX
DT   25-JUN-1998  (first entry)
XX
DE   Mouse beta4 globin gene.
XX
KW   Butyrophilin; btn gene; promoter; mouse; transgenic animal;
KW   mammary gland specific gene expression; breast cancer; disease;
KW   ds.
XX
OS   Mus musculus.
XX
FH   Key             Location/Qualifiers
FT   promoter        1..[illegible]
FT                   /*tag= a
FT                   /note= "Region I"
FT   TATA signal     [illegible]
FT                   /*tag= b
FT   prim_transcript [illegible]
FT                   /*tag= c
FT                   /evidence= EXPERIMENTAL
FT                   /standard_name= "transcription start site"
FT                   /note= "most frequently used site"
```

```
FT   misc_signal      4645..4651
FT                    /*tag= d
FT                    /note= "AT-rich, TATAA-like element"
FT   misc_signal      4584..4588
FT                    /*tag= e
FT                    /note= "AT-rich, TATAA-like element"
FT   misc_signal      4597..4603
FT                    /*tag= f
FT                    /note= "GCAAT-like element"
FT   misc_signal      4546..4551
FT                    /*tag= g
FT                    /note= "GCAAT-like element"
FT   misc_signal      4533..4547
FT                    /*tag= h
FT                    /note= "GCAAT-like element"
FT   prim_transcript  4675
FT                    /*tag= i
FT                    /evidence= EXPERIMENTAL
FT                    /standard_name= transcription start site
FT   prim_transcript  4694
FT                    /*tag= j
FT                    /evidence= EXPERIMENTAL
FT                    /standard_name= transcription start site
FT   polyA_signal     14091..14096
FT                    /*tag= k
FT                    /evidence= EXPERIMENTAL
FT   prim_transcript  14097..14199
FT                    /*tag= l
FT                    /evidence= EXPERIMENTAL
FT                    /standard_name= "3' end of transcript
FT   UTR              4923..11497
FT                    /*tag= m
FT                    /evidence= EXPERIMENTAL
FT                    /note= "contains introns"
FT   sig_peptide      4923..5001
FT                    /*tag= n
FT   CDS              4650..4651
FT                    /*tag= o
FT                    /evidence= EXPERIMENTAL
FT                    /standard_name= translational initiation codon
FT   CDS              4743..4745
FT                    /*tag= p
FT                    /evidence= EXPERIMENTAL
FT                    /standard_name= translational initiation codon
FT   CDS              4765..4767
FT                    /*tag= q
FT                    /evidence= EXPERIMENTAL
FT                    /standard_name= translational initiation codon
FT   CDS              4776..4778
FT                    /*tag= r
FT                    /evidence= EXPERIMENTAL
FT                    /standard_name= translational initiation codon
FT   exon             4611..5001
FT                    /*tag= s
FT                    /codon_start= 4923..4925
FT                    /number= 1
FT   intron           5002..5520
FT                    /*tag= t
FT                    /evidence= EXPERIMENTAL
FT                    /number= A
FT   exon             5521..5871
FT                    /*tag= u
FT                    /number= 2
FT   intron           5872..8332
FT                    /*tag= v
FT                    /evidence= EXPERIMENTAL
FT                    /number= B
FT   exon             8333..8614
FT                    /*tag= w
FT                    /number= 3
FT   intron           8615..9485
FT                    /*tag= x
FT                    /evidence= EXPERIMENTAL
FT                    /number= C
FT   exon             9486..9666
FT                    /*tag= y
FT                    /number= 4
FT   intron           9667..10225
FT                    /*tag= z
FT                    /evidence= EXPERIMENTAL
FT                    /number= D
FT   exon             10226..10427
FT                    /*tag= aa
FT                    /number= 5
FT   intron           10428..10520
FT                    /*tag= ab
FT                    /evidence= EXPERIMENTAL
FT                    /number= E
FT   exon             10521..10617
FT                    /*tag= ac
FT                    /number= 6
FT   intron           10618..10738
FT                    /*tag= ad
FT                    /evidence= EXPERIMENTAL
FT                    /number= F
FT   exon             10739..11509
FT                    /*tag= ae
FT                    /number= 7
FT   repeat_unit      4607..4814
FT                    /*tag= a1
FT                    /rpt_type= INVERTED
FT   repeat_unit      12556..12563
FT                    /*tag= a2
FT                    /rpt_type= INVERTED
FT   protein_bind     2949..2959
FT                    /*tag= a3
FT                    /note= "NF1"
FT   protein_bind     complement (2971..2979)
FT                    /*tag= a4
FT                    /note= "gamma IRE"
FT   protein_bind     complement (3011..3017)
FT                    /*tag= a5
FT                    /note= "MYE"
FT   protein_bind     complement (3058..3068)
FT                    /*tag= ak
FT                    /note= "YY1"
FT   protein_bind     complement (<113..<136)
FT                    /*tag= a6
FT                    /note= "gamma-IRE"
FT   protein_bind     142..<150
FT                    /*tag= a6
FT                    /note= "YY1"
FT   protein_bind     152..<176
FT                    /*tag= a7
FT                    /note= "NF1"
FT   protein_bind     198..<210
FT                    /*tag= a8
FT                    /note= "STAT"
FT   protein_bind     complement (<135..<150)
FT                    /*tag= a9
FT                    /note= "SMAD"
FT   protein_bind     <181..<209
FT                    /*tag= a9
FT                    /note= "SP/GC"
FT   protein_bind     complement (<187..<197)
FT                    /*tag= a1
FT                    /note= "SP/GC"
FT   protein_bind     <196..<205
FT                    /*tag= a8
FT                    /note= "ETF"
FT   protein_bind     complement (<164..242)
FT                    /*tag= a1
FT                    /note= "alpha IFN"
FT   protein_bind     <195..<205
FT                    /*tag= a6
FT                    /note= "SMAD"
```

```
FT   protein_bind    3253..3259
FT                   /*tag= az
FT                   /note= "gamma IRE"
FT   protein_bind    3370..3378
FT                   /*tag= aw
FT                   /note= "GRE"
FT   protein_bind    complement (3397..3406)
FT                   /*tag= ax
FT                   /note= "GRE"
FT   protein_bind    complement (3399..3405)
FT                   /*tag= ay
FT                   /note= "gamma IRE"
FT   protein_bind    3416..3422
FT                   /*tag= az
FT                   /note= "STAT"
FT   protein_bind    3439..3445
FT                   /*tag= ba
FT                   /note= "gamma IRE"
FT   protein_bind    3450..3454
FT                   /*tag= bb
FT                   /note= "GMCSF"
FT   protein_bind    3456..3462
FT                   /*tag= bc
FT                   /note= "STAT"
FT   protein_bind    3457..3463
FT                   /*tag= bd
FT                   /note= "Y/EBF"
FT   protein_bind    complement (3464..3468)
FT                   /*tag= be

  Query Match             86.3%;  Score 16.4;  DB 19;  Length 11190;
  Best Local Similarity   94.4%;  Pred. No. 2.[illegible];
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    [illegible];  Gaps    0;

Qy          1 [illegible]GAAGGAGGATGAACC[illegible] 18
              ||| ||||||||||||||
Db       4[illegible] [illegible]GGAGGAGGATGAACC[illegible] 410[illegible]


RESULT [illegible]
AAV84692
ID   AAV84692 standard; cDNA; 631 BP.
XX
AC   AAV84692;
XX
DT   12 APR 1999  (first entry)
XX
DE   Rice EST showing homology to Arabidopsis ESD4 gene.
XX
KW   ESD4 gene; early short days 4; flowering; transgenic plant; rice;
KW   ss.
XX
OS   Oryza sativa.
XX
FH   Key             Location/Qualifiers
FT   [illegible]             [illegible]..629
FT                   /*tag= a
XX
PN   W[illegible]AI.
XX
PD   [illegible] 1998.
XX
PF   12-JUN-1998;   98WO-GB01714.
XX
PR   1[illegible]-JUN-1997;   97GB-0012415.
XX
PA   (PLAN-) PLANT BIOSCIENCE LTD.
XX
PI   [illegible] and GM;
XX
DR   WPI; 1999-070324/06.
DR   P-PSDB; AAW86185.
XX
```

```
PT   New nucleic acid of the Arabidopsis thaliana ESD4 gene [illegible]
PT   regulating flowering time in plants
XX
PS   Example [illegible]
XX
CC   This is the [illegible]
CC   clone isolated from the GenBank database [illegible]
CC   to the [illegible] terminal region of the new early short days 4 (ESD4) gene
CC   (see V[illegible]) [illegible] Arabidopsis thaliana [illegible]
CC   in genes from [illegible] elegans, humans (see V[illegible]) [illegible]
CC   residues shared by the encoded proteins (see W[illegible]) [illegible]
CC   a functional domain [illegible] the protein. [illegible] ESD4 gene
CC   expression can be used to regulate flowering time in [illegible]
CC   plants.
XX
SQ   Sequence 631 BP; [illegible] A; [illegible] other;

  Query Match             [illegible]
  Best Local Similarity   [illegible];  Pred. No. [illegible];
  Matches   [illegible];  Conservative  [illegible];  Mismatches  [illegible];  Indels  [illegible];  Gaps  [illegible];

Qy          [illegible]
              [illegible]
Db        52 [illegible]GAAGGAGGATGAA[illegible]


RESULT [illegible]
AAK[illegible]
ID   AAK[illegible] standard; DNA; [illegible] BP.
XX
AC   AAK[illegible];
XX
DT   [illegible] NOV 2001  (first entry)
XX
DE   Human immune/haematopoietic antigen genomic sequence SEQ ID N[illegible]
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; [illegible]
KW   cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS   Homo sapiens.
XX
PN   WO200[illegible]A.
XX
PD   [illegible] AUG [illegible]
XX
PF   17 JAN 2001; 2001WO-[illegible].
XX
PR   31 JAN 2000; 2000US-0179065.
PR   04 FEB 2000; 2000US-0180[illegible].
PR   24 FEB 2000; 2000US-0184[illegible].
PR   02 MAR 2000; 2000US-0186350.
PR   16 MAR 2000; 2000US-0189[illegible].
PR   17 MAR 2000; 2000US-0190[illegible].
PR   18 APR 2000; 2000US-0198123.
PR   19 MAY 2000; 2000US-0205[illegible].
PR   07 JUN 2000; 2000US-0209[illegible].
PR   28 JUN 2000; 2000US-0211[illegible].
PR   30 JUN 2000; 2000US-0215[illegible].
PR   07 JUL 2000; 2000US-0216[illegible].
PR   [illegible] JUL 2000; 2000US-[illegible].
PR   11 JUL 2000; 2000US-[illegible].
PR   11 JUL 2000; 2000US-0217[illegible].
PR   14 JUL 2000; 2000US-[illegible].
PR   26 JUL 2000; 2000US-[illegible].
PR   26 JUL 2000; 2000US-0220[illegible].
PR   14 AUG 2000; 2000US-0224[illegible].
PR   14 AUG 2000; 2000US-0225[illegible].
PR   14 AUG 2000; 2000US-0225[illegible].
PR   14 AUG 2000; 2000US-0225[illegible].
PR   14 AUG 2000; 2000US-0225[illegible].
PR   14 AUG 2000; 2000US-0225[illegible].
PR   14 AUG 2000; 2000US-0225[illegible].
PR   14 AUG 2000; 2000US-0225[illegible].
```

PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 25-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236927.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246542.
PR 08-NOV-2000; 2000US-0246664.
PR 08-NOV-2000; 2000US-0246665.
PR 08-NOV-2000; 2000US-0246671.
PR 08-NOV-2000; 2000US-0246715.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249241.
PR 17-NOV-2000; 2000US-0249243.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249267.
PR 17-NOV-2000; 2000US-0249269.
PR 17-NOV-2000; 2000US-0249270.
PR 01-DEC-2000; 2000US-0250760.
PR 04-DEC-2000; 2000US-0250971.
PR 05-DEC-2000; 2000US-0251057.
PR 05-DEC-2000; 2000US-0251088.
PR 05-DEC-2000; 2000US-0251219.
PR 06-DEC-2000; 2000US-0251424.
PR 08-DEC-2000; 2000US-0251866.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251889.
PR 08-DEC-2000; 2000US-0251891.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0256728.
XX
PA (HUMA) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-454626/52.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis
XX
PS Disclosure; SEQ ID NO 20112; 507pp; English.
XX
CC AAK54251 to AAK54762 encode the human immune/hematopoietic antigen
CC amino acid sequences given in AAM82170 to AAM82681. (1) have use in the
CC activity, and can be used in gene therapy and vaccine production. (2)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (1) expression. For
CC example, they may be used to treat disorders associated with a reduced
CC expression by identifying mutations or deletions in a patient's gene
CC that affect the activity of (1) by expressing inactive protein or
CC supplement the patient's own production of (1). Additionally, the
CC polynucleotides may be used to produce the secreted (1), by introducing
CC the nucleic acids into a host cell and culturing the cell. Expression of
CC protein. (1) proteins and polynucleotides may be used to produce
CC diagnose and treat immune/haematopoietic related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK82682
CC to AAK82694 represent human immune/haematopoietic antigen polypeptide
CC sequences from the present invention. AAK54242 to AAK54250 and AAM82695
CC represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 2291 BP; 622 A; 465 C; 525 G; 680 T; 0 other;

Query Match 81.2%; Score 16; DB 22; Length 2291;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        [illegible] TGAAGGAGGATGAAC 1[illegible]
                [illegible]
Db     1[illegible] TGAAGGAGGATGAAC 18[illegible]


RESULT [illegible]
ABN[illegible]
ID   ABN[illegible] standard; cDNA; [illegible] BP.
XX
AC   ABN[illegible];
XX
DT   24 JUN 2002  (first entry)
XX
DE   Human ORFX polynucleotide sequence SEQ ID NO:[illegible].
XX
KW   Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
KW   hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
KW   degenerative disorder; osteoarthritis; neurodegenerative disorder;
KW   cardiovascular disease, diabetes mellitus, systemic lupus erythematosus;
KW   hypertension; hypothyroidism; cholesterol ester storage disease;
KW   immune deficiency; immune disorder; infectious disease;
KW   autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
KW   myasthenia gravis; gene; ss.
XX
OS   Homo sapiens.
XX
PN   WO[illegible]92523 A2.
XX
PD   [illegible] DEC 2001.
XX
PF   [illegible] MAY 2001; 2001WO-US1[illegible].
XX
PR   [illegible] MAY 2000; 2000US-[illegible].
PR   [illegible] AUG 2000; 2000US-2287[illegible]P.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Chirk[illegible]s RA, Leach MD;
XX
DR   WPI; 2002-106308/14.
DR   P-PSDB; ABP07414.
XX
PT   Novel human polypeptides and polynucleotides useful for diagnosing,
PT   preventing and treating cardiovascular disease, neurodegenerative,
PT   hyperproliferative disorders and autoimmune disorders
XX
PS   Disclosure; SEQ ID 14809; 1037pp; English.
XX
CC   The present invention describes substantially purified human proteins
CC   (referred to as open reading frame, ORFX, where X is 1-[illegible] (see table 1
CC   in the specification). ABN1[illegible]762 to ABN2[illegible], encode the human ORFX
CC   proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
CC   treating or preventing a pathology associated with an ORFX associated
CC   disorder in humans, and in the manufacture of a medicament for treating a
CC   syndrome associated with ORFX associated disorder. ORFX polynucleotide
CC   sequences can be used in gene therapy. ORFX sequences can be used in the
CC   treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
CC   psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
CC   osteoarthritis, neurodegenerative disorders, disorders related to organ
CC   transplantation, cardiovascular diseases, diabetes mellitus, systemic
CC   lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
CC   storage disease, various immune deficiencies and disorders, infectious
CC   diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
CC   arthritis, autoimmune thyroiditis, myasthenia gravis, graft versus host
CC   disease and autoimmune inflammatory eye disease. ORFX proteins are also
CC   useful for treating burns, incisions, ulcers, for treating osteoporosis,
CC   bone degenerative disorders, or periodontal disease, and for nerve
CC   protection or regeneration and treatment of lung or liver fibrosis,
CC   reperfusion injury in various tissues and conditions resulting from
CC   systemic cytokine damage.
CC   N.B. The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
```

```
CC   at [illegible]
XX
SQ   Sequence [illegible] BP; [illegible] A; [illegible] other;

  Query Match             [illegible];  Score [illegible];  DB 2[illegible];  Length [illegible];
  Best Local Similarity   [illegible];  Pred. No. [illegible];
  Matches   1[illegible];  Conservative  [illegible];  Mismatches  [illegible];  Indels  [illegible];  Gaps  [illegible];

Qy        1 GGAAGGAGGATGAAC[illegible] 1[illegible]
              [illegible]
Db      [illegible] GGAAGGAGGATGAAC[illegible]


RESULT 1[illegible]
AAI8[illegible]
ID   AAI8[illegible] standard; cDNA; [illegible] BP.
XX
AC   AAI8[illegible];
XX
DT   06 NOV 2001  (first entry)
XX
DE   Human polynucleotide SEQ ID NO [illegible]745.
XX
KW   Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW   vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW   tissue growth factor; immunomodulator; cancer; leukaemia;
KW   nervous system disorder; arthritis; inflammation; ss.
XX
OS   Homo sapiens.
XX
PN   WO[illegible] A[illegible].
XX
PD   07 SEP 2001.
XX
PF   26 FEB 2001; 2001WO-[illegible].
XX
PR   28 FEB [illegible].
PR   18 MAY 2000; 2000US-[illegible].
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT, [illegible];
XX
DR   WPI; 2001-[illegible].
DR   P-PSDB; AA[illegible].
XX
PT   Isolated nucleic acids and polypeptides, useful for preventing,
PT   diagnosing and treating e.g. leukemia, inflammation and immune
PT   disorders
XX
PS   Claim 1; SEQ ID NO [illegible]; [illegible]pp; [illegible]; English.
XX
CC   The invention relates to human polynucleotides (AAI7[illegible] - AA[illegible]) and
CC   the encoded proteins (AA[illegible] - AA[illegible]) that exhibit activity as [illegible]
CC   cytokines, cell proliferation or cell differentiation or which induce
CC   production of other cytokines in other cell populations. The
CC   polynucleotides and polypeptides are useful in gene therapy [illegible]
CC   peptide therapy. The polypeptides have various cytokine-like [illegible]
CC   e.g. stem cell growth factor activity, haematopoiesis regulating
CC   activity, tissue growth factor activity, immunomodulatory [illegible] and
CC   activin/inhibin activity, and may be useful in the diagnosis [illegible]
CC   treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC   inflammation.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at [illegible]
XX
SQ   Sequence [illegible] BP; [illegible] A; [illegible] other;

  Query Match             [illegible];  Score [illegible];  DB 22;  Length [illegible];
  Best Local Similarity   [illegible];  Pred. No. 4[illegible];
  Matches  1[illegible];  Conservative  [illegible];  Mismatches  [illegible];  Indels  [illegible];  Gaps  [illegible];
```

```
Qy          1 GGGAAGGAGGATGAACCCC 19
              ||||||| ||| |||||||
Db        173 GGGAAGGGGGAAGAACCCC 191


RESULT 14
AAK88550
ID   AAK88550 standard; cDNA; 489 BP.
XX
AC   AAK88550;
XX
DT   05-NOV-2001  (first entry)
XX
DE   Human digestive system antigen coding sequence SEQ ID NO: 866.
XX
KW   Human; digestive system antigen; gene therapy; cancer; appendicitis;
KW   ulcerative colitis; infection; Hirschsprung's disease; chronic colitis;
KW   digestive system disorder; Meckel's diverticulum; ss.
XX
OS   Homo sapiens.
XX
PN   WO200155414 A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01424.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186850.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218299.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   23-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227099.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231243.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231410.
PR   08-SEP-2000; 2000US-0231411.
PR   08-SEP-2000; 2000US-0232080.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231668.
PR   14-SEP-2000; 2000US-0232507.
PR   14-SEP-2000; 2000US-0232508.
PR   14-SEP-2000; 2000US-0232509.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0233062.
PR   14-SEP-2000; 2000US-0233063.
PR   14-SEP-2000; 2000US-0233065.
PR   21-SEP-2000; 2000US-0234225.
PR   21-SEP-2000; 2000US-0234274.
PR   25-SEP-2000; 2000US-0234997.
PR   25-SEP-2000; 2000US-0234998.
PR   26-SEP-2000; 2000US-0235484.
PR   27-SEP-2000; 2000US-0235834.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236327.
PR   29-SEP-2000; 2000US-0236367.
PR   29-SEP-2000; 2000US-0236368.
PR   29-SEP-2000; 2000US-0236464.
PR   29-SEP-2000; 2000US-0236470.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237137.
PR   02-OCT-2000; 2000US-0237138.
PR   02-OCT-2000; 2000US-0237139.
PR   02-OCT-2000; 2000US-0237140.
PR   13-OCT-2000; 2000US-0240965.
PR   13-OCT-2000; 2000US-0240967.
PR   20-OCT-2000; 2000US-0241220.
PR   20-OCT-2000; 2000US-0241221.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-0246609.
PR   08-NOV-2000; 2000US-0246610.
PR   08-NOV-2000; 2000US-0246611.
PR   08-NOV-2000; 2000US-0246613.
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
PR   17-NOV-2000; 2000US-0249215.
PR   17-NOV-2000; 2000US-0249216.
PR   17-NOV-2000; 2000US-0249217.
PR   17-NOV-2000; 2000US-0249218.
PR   17-NOV-2000; 2000US-0249244.
PR   17-NOV-2000; 2000US-0249245.
PR   17-NOV-2000; 2000US-0249264.
```

```
PR   1? NOV 2000; 2000US-0249265.
PR   1? NOV 2000; 2000US-0249297.
PR   1? NOV 2000; 2000US-0249299.
PR   1? NOV 2000; 2000US-0249300.
PR   01 DEC 2000; 2000US-0250160.
PR   01 DEC 2000; 2000US-0250391.
PR   05 DEC 2000; 2000US-0251030.
PR   0? DEC 2000; 2000US-0251988.
PR   0? DEC 2000; 2000US-0256719.
PR   0? DEC 2000; 2000US-0251479.
PR   08 DEC 2000; 2000US-0251856.
PR   08 DEC 2000; 2000US-0251868.
PR   08 DEC 2000; 2000US-0251869.
PR   08 DEC 2000; 2000US-0251989.
PR   08 DEC 2000; 2000US-0251990.
PR   11 DEC 2000; 2000US-0254097.
PR   0? JAN 2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA, Barash SC, Ruben SM;
XX
DR   WPI; 2001-502630/55.
DR   P-PSDB; AAM92777.
XX
PT   Polynucleotides encoding digestive system antigens, used e.g. for
PT   diagnosing, treating, preventing and/or prognosing disorders of the
PT   digestive system, particularly cancer and cancer metastases -
XX
PS   Claim 1; SEQ ID NO 866; 980pp; English.
XX
CC   The present invention provides the protein and coding sequences of a
CC   number of human digestive system antigens. These can be used in the
CC   diagnosis, treatment and prevention of digestive system disorders,
CC   including cancer, Meckel's diverticulum, bacterial or parasitic
CC   infections, appendicitis, Hirschsprung's disease, chronic colitis or
CC   ulcerative colitis. The present sequence is a cDNA encoding a digestive
CC   system antigen of the invention.
XX
SQ   Sequence 489 BP; 126 A; 133 C; 93 G; 133 T; 4 other;

  Query Match             83.2%;  Score 15.8;  DB 22;  Length 489;
  Best Local Similarity   8?.?%;  Pred. No. 4.??e+02;
  Matches   17;  Conservative    [illegible];  Mismatches   [illegible];  Indels   [illegible];  Gaps   [illegible];

Qy          1 GGGAAGGAGGATGAACCCC 19
                ||||||||| ||| ||||
Db        2?? GGGAAGGAGAATGGACCCC 2??


RESULT 15
ABQ54458/c
ID   ABQ54458 standard; cDNA; 607 BP.
XX
AC   ABQ54458;
XX
DT   ?? APR 2002  (first entry)
XX
DE   Human ovarian antigen HOEEP16 cDNA, SEQ ID NO:[illegible].
XX
KW   Human; ovarian antigen; ovary; ovarian; breast; cancer; tumour;
KW   ovarian cancer; breast cancer; tumour; reproductive system disorder;
KW   infertility; pregnancy disorder; anovulation; polycystic ovary syndrome;
KW   PCOS; ovarian cyst; dysmenorrhoea; endocrine disorder; infection;
KW   inflammatory condition; immune disorder; blood disorder;
KW   cardiovascular disorder; respiratory disorder; neural disorder;
KW   gastrointestinal disorder; urinary system disorder; drug screening;
KW   gene therapy; chromosome mapping; forensic analysis;
KW   antibody preparation; cytostatic; immunomodulator; neuroprotective;
KW   antiinflammatory; gynaecological; reproductive; gene; ss.
XX
OS   Homo sapiens.
XX
PN   WO200200??7-A1.
XX
PD   03-JAN-2002.
XX
PF   07-JUN-2001; 2001WO-US18066.
XX
PR   07-JUN-2000; 2000US-[illegible].
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben CE, Rosen CA;
XX
DR   WPI; 2002-[illegible]/1?.
DR   P-PSDB; ABP[illegible].
XX
PT   Isolated nucleic acid molecules encoding ovarian antigen polypeptides,
PT   useful in the prevention, treatment and diagnosis of cancer (e.g.
PT   ovarian cancer), immune disorders, cardiovascular disorders and
PT   neurological diseases -
XX
PS   Claim 1; SEQ ID NO [illegible]; [illegible]pp; English.
XX
CC   The invention relates to 2?? novel human ovarian antigens (ABP[illegible] -
CC   ABP43228) and to cDNAs encoding them (ABQ5[illegible] - ABQ5[illegible]). The invention
CC   encompasses polypeptides 90% identical and polynucleotides 95% identical
CC   to the sequences of the invention. The invention additionally relates to
CC   recombinant vectors and host cells comprising human ovarian antigen
CC   polynucleotides, antibodies against human ovarian antigens, and the use
CC   of ovarian antigen polynucleotides and polypeptides in diagnosis, in
CC   treating, prognosing or preventing ovary and/or breast related
CC   disorders. Such conditions include ovarian cancer and breast cancer and
CC   metastatic tumours of ovarian or breast origin, reproductive system
CC   disorders (e.g., infertility, disorders of pregnancy, anovulation,
CC   polycystic ovary syndrome, ovarian cysts, and dysmenorrhoea), endocrine
CC   disorders, infections (e.g., chlamydia, HIV, toxoplasmosis, and toxic
CC   shock syndrome), inflammatory conditions (e.g., mastitis, [illegible] and
CC   vaginitis), immune disorders (e.g., congenital and acquired
CC   immunodeficiencies, autoimmune oophoritis, systemic lupus [illegible]),
CC   blood related disorders (e.g., anaemia), cardiovascular disorders,
CC   respiratory disorders, neurological disorders, gastrointestinal disorders
CC   and urinary system disorders. Ovarian antigen polypeptides and
CC   polynucleotides may also be used in screening for compounds that
CC   modulate ovarian antigen expression or activity. The polynucleotides may
CC   further be used for gene therapy, chromosome mapping, in the
CC   identification of individuals and in forensic analysis, and the
CC   polypeptides may be used as food additives or to prepare antibodies
CC   useful in disease diagnosis, drug targeting and phenotyping. The present
CC   sequence represents cDNA encoding a human ovarian antigen of the
CC   invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence [illegible] BP; [illegible] A; [illegible] C; [illegible] G; [illegible] T; [illegible] other;

  Query Match             [illegible];  Score [illegible];  DB [illegible];  Length [illegible];
  Best Local Similarity   [illegible];  Pred. No. [illegible];
  Matches   [illegible];  Conservative    [illegible];  Mismatches   [illegible];  Indels   [illegible];  Gaps   [illegible];

Qy          1 GGGAAGGAGGATGAACCCC [illegible]
              [illegible]
Db        20? GGGAAGGAGAAGGAACCCC [illegible]


RESULT 16
ABA67480/c
ID   ABA6?480 standard; cDNA; [illegible] BP.
XX
AC   ABA67480;
XX
DT   11-JAN-2002  (first entry)
XX
DE   Human ovarian and breast cancer associated polynucleotide [illegible] SEQ ID N
```

XX
KW [illegible]static; immunosuppressive; nootropic; neuroprotective; antiviral;
KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW vitamin; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein; ss.
XX
OS Homo sapiens.
XX
PN WO200155325-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01345.
XX
PR 21-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186450.
PR 10-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 28-APR-2000; 2000US-0198123.
PR 15-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217796.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 15-AUG-2000; 2000US-0226379.
PR 22-AUG-2000; 2000US-0225681.
PR 22-AUG-2000; 2000US-0226869.
PR 22-AUG-2000; 2000US-0227182.
PR 25-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0241968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234224.
PR 25-SEP-2000; 2000US-0235067.
PR 25-SEP-2000; 2000US-0235068.
PR 26-SEP-2000; 2000US-0235184.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236527.
PR 29-SEP-2000; 2000US-0236537.
PR 29-SEP-2000; 2000US-0236538.
PR 29-SEP-2000; 2000US-0236545.
PR 29-SEP-2000; 2000US-0236570.
PR 02-OCT-2000; 2000US-0236842.
PR 02-OCT-2000; 2000US-0236847.
PR 02-OCT-2000; 2000US-0236848.
PR 02-OCT-2000; 2000US-0237040.
PR 02-OCT-2000; 2000US-0237041.
PR 13-OCT-2000; 2000US-0239667.
PR 13-OCT-2000; 2000US-0239668.
PR 20-OCT-2000; 2000US-0241060.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241788.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244017.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246520.
PR 08-NOV-2000; 2000US-0246521.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246552.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246615.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249267.
PR 17-NOV-2000; 2000US-0249269.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250161.
PR 05-DEC-2000; 2000US-0251087.
PR 05-DEC-2000; 2000US-0251088.
PR 05-DEC-2000; 2000US-0251719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251866.
PR 08-DEC-2000; 2000US-0251868.

```
PR   [illegible] 2000; 2000US [illegible].
PR   [illegible] 2000; 2000US [illegible].
PR   [illegible] 2000; 2000US [illegible].
PR   11 [illegible] 2000; 2000US [illegible].
PR   05 JAN 2001; 2001US [illegible]678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   [illegible] CA, Barash SC, Ruben SM;
XX
DR   WPI; 2001-488786/53.
DR   P-PSDB; ABB10769.
XX
PT   New isolated ovarian and/or breast cancer related nucleic acids and
PT   polypeptides, useful for diagnosing, treating and/or preventing human
PT   diseases and disorders, particularly ovarian and/or breast cancer
XX
PS   Claim 1; SEQ ID NO 37; 577pp; Sequence Listing: English.
XX
CC   The invention relates to novel genes (ABA[illegible] ABA[illegible]) and proteins
CC   (ABB1[illegible]743-ABB10980) useful for preventing, treating or ameliorating
CC   medical conditions e.g. by protein or gene therapy. The genes are
CC   isolated from a range of human tissues disclosed in the specification.
CC   The nucleic acids, proteins, antibodies and (ant)agonists are useful
CC   in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast
CC   and ovarian cancer and other cancers of the adrenal gland, bone, bone
CC   marrow, breast, gastrointestinal tract, liver, lung, or urogenital;
CC   (b) immune disorders e.g. Addison's disease, allergies, autoimmune
CC   haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's
CC   disease, multiple sclerosis, rheumatoid arthritis and ulcerative
CC   colitis; (c) cardiovascular disorders such as myocardial infarction;
CC   (d) wound healing; (e) neurological diseases e.g. [illegible]
CC   epilepsy; and (f) infectious diseases such as viral, bacterial, fungal
CC   and parasitic infections.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 60[illegible] BP; 135 A; 149 C; 164 G; 156 T; [illegible] other;

  Query Match            [illegible].2%;  Score 15.[illegible];  DB [illegible];  Length [illegible];
  Best Local Similarity   89.5%;  Pred. No. 4.2[illegible];
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    [illegible];  Gaps    [illegible];

Qy          1 [illegible]GAAGGAGGATGAACCCC 19
              [illegible]|| | |||||||
Db        [illegible] [illegible]GGAAGGAGAAAGAACCCC 18[illegible]


RESULT [illegible]
AAI[illegible]
ID   AAI[illegible] standard; cDNA; 6[illegible] BP.
XX
AC   AAI[illegible];
XX
DT   [illegible]-NOV-2001  (first entry)
XX
DE   Human reproductive system related antigen cDNA SEQ ID NO: [illegible]
XX
KW   Human; reproductive system related antigen; reproductive system disorder;
KW   cancer; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   WO[illegible]A2.
XX
PD   [illegible] AUG 2001.
XX
PF   1[illegible] JAN 2001; 2001WO-US01[illegible].
XX
PR   [illegible] JAN 2000; 2000US-017[illegible].
PR   [illegible] FEB 2000; 2000US-018[illegible]28.
PR   24 FEB 2000; 2000US-0184[illegible].
PR   [illegible] MAR 2000; 2000US [illegible].
PR   16 MAR 2000; 2000US [illegible].
PR   17 MAR 2000; 2000US [illegible].
PR   18 APR 2000; 2000US [illegible].
PR   19 MAY 2000; 2000US [illegible].
PR   [illegible] JUN 2000; 2000US [illegible].
PR   [illegible] JUN 2000; 2000US [illegible].
PR   30 JUN 2000; 2000US [illegible].
PR   07 JUL 2000; 2000US [illegible].
PR   07 JUL 2000; 2000US [illegible].
PR   11 JUL 2000; 2000US [illegible].
PR   11 JUL 2000; 2000US [illegible].
PR   14 JUL 2000; 2000US [illegible].
PR   26 JUL 2000; 2000US [illegible].
PR   26 JUL 2000; 2000US [illegible].
PR   14 AUG 2000; 2000US [illegible].
PR   14 AUG 2000; 2000US [illegible].
PR   14 AUG 2000; 2000US [illegible].
PR   14 AUG 2000; 2000US [illegible].
PR   14 AUG 2000; 2000US [illegible].
PR   14 AUG 2000; 2000US [illegible].
PR   14 AUG 2000; 2000US [illegible].
PR   14 AUG 2000; 2000US [illegible].
PR   14 AUG 2000; 2000US [illegible].
PR   14 AUG 2000; 2000US [illegible].
PR   14 AUG 2000; 2000US [illegible].
PR   14 AUG 2000; 2000US [illegible].
PR   18 AUG 2000; 2000US [illegible].
PR   22 AUG 2000; 2000US [illegible].
PR   22 AUG 2000; 2000US [illegible].
PR   2[illegible] AUG 2000; 2000US [illegible].
PR   2[illegible] AUG 2000; 2000US [illegible].
PR   [illegible] AUG 2000; 2000US [illegible].
PR   01 SEP 2000; 2000US [illegible].
PR   01 SEP 2000; 2000US [illegible].
PR   01 SEP 2000; 2000US [illegible].
PR   01 SEP 2000; 2000US [illegible].
PR   0[illegible] SEP 2000; 2000US [illegible].
PR   0[illegible] SEP 2000; 2000US [illegible].
PR   06 SEP 2000; 2000US [illegible].
PR   06 SEP 2000; 2000US [illegible].
PR   08 SEP 2000; 2000US [illegible].
PR   08 SEP 2000; 2000US [illegible].
PR   08 SEP 2000; 2000US [illegible].
PR   08 SEP 2000; 2000US [illegible].
PR   08 SEP 2000; 2000US [illegible].
PR   08 SEP 2000; 2000US [illegible].
PR   08 SEP 2000; 2000US [illegible].
PR   12 SEP 2000; 2000US [illegible].
PR   14 SEP 2000; 2000US [illegible].
PR   14 SEP 2000; 2000US [illegible].
PR   14 SEP 2000; 2000US [illegible].
PR   14 SEP 2000; 2000US [illegible].
PR   14 SEP 2000; 2000US [illegible].
PR   14 SEP 2000; 2000US [illegible].
PR   14 SEP 2000; 2000US [illegible].
PR   14 SEP 2000; 2000US [illegible].
PR   21 SEP 2000; 2000US [illegible].
PR   21 SEP 2000; 2000US [illegible].
PR   2[illegible] SEP 2000; 2000US [illegible].
PR   2[illegible] SEP 2000; 2000US [illegible].
PR   26 SEP 2000; 2000US [illegible].
PR   27 SEP 2000; 2000US [illegible].
PR   2[illegible] SEP 2000; 2000US [illegible].
PR   29 SEP 2000; 2000US [illegible].
PR   29 SEP 2000; 2000US [illegible].
PR   29 SEP 2000; 2000US [illegible].
PR   29 SEP 2000; 2000US [illegible].
PR   [illegible] SEP 2000; 2000US [illegible].
PR   0[illegible] OCT 2000; 2000US [illegible].
PR   02 OCT 2000; 2000US [illegible].
PR   02 OCT 2000; 2000US [illegible].
PR   02 OCT 2000; 2000US [illegible].
```

PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246614.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465570/50.
DR P-PSDB; AAM94432.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen -
PT is used in preventing, treating or ameliorating a medical condition -
XX
PS Claim 1; SEQ ID NO 403; 1297pp ; Sequence Listing; English.
XX

CC The present invention provides the protein and coding sequence of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders
CC including cancer. The present sequence is a coding sequence of the
CC invention.
XX
SQ Sequence 609 BP; 145 A; 144 C; 164 G; 156 T; 5 other;

Query Match 83.2%; Score 15.8; DB 22; Length
Best Local Similarity 89.5%; Pred. No. 4.2e-02;
Matches 17; Conservative 0; Mismatches 2; Indels

QY 1 GGGAAGTAGGATAAC 15
||||||||| | |||||||
Db 201 GGGAAGTAGGAAGAAC 185

RESULT 18
AAS80239
ID AAS80239 standard; cDNA; 1666 BP.
XX
AC AAS80239;
XX
DT 13-FEB-2002 (first entry)
XX
DE DNA encoding novel human diagnostic protein #16043.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175007-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US008631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 24-AUG-2000; 2000US-0644167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-633622/73.
DR P-PSDB; AAS16052.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of medical
PT responsible for genetic disorders or other traits and to assess
PT biodiversity
XX
PS Claim 1; SEQ ID NO 1666; 1298pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes
CC polymerase chain reaction (PCR) primers, oligomers, and in
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed
CC for identifying expressed genes. (I) is useful in gene therapy
CC to restore normal activity of (II) or to treat disease states
CC (II). (II) is useful for generating antibodies against it,
CC quantitating a polypeptide in tissue, as molecular weight
CC a food supplement. (II) and its binding partners are useful
CC imaging of sites expressing (II). (I) and (II) are useful
CC disorders involving aberrant protein expression or biological
CC The polypeptide and polynucleotide sequences have applications
CC diagnostics, forensics, gene mapping, identification of
CC responsible for genetic disorders or other traits to assess
CC and to produce other types of data and products dependent
CC amino acid sequences. AAS81147-AAS81564 represent novel human
CC diagnostic coding sequences of the invention.

```
CC   Notes: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIP
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 1606 BP; 440 A; 360 C; 443 G; 373 T; 0 Other;

  Query Match             85.2%;  Score 15.8;  DB 2;  Length 1606;
  Best Local Similarity   89.5%;  Prod. No. 1.1e-05;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 CCGGAAGGAGCATGAACCCC 20
           ||||||||||| |||| ||||
Db    1606 CCGGAAGGAGCTTGGACCCC 1587


RESULT 19
AAX20481/c
ID   AAX20481 standard; cDNA; 1611 BP.
XX
AC   AAX20481;
XX
DT   27-MAY-1999  (first entry)
XX
DE   cDNA encoding a EPHG4Spt polypeptide.
XX
KW   EPHG4Spt; anaemia; polycythaemia; cancer;
KW   acquired immunodeficiency syndrome; AIDS; drug induced anaemia;
XX
OS   Homo sapiens.
XX
PN   WO9932442-A1.
XX
PD   29-JUL-1999.
XX
PF   07-JAN-1999;  98WO-US000107.
XX
PR   31-DEC-1997;  97US-0044164.
XX
PA   (SMIK ) SMITHKLINE BEECHAM CORP.
XX
PI   Lily JD, Lord KA;
XX
DR   WPI; 1999-513702/43.
DR   P-PSDB; AAW97417.
XX
PT   Newly isolated EPHG4Spt polypeptides and polynucleotides useful
PT   for treating diseases and conditions associated with EPHG4Spt
PT   imbalance
XX
PS   Claim 2; Page 28; 42pp; English.
XX
CC   The present sequence encodes a EPHG4Spt polypeptide. The polypeptides
CC   are useful for identifying (anti)agonists and inhibitors of EPHG4Spt,
CC   which together with the polypeptides and polynucleotides are useful
CC   in treating diseases or conditions associated with EPHG4Spt imbalance.
CC   These diseases or conditions include anaemia, polycythaemia, cancer,
CC   acquired immunodeficiency syndrome (AIDS) and drug induced anaemia.
CC   The various elements of the polypeptides are also useful for diagnosing
CC   such diseases or conditions. The polynucleotides are useful for producing
CC   the polypeptides, and as probes and primers for isolating full length
CC   cDNAs and genomic clones encoding EPHG4Spt polypeptides or other genes
CC   with high homology to EPHG4Spt polypeptides. The polypeptides and
CC   polypeptides form compositions for eliciting immune responses and
CC   across the polypeptides. The polypeptides are useful for
CC   identifying membrane bound or soluble receptors.
XX
SQ   Sequence 1611 BP; 431 A; 432 C; 411 G; 337 T; 0 Other;

  Query Match             83.2%;  Score 15.4;  DB 2;  Length 1611;
  Best Local Similarity   89.5%;  Prod. No. 4.4e-05;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 CCGGAAGGAGCATGAACCCC 20
           ||||||||||| |||| ||||
Db    1611 CCGGAAGGAGCTTGGACCCC 1592


RESULT 20
AAW97417/c
ID   AAW97417 standard; cDNA; 1611 BP.
XX
AC   AAW97417;
XX
DT   01-JUL-1999  (first entry)
XX
DE   EPHG4Spt receptor sequence.
XX
KW   EPHG4Spt; receptor; anaemia; polycythaemia; cancer; AIDS;
KW   acquired immunodeficiency syndrome; drug induced anaemia; polycythaemia;
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             1..1611
FT                   /product="EPHG4Spt"
FT                   /gene="EPHG4Spt"
XX
PN   WO9932442-A1.
XX
PD   29-JUL-1999.
XX
PF   07-JAN-1999;  99WO-US000107.
XX
PR   31-DEC-1997;  97US-0044164.
XX
PA   (SMIK ) SMITHKLINE BEECHAM CORP.
XX
PI   Lily JD, Lord KA;
XX
DR   WPI; 1999-513702/43.
DR   P-PSDB; AAW97416.
XX
PT   New polypeptides useful in diagnosis of treating anaemia,
PT   polycythaemia, cancer, AIDS, drug induced anaemia, or in assays for
PT   producing immunospecific antibodies - comprises the EPHG4Spt
PT   (EPHG4Spt) polypeptides
XX
PS   Disclosure; Column 1; 22pp; English.
XX
CC   This invention relates to an isolated polypeptide, EPHG4Spt, which
CC   is cytostatic, antianaemic, anti-HIV and haematological in its
CC   action. The polypeptide is useful in therapy and diagnostics, in
CC   particular, the polypeptides, as well the polynucleotide encoding it,
CC   useful for diagnosing or treating anaemia, polycythaemia, cancer, AIDS,
CC   drug induced anaemia. The polypeptide also useful as an assay for
CC   producing antibodies immunospecific for the polypeptide, etc.
CC   Sequence represents the nucleotide encoding sequence of the EPHG4Spt
CC   receptor EPHG4Spt protein.
XX
SQ   Sequence 1611 BP; 431 A; 432 C; 411 G; 337 T; 0 Other;

  Query Match             83.2%;  Score 15.4;  DB 2;  Length 1611;
  Best Local Similarity   89.5%;  Prod. No. 4.4e-05;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 CCGGAAGGAGCATGAACCCC 20
           ||||||||||| |||| ||||
Db    1611 CCGGAAGGAGCTTGGACCCC 1592


RESULT 21
ABL00544
ID   ABL00544 standard; cDNA; 2[illegible] BP.
XX
```

```
AC   AR[illegible]44;
XX
DT   27-AUG-2002  (first entry)
XX
DE   Human lipid metabolism enzyme (LME)-8 cDNA (clone id: 2484327CB1).
XX
KW   Human; lipid metabolism enzyme; LME; cytostatic; neuroprotective; acute;
KW   nootropic; cerebroprotective; antiparkinsonian; antialzheimers; vaccine;
KW   antisclerotic; antimicrobial; anti-AIDS; cardiovascular; antiaminal;
KW   gene therapy; protein therapy; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             44..2520
FT                   /*tag= a
FT                   /product= "lipid metabolism enzyme"
FT                   /note= "LME 8"
XX
PN   WO-200229046-A2.
XX
PD   11-APR-2002.
XX
PF   05-OCT-2001; 2001WO-US31302.
XX
PR   06-OCT-2000; 2000US-238488P.
PR   15-OCT-2000; 2000US-240616P.
PR   02-NOV-2000; 2000US-245719P.
PR   09-NOV-2000; 2000US-247503P.
PR   17-NOV-2000; 2000US-249503P.
XX
PA   (INCY-) INCYTE GENOMICS INC.
XX
PI   Harland L, Arvizu C, Das D, Griffin JA, Ramaiah MR, Ding L;
PI   Walia NK, Yao MG, Lu Y, Elliott VS, Thangavelu K, Ramkumar J;
PI   Lal PG, Tribouley CM;
XX
DR   WPI; 2002-315862/35.
DR   P-PSDB; ABB08008.
XX
PT   Lipid Metabolism Enzymes and nucleic acids, useful for preventing,
PT   diagnosing and treating e.g. cancer, Alzheimer's disease and
PT   Creutzfeld-Jakob disease -
XX
PS   Claim 5; Page 126-127; 127pp; English.
XX
CC   The invention relates to human lipid metabolism enzymes (LMES) and
CC   encoding polynucleotides. The LMES can be expressed by standard
CC   recombinant technology. The LME polypeptides, polynucleotides and
CC   modulators may be used in the prevention, diagnosis and treatment of
CC   diseases associated with inappropriate LME expression such as cancer
CC   (e.g. myeloma, sarcoma and breast cancer), neurological disorders (e.g.
CC   Parkinson's, Alzheimer's and multiple sclerosis), microbial infections
CC   (e.g. Creutzfeld-Jakob disease and Acquired Immune deficiency syndrome
CC   (AIDS)) and/or cardiovascular disorders (e.g. cardiomyopathy, angina
CC   pectoris and mitral valve prolapse). The present sequence represents the
CC   human LME-8 encoding cDNA.
XX
SQ   Sequence 2520 BP; 605 A; 656 C; 694 G; 566 T; 0 other;

  Query Match             83.2%;  Score 15.8;  DB 24;  Length 2520;
  Best Local Similarity   89.5%;  Prod. No. 4.5e-02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    1;  Gaps    0;

Qy       1 GGGAAGGAGGATGAACCCC 19
           ||||||||||  || |||||
Db    108 GGGAAGGAGGTTGGACCCC 126


RESULT 22
AAZ22283/c
ID   AAZ22283 standard; DNA; 4200 BP.
XX
AC   AAZ22283;
XX
DT   06-DEC-1999  (first entry)
XX
DE   Nucleic acid sequence #1 [illegible].
XX
KW   RGS; guanine nucleotide exchange factor; GEF; RGS domain; [illegible]
KW   G protein alpha subunit; cell proliferation; growth control; [illegible]
KW   morphogenesis; stress fiber formation; integrin-mediated [illegible]
KW   embryonic development; tumor cell growth; cell death; [illegible]
KW   bone resorption; clot retraction; dbl homology domain; [illegible]
KW   pleckstrin homology domain; [illegible] ss.
XX
OS   Mus sp.
XX
PN   WO9947557-A2.
XX
PD   23-SEP-1999.
XX
PF   18-MAR-1999;  99WO-US05951.
XX
PR   18-MAR-1998;  98US-078784.
XX
PA   (CNYX ) CNYX PHARM INC.
XX
PI   Bollag G, Ruggieri RM, Boguski M, Polakis P, Stratowris P, K[illegible]
PI   Jiang X;
XX
DR   WPI; 1999-571621/48.
DR   P-PSDB; AAY41011.
XX
PT   New isolated RGS GEF polypeptides, used to develop products [illegible]
PT   modulating, e.g. cell proliferation and integrin-mediated [illegible]
PT   -
XX
PS   Examples; Fig 15; 75pp; English.
XX
CC   The invention relates to isolated RGS guanine nucleotide [illegible]
CC   (GEF) polypeptides. The novel isolated RGS-GEF polypeptide [illegible]
CC   RGS domain of a GEF protein and does not comprise a dbl hom[illegible]
CC   domain or a pleckstrin homology (PH) domain. The RGS-GEF [illegible]
CC   be used for modulating an activity of a G protein alpha subu[illegible]
CC   The products can be used for the regulation of biological [illegible]
CC   which a RGS-GEF polypeptide is involved, particularly path[illegible]
CC   conditions, e.g. cell proliferation (e.g. cancer), morphog[illegible]
CC   control, stress fiber formation, and integrin-mediated [illegible]
CC   as embryonic development, tumor cell growth and metastasis[illegible]
CC   cell death, homostasis, leukocyte homing and activation, [illegible]
CC   clot retraction, and the response of cells to mechanical [illegible]
CC   products can also be used for detection, diagnosis and [illegible]
CC   transgenic animals. The present sequence represents the [illegible]
CC   sequence of [illegible].
XX
SQ   Sequence 4200 BP; 710 A; 985 C; 944 G; 561 T; 0 other;

  Query Match             83.2%;  Score 15.8;  DB 20;  Length [illegible]
  Best Local Similarity   89.5%;  Prob. No. 4.6e-02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    1;  Gaps    0;

Qy       1 GGGAAGGAGGATGAACCCC 19
           ||||||||||  || |||||
Db    3118 GGGAAGGAGGTGGACCCCC 3136


RESULT 23
AAQ72913/c
ID   AAQ72913 standard; DNA; 467 BP.
XX
AC   AAQ72913;
XX
DT   26-OCT-1999  (first entry)
XX
DE   Human receptor-type protein tyrosine phosphatase (PTP) kappa
```

XX
KW Receptor type protein tyrosine phosphatase [illegible]
KW RPTPase kappa; PTPase; enzyme; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..4329
FT /*tag= a
XX
PN WO9424161-A.
XX
PD 27-OCT-1994.
XX
PF 20-APR-1994; 94WO-US04577.
XX
PR 21-APR-1993; 93US-0049384.
PR 1-JUL-1993; 93US-0087244.
XX
PA (PLAC) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN.
PA (UYNY) UNIV NEW YORK MEDICAL CENT.
XX
PI Fuchs M, Sap JM, Schlessinger J, Ullrich A, Vogel W;
XX
DR WPI; 1994-341765/42.
DR P-PSDB; AAR62632.
XX
PT Mammalian receptor-type protein tyrosine phosphatase kappa
PT (RPTP k) protein and DNA - useful to identify [illegible]
PT to RPTP k and modulate enzymatic activity. Also [illegible]
PT type II RPTP homophilic binding (Eng).
XX
PS [illegible]; Fig 15; 144pp; English.
XX
CC The novel receptor type protein tyrosine phosphatase protein or
CC glycoprotein is termed RPTP kappa (also known as PTPase-kappa).
CC Human breast cancer cell line SK BR-3 was examined by PCR using
CC primers corresp. to conserved sequences within the PTP catalytic
CC domains shared by all identified PTPases. Several known PTPases
CC were revealed together with some novel members of the PTPase
CC family. One of the novel sequences, designated MCP7 (Mammary
CC carcinoma derived PTPase clone 7) was highly represented in all
CC [illegible] clones examined. The MCP7 PCR fragment was used to screen a
CC SK BR 3 cDNA library. The results are AAQ[illegible] and its deduced
CC AA sequence AAR63632. The AA sequence displays the structural
CC organisation of a type II transmembrane PTPase. The N-terminal
CC hydrophobic stretch of 20-26 AAs is typical of signals peptides.
CC A second region consisting of hydrophobic residues (see PT) is
CC predicted to be a single alpha helical transmembrane domain. It
CC is followed by a short region of mainly basic residues
CC characteristic of a transfer stop sequence. The amino-terminal
CC portion of the putative extracellular domain contains a sequence
CC motif, a so-called MAM domain, spanning a region of about [illegible]
CC residues. This motif is followed by one possible Ig like domain
CC (see FT).
XX
SQ Sequence 4651 BP; 1350 A; 1024 C; 1074 G; 1203 T; [illegible] other;

Query Match 83.2%; Score 15.8; DB [illegible]; Length 4651;
Best Local Similarity 89.5%; Pred. No. 4.6[illegible];
Matches 17; Conservative 0; Mismatches [illegible]; Indels [illegible]; Gaps [illegible];

Qy 1 [illegible]GGAAGGAGGATGAAC[illegible] 19
Db [illegible] GAGAAGGAGGATGAACACC 228[illegible]

RESULT 14
AAS[illegible]
ID AAS[illegible] standard; cDNA; 4[illegible] BP.
XX
AC AAS[illegible];
XX
DT 13-FEB-2002 (first entry)
XX
DE DNA encoding novel human diagnostic protein #[illegible]
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder[illegible]
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-[illegible].
XX
PR 31-MAR-2000; 2000US-[illegible].
PR 23-AUG-2000; 2000US-[illegible].
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-[illegible]/7[illegible].
DR P-PSDB; AB[illegible].
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity
XX
PS Claim 1; SEQ ID NO [illegible]; [illegible]pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for [illegible]
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states [illegible]
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or [illegible]
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess [illegible]
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. AAS[illegible] AAS[illegible] represent novel human
CC diagnostic coding sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 1[illegible] BP; [illegible] A; [illegible] C; [illegible] G; [illegible] T; [illegible] other;

Query Match [illegible]; Score 15.[illegible]; DB [illegible]; Length 1[illegible];
Best Local Similarity [illegible]; Pred. No. [illegible];
Matches [illegible]; Conservative [illegible]; Mismatches [illegible]; Indels [illegible]; Gaps [illegible];

Qy 1 [illegible]GGAAGGAGGATGAA[illegible] 19
Db [illegible] GAGAAGGAGGATGAACACC [illegible]

RESULT 15
AAS[illegible]
ID AAS[illegible] standard; cDNA; [illegible] BP.
XX
AC AAS[illegible];
XX
DT 13-FEB-2002 (first entry)
XX

```
DE   Human protein phosphatase k encoding cDNA.
XX
KW   Human; protein phosphatase k; HPIPK; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             15..1438
FT                   /*tag   a
FT                   /product  "protein phosphatase k"
XX
PN   KR9606246-A.
XX
PD   15-JUL-1998.
XX
PF   08-OCT-1996;    96KR-0044614.
XX
PR   08-OCT-1996;    96KR-0044614.
XX
PA   (KOAD ) KOREA ADV INST SCI & TECHNOLOGY.
XX
PI   Byun SH,  Hah BJ,  Kil MC,  Yang Y;
XX
DR   WPI; 1999-335582/28.
DR   P-PSDB; AAY29591.
XX
PT   Human protein phosphatase, base sequence thereof and amino acid
PT   sequence thereof NoAbstract
XX
PS   Disclosure; Page 6-9; 14pp; Korean.
XX
CC   The present sequence encodes human protein phosphatase k (HPIPK).
XX
SQ   Sequence 5775 BP; 1711 A; 1197 C; 1261 G; 1606 T; 0 other;

  Query Match             83.2%;  Score 15.8;  DB 20;  Length 5775;
  Best Local Similarity   89.5%;  Pred. No. 4.7e-02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 CCGAAGGAGGATGAACCCC 19
           | ||||||||||||||||| ||
Db    2319 GAGAAGGAGGATGAACACC 2301


RESULT 2
AAK66832
ID   AAK66832 standard; DNA; 72215 BP.
XX
AC   AAK66832;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Human immune/haematopoietic antigen genomic sequence SEQ ID NO:41644.
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW   cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS   Homo sapiens.
XX
PN   WO200157182-A2.
XX
PD   09-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01354.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209487.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215145.
PR   07-JUL-2000; 2000US-0216042.
PR   07-JUL-2000; 2000US-0216886.
PR   11-JUL-2000; 2000US-0217187.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220965.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226686.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227696.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229589.
PR   05-SEP-2000; 2000US-0229613.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231245.
PR   08-SEP-2000; 2000US-0231241.
PR   08-SEP-2000; 2000US-0231113.
PR   08-SEP-2000; 2000US-0231114.
PR   08-SEP-2000; 2000US-0232087.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231968.
PR   14-SEP-2000; 2000US-0232547.
PR   14-SEP-2000; 2000US-0232548.
PR   14-SEP-2000; 2000US-0232549.
PR   14-SEP-2000; 2000US-0232460.
PR   14-SEP-2000; 2000US-0232461.
PR   14-SEP-2000; 2000US-0232563.
PR   14-SEP-2000; 2000US-0232564.
PR   14-SEP-2000; 2000US-0232565.
PR   21-SEP-2000; 2000US-0234225.
PR   21-SEP-2000; 2000US-0234271.
PR   25-SEP-2000; 2000US-0234947.
PR   25-SEP-2000; 2000US-0234998.
PR   26-SEP-2000; 2000US-0235341.
PR   27-SEP-2000; 2000US-0235834.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236527.
PR   29-SEP-2000; 2000US-0236537.
PR   29-SEP-2000; 2000US-0236538.
PR   29-SEP-2000; 2000US-0236539.
PR   29-SEP-2000; 2000US-0236572.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237041.
PR   13-OCT-2000; 2000US-0239955.
PR   13-OCT-2000; 2000US-0239957.
PR   20-OCT-2000; 2000US-0241660.
PR   20-OCT-2000; 2000US-0241221.
```

```
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-02466[illegible].
PR   08-NOV-2000; 2000US-02466[illegible].
PR   08-NOV-2000; 2000US-0246611.
PR   08-NOV-2000; 2000US-0246613.
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
PR   17-NOV-2000; 2000US-0249215.
PR   17-NOV-2000; 2000US-0249216.
PR   17-NOV-2000; 2000US-0249217.
PR   17-NOV-2000; 2000US-0249218.
PR   17-NOV-2000; 2000US-0249244.
PR   17-NOV-2000; 2000US-0249245.
PR   17-NOV-2000; 2000US-0249264.
PR   17-NOV-2000; 2000US-0249265.
PR   17-NOV-2000; 2000US-0249297.
PR   17-NOV-2000; 2000US-0249299.
PR   17-NOV-2000; 2000US-0249300.
PR   01-DEC-2000; 2000US-0250160.
PR   01-DEC-2000; 2000US-0250391.
PR   05-DEC-2000; 2000US-0251030.
PR   05-DEC-2000; 2000US-0251988.
PR   05-DEC-2000; 2000US-0256719.
PR   06-DEC-2000; 2000US-0251479.
PR   08-DEC-2000; 2000US-025185[illegible]
PR   08-DEC-2000; 2000US-0251868.
PR   08-DEC-2000; 2000US-0251869.
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-483426/52.
XX
PT   Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT   useful for preventing, diagnosing and/or treating cancers and
PT   metastasis
XX
PS   Disclosure; SEQ ID NO 41644; 3871pp; Sequence Listing; English.
XX
CC   AAK51451 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC   amino acid sequences given in AAM82170 to AAM9[illegible]. (I) has cytostatic
CC   activity, and can be used in gene therapy and vaccine production. (I)
CC   proteins and polynucleotides may be used in the prevention, diagnosis and
CC   treatment of diseases associated with inappropriate (I) expression. For
CC   example, they may be used to treat disorders associated with [illegible]
CC   expression by rectifying mutations or deletions in a patient's [illegible]
CC   that affect the activity of (I) by expressing inactive proteins or [illegible]
CC   supplement the patient's own production of (I). Additionally, [illegible]
CC   polynucleotides may be used to produce the secreted (I), by inserting
CC   the nucleic acids into a host cell and culturing the cell to express [illegible]
CC   protein. (I) proteins and polynucleotides may be used to prevent,
CC   diagnose and treat immune/haematopoietic related diseases, [illegible]
CC   cancers and cancer metastasis of haematopoietic derived [illegible]
CC   to AAK[illegible] represent human immune/haematopoietic antigen [illegible]
CC   sequences from the present invention. AAK[illegible] to AAK[illegible] and [illegible]
CC   represent sequences used in the exemplification of the present [illegible]
XX
SQ   Sequence [illegible] BP; [illegible] A; [illegible] C; [illegible] G; [illegible] T; [illegible] other;

  Query Match             [illegible] Score [illegible]; DB [illegible]; Length [illegible];
  Best Local Similarity   [illegible]; Pred. No. [illegible];
  Matches [illegible]; Conservative [illegible]; Mismatches [illegible]; Indels [illegible]; Gaps [illegible];

Qy          1 [illegible]AA[illegible]A[illegible]AA[illegible] [illegible]
                [illegible]
Db      41242 GGGTAGGAGGATGGA[illegible] 41[illegible]


RESULT [illegible]
ABK[illegible]/c
ID   ABK[illegible] standard; cDNA; [illegible] BP.
XX
AC   ABK[illegible];
XX
DT   14-AUG-2002  (first entry)
XX
DE   Human cDNA differentially expressed in granulocytic cells #[illegible]
XX
KW   Human; ss; granulocytic [illegible]; DNA chip; bacterial infection;
KW   viral infection; parasitic infection; protozoal infection;
KW   fungal infection; sterile inflammatory disease; [illegible];
KW   rheumatoid arthritis; glomerular nephritis; asthma; [illegible];
KW   cardiac reperfusion injury; renal reperfusion injury; ARDS;
KW   adult respiratory distress syndrome; inflammatory bowel disease;
KW   Crohn's disease; ulcerative colitis; periodontal disease;
KW   granulocyte activation; chronic inflammation; allergy.
XX
OS   Homo sapiens.
XX
PN   WO200[illegible]-A2.
XX
PD   11-APR-2002.
XX
PF   0[illegible]-OCT-2001; 2001WO-US[illegible].
XX
PR   0[illegible]-OCT-2000; 2000US-[illegible].
XX
PA   (GENE-) GENE LOGIC INC.
XX
PI   Be[illegible], Bar[illegible] Y, W[illegible] JM, Y[illegible], V[illegible];
XX
DR   WPI; 2002-[illegible].
XX
PT   Detecting granulocyte activation by detecting differential [illegible]
PT   of genes [illegible] [illegible], which [illegible]
PT   diagnostic markers that [illegible] for mediated disease [illegible]
PT   drug [illegible]
XX
PS   Claim [illegible]; SEQ ID NO [illegible]; [illegible]pp; English.
XX
CC   The invention relates to detecting (M1) granulocyte (G) activation
CC   (GA), by detecting the level of expression of gene(s) (G[illegible]) [illegible]
CC   DNA chip analysis as given in the specification, and comparing
CC   the expression level to an expression level in an unactivated
CC   G, where differential expression of G[illegible] is indicative of GA.
CC   Also included are modulating (M2) GA by contacting G with an agent
CC   that alters the expression of at least one gene in G[illegible] [illegible]
```

CC to: 1) an agent capable of modulating GCA or an inflammation (especially
CC chronic) in a tissue, an allergic response in a subject, exposure of a
CC subject to a pathogen or sterile inflammatory disease using the
CC gene expression profile; (3) detecting (M4) an inflammation (especially
CC chronic) in a tissue, an allergic response in a subject, exposure of a
CC subject to a pathogen or sterile inflammatory disease, by detecting the
CC level of expression in a sample of the tissue of gene(s) from GS, where
CC the level of expression of the gene is indicative of inflammation;
CC (4) treating (M5) an inflammation (especially chronic) or in a tissue,
CC an allergic response in a subject, exposure of a subject to a pathogen
CC or sterile inflammatory disease, by contacting a tissue having
CC inflammation with an agent that modulates the expression of gene(s)
CC from GS in the tissue. M1 is useful for detecting GCA; M2 is useful for
CC modulating GA; M3 is usetul for screening an agent capable of modulating
CC GCA preferably in an inflammation in a tissue; M4 is useful for
CC detecting an inflammation (especially chronic) in a tissue, an allergic
CC response in a subject, exposure of a subject to a pathogen or sterile
CC inflammatory disease (e.g. psoriasis, rheumatoid arthritis,
CC glomerulonephritis, asthma, thrombosis, cardiac repertusion injury, renal
CC reperfusion injury, ARDS, adult respiratory distress syndrome,
CC inflammatory bowel disease, Crohn's disease, ulcerative colitis,
CC periodontal disease; also bacterial infection, viral infection,
CC parasitic infection, protozoal infection, fungal infection and M5 is
CC useful for treating one of the above conditions. The present
CC sequence represents a gene differentially expressed in granulocytes.
CC Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from WIPO at
CC ftp://pbpub.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 227968 BP; 53185 A; 60440 C; 61985 G; 52358 T; 0 other;

Query Match 83.2%; Score 15.8; DB 24; Length 227968;
Best Local Similarity 89.5%; Pred. No. 5.3e-02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGGAAGGAGGATGAACCCC 19
||||||||| | |||||||
Db 82760 GGGAAGGAGAAAGAACCCC 82742

RESULT 28
ABL72171
ID ABL72171 standard; cDNA; 269 BP.
XX
AC ABL72171;
XX
DT 14-MAY-2002 (first entry)
XX
DE Corn tassel-derived polynucleotide (cdps) SEQ ID NO:1545.
XX
KW Corn; corn tassel-derived polynucleotide; cdps; hybrid breeding; CDPS;
KW inheritance; characteristic; growth; development; disease resistance;
KW environmental adaptability; quality; yield; molecular marker;
KW multigene trait; plant breeding; corn tassel; gene; ss.
XX
OS Zea mays.
XX
PN US20051335-A1.
XX
PD 13-DEC-2001.
XX
PF 16-APR-1999; 99US-0294094.
XX
PR 21-APR-1998; 98US-082567P.
XX
PA (LALG/) LALGUDI R V.
PA (ITOL/) ITO L Y.
PA (SHER/) SHERMAN B K.
XX
PI Lalgudi RV, Ito LY, Sherman BK;
XX
DR WPI; 2002-163647/21.
XX
PT Novel purified corn tassel derived polynucleotide useful for
PT determining altered gene expression, to recover regulatory elements
PT to follow inheritance of desirable characteristics through
PT breeding programs
XX
PS Claim 1; SEQ ID 1545; 269pp; English.
XX
CC The present sequence describes a purified corn tassel derived
CC polynucleotide sequence (cdps) comprising a nucleic acid sequence
CC selected from those given in ABL70627 to ABL70833. The cdps sequences
CC encode corn tassel-derived polypeptides (CDPS). The cdps sequences
CC can be used for determining altered gene expression, to recover
CC regulatory elements and to follow inheritance of desirable
CC characteristics through hybrid breeding programs. (1) are also useful
CC in the evaluation, and alteration of desired characteristics associated
CC with growth and development, disease resistance, environmental
CC adaptability, quality and yield, and as molecular markers in plant
CC inheritance of multigene traits in a plant breeding program. (2) can be
CC used to produce a tassel-specific profile of gene transcripts
CC transcript image, to clone regulatory elements for use in tassel-
CC vectors, to express a polypeptide, to identify, isolate or clone
CC identical or related corn tassel nucleic acid sequences from cDNA
CC libraries, in nucleic acid hybridisation or amplification tests
CC as query sequences to determine homology of known sequences, as
CC for use in Southern or Northern hybridisation, and to identify the
CC presence of and/or to determine the degree of similarity between two
CC (or more) nucleic acid sequences.
XX
SQ Sequence 269 BP; 72 A; 68 C; 69 G; 60 T; 0 other;

Query Match 81.1%; Score 15.4; DB 24; Length 269;
Best Local Similarity 94.1%; Pred. No. 7.5e-02;
Matches 16; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

Qy 8 GAAGGAGGATGAACCCC 19
|||||||||||||| |||
Db 125 GAAGGAGGAGAAAGAACCCC 141

RESULT 29
ABL70924
ID ABL70924 standard; cDNA; 290 BP.
XX
AC ABL70924;
XX
DT 14-MAY-2002 (first entry)
XX
DE Corn tassel derived polynucleotide (cdps) SEQ ID NO:1298.
XX
KW Corn; corn tassel-derived polynucleotide; cdps; hybrid breeding; CDPS;
KW inheritance; characteristic; growth; development; disease resistance;
KW environmental adaptability; quality; yield; molecular marker;
KW multigene trait; plant breeding; corn tassel; gene; ss.
XX
OS Zea mays.
XX
PN US20051335-A1.
XX
PD 13-DEC-2001.
XX
PF 16-APR-1999; 99US-0294094.
XX
PR 21-APR-1998; 98US-082567P.
XX
PA (LALG/) LALGUDI R V.
PA (ITOL/) ITO L Y.
PA (SHER/) SHERMAN B K.
XX
PI Lalgudi RV, Ito LY, Sherman BK;
XX
DR WPI; 2002-163647/21.
XX

```
PT   Novel purified corn tassel derived polynucleotide [illegible] for
PT   determining altered gene expression, to recover regulatory elements and
PT   to follow inheritance of desirable characteristics through hybrid
PT   breeding programs
XX
PS   Claim 1; SEQ ID 298; 201pp; English.
XX
CC   The present sequence describes a purified corn tassel derived
CC   polynucleotide sequence (cdps) comprising a nucleic acid sequence
CC   selected from those given in ABL70627 to ABL70[illegible]. The cdps sequences
CC   encode corn tassel derived polypeptides (CDPs). The cdps sequences (I)
CC   can be used for determining altered gene expression, to recover
CC   regulatory elements and to follow inheritance of desirable
CC   characteristics through hybrid breeding programs. (I) are also useful
CC   in the evaluation, and alteration of desired characteristics associated
CC   with growth and development, disease resistance, environmental
CC   adaptability, quality and yield, and as molecular markers for studying
CC   inheritance of multigene traits in a plant breeding program. (I) can be
CC   used to produce a tassel-specific profile of gene transcription, a
CC   transcript image, to clone regulatory elements for use in transformation
CC   vectors, to express a polypeptide, to identify, isolate or extend
CC   identical or related corn tassel nucleic acid sequences from DNA
CC   libraries, in nucleic acid hybridisation or amplification technologies,
CC   as query sequences to determine homology of known sequences, as probe
CC   for use in Southern or Northern hybridisation, and to identify the
CC   presence of and/or to determine the degree of similarity [illegible]
CC   (or more) nucleic acid sequences.
XX
SQ   Sequence 290 BP; 77 A; 77 C; 72 G; 64 T; 0 other;

  Query Match             81.1%;  Score 15.4;  DB 21;  Length [illegible];
  Best Local Similarity   94.1%;  Pred. No. [illegible];
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          3 GAAGGAGGATGAAC[illegible] 19
              ||||||||||||||| ||
Db        12[illegible] GAAGGAGGATGAAACC 141


RESULT [illegible]
ABQ8[illegible]
ID   ABQ8[illegible] standard; DNA; [illegible] BP.
XX
AC   ABQ8[illegible];
XX
DT   [illegible] 2002  (first entry)
XX
DE   Arabidopsis thaliana expressed polynucleotide SEQ ID NO [illegible]
XX
KW   Plant; Arabidopsis; transgenic; fungicide; insecticide; [illegible]
XX
OS   Arabidopsis thaliana.
XX
PN   [illegible]2014 A1.
XX
PD   [illegible] MAY 2002.
XX
PF   [illegible] JAN 2001; 2001US [illegible]
XX
PR   [illegible] JAN 2000; 2000US [illegible]
XX
PA   ([illegible]/) GORLACH J.
PA   (ANYY/) AN Y.
PA   (HAMI/) HAMILTON C M.
PA   ([illegible]/) PRICE J L.
PA   (RAIN/) RAINES I M.
PA   (YUYY/) YU Y.
PA   (RAME/) RAMEAKA J G.
PA   ([illegible]/) PAGE A.
PA   (MATH/) MATHEW A V.
PA   ([illegible]/) LEDFORD R L.
PA   (WOES/) WOESSNER J P.
PA   (HAAS/) HAAS W D.
PA   (GARC/) GARCIA C A.
PA   (KREC/) KRECKER M.
PA   (SLAT/) SLATER S.
PA   (DAVI/) DAVIS K R.
PA   (ALLE/) ALLEN K.
PA   (HOFF/) HOFFMAN N.
PA   (HUEB/) HUEBNAN [illegible]
XX
PI   Gorlach J, An Y, Hamilton CM, Price J, Raines IM, Yu Y
PI   Rameaka JG, Page A, Mathew AV, Ledford RL, Woessner JP, Haas W,
PI   Garcia CA, Krecker M, Slater S, [illegible] Kr, Allen K, Hoffman N,
PI   Hurban P;
XX
DR   WPI; 2002-[illegible]
XX
PT   New nucleic acid sequences of Arabidopsis thaliana and their encoded
PT   products are useful to produce transgenic plants, to screen for
PT   biologically active agents such as fungicides and insecticides [illegible]
PT   genetic studies
XX
PS   Claim 1; SEQ ID NO [illegible]; [illegible]pp + Sequence Listing; English.
XX
CC   The invention relates to a novel nucleic acid of Arabidopsis thaliana
CC   comprising a sequence capable of hybridising under stringent [illegible]
CC   the [illegible] sequences referred to but not defined in the specification
CC   (ABL[illegible] ABL[illegible]). The nucleic acid sequences are useful to identify
CC   homologues or related genes, to produce compositions that modulate
CC   expression or function of the encoded proteins, to map functional [illegible]
CC   of the proteins, to study associated physiological pathways, to
CC   genetically manipulate cells and plants, the encoded products are useful
CC   to screen for biologically active agents such as fungicides [illegible]
CC   insecticides and to elucidate [illegible] pathways.
XX
SQ   Sequence [illegible] BP; [illegible] A; [illegible] other;

  Query Match             [illegible]
  Best Local Similarity   [illegible]
  Matches   [illegible]

Qy          3 GAAGGAGGATGAAC[illegible] 19
              [illegible]
Db        [illegible] GAAGGAGGATGAAC[illegible]


RESULT [illegible]
AAS[illegible]
ID   AAS[illegible] standard; cDNA; [illegible]
XX
AC   AAS[illegible];
XX
DT   [illegible] 2001  (first entry)
XX
DE   cDNA encoding novel human secreted protein [illegible]
XX
KW   Human; secreted; [illegible] enzyme; transferase; hydrolase; [illegible]
KW   ligase; [illegible] disorder; [illegible]
KW   autoimmune disorder; neurological disorder; metabolic [illegible]
KW   inflammatory disorder; cardiovascular disorder; reproductive [illegible]
KW   blood related disorder; infectious disorder; gene therapy [illegible]
KW   antiarthritic; nephrotropic; anticoagulant; [illegible]
XX
OS   Homo sapiens.
XX
PN   WO[illegible] A[illegible]
XX
PD   [illegible]
XX
PF   [illegible] JAN [illegible]
XX
PR   [illegible] JAN [illegible]
PR   04 FEB [illegible]
PR   24 FEB [illegible]
PR   [illegible] MAR [illegible]
```

PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235846.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.

PR 13-OCT-2000; 2000US-0239845.
PR 13-OCT-2000; 2000US-0239857.
PR 20-OCT-2000; 2000US-0240660.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241804.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250760.
PR 01-DEC-2000; 2000US-0250891.
PR 05-DEC-2000; 2000US-0251044.
PR 05-DEC-2000; 2000US-0251088.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251860.
PR 08-DEC-2000; 2000US-0251867.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA; Barash SC; Rubin SM;
XX
DR WPI; 2001-465066/50.
DR P-PSDB; AAU23272.
XX
PT Novel polypeptides and polynucleotides useful for diagnosis,
PT preventing, treating neural, immune system, muscular, reproductive,
PT pulmonary, cardiovascular, renal, proliferative disorders and
PT diseases
XX
PS Claim 4; SEQ ID NO 668; 1862pp; English.

```
XX
PT   The present invention relates to the isolation of novel human enzyme
PT   polypeptides (AA42915 AA43814), and the cDNA and genomic sequences
PT   encoding them. The enzyme polypeptides of the invention may comprise the
PT   functional classes of oxidoreductases, transferases, hydrolases, lyases,
PT   isomerases or ligases. The sequences of the invention are useful in the
PT   diagnosis, treatment, prevention and/or prognosis of a wide range of
PT   disorders including hyperproliferative disorders (e.g. cancer),
PT   immunodeficiency disorders (e.g. AIDS) autoimmune disorders
PT   (e.g. arthritis), neurological disorders (e.g. Alzheimer's disease),
PT   metabolic disorders (e.g. phenylketonuria), inflammatory disorders
PT   (e.g. asthma), cardiovascular disorders (e.g. atherosclerosis),
PT   blood-related disorders (e.g. haemophilia), reproductive disorders
PT   (e.g. infertility) and infectious disorders (e.g. tuberculosis). The
PT   polynucleotides of the invention can also be used in gene therapy.
PT   AA84 to AA841684 represent cDNA sequences encoding novel human
PT   enzyme polypeptides of the invention.
PT   Note: The sequence data for this patent did not form part of the printed
PT   specification, but was obtained in electronic format directly from WIPO
PT   at ftp://wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 689 BP; 192 A; 165 C; 164 G; 168 T; 0 other;

  Query Match          81.1%;  Score 15.1;  DB 2;  Length 689;
  Best Local Similarity   94.1%;  Pred. No. 6.6e-05;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          5 GAAGGAGGAAGAAGCC 20
              ||||||||||||||||
Db        673 GAAGGAGGAAGAAGCC 658


RESULT 2
AR84820
ID   AR84820 standard; cDNA; 689 BP.
XX
AC   AR84820;
XX
DT   05-JUN-2002  (first entry)
XX
DE   DNA encoding novel central nervous system protein #26.
XX
KW   Central nervous system; CNS; autoimmune disease; rheumatoid arthritis;
KW   hyperproliferative disorder; neoplasm; cardiovascular disorder;
KW   cardiac arrest; cerebrovascular disorder; ischaemia; arteriosclerosis;
KW   nervous system disorder; Alzheimer's disease; AIDS; cystic fibrosis;
KW   acquired immunodeficiency virus; dysphasia; gastrointestinal disorder;
KW   adenocarcinoma; reproductive system disorder; testicular feminisation;
KW   endocrine disorder; diabetes; cancer; leukaemia; neurosensory disorder;
KW   respiratory disorder; renal disorder; kidney failure; blood disorder;
KW   myocardial infarction; wound healing; cell proliferative disorder;
KW   food additive; food preservative; gene therapy; gene; ss.
XX
OS   Homo sapiens.
XX
PN   WO200230985-A2.
XX
PD   18-APR-2002.
XX
PF   17-JAN-2001; 2001WO-GB000183.
XX
PR   21-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   21-FEB-2000; 2000US-0184664.
PR   06-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189971.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   10-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216648.
PR   11-JUL-2000; 2000US-0217467.
PR   11-JUL-2000; 2000US-0217468.
PR   14-JUL-2000; 2000US-0218622.
PR   26-JUL-2000; 2000US-0220903.
PR   26-JUL-2000; 2000US-0220961.
PR   14-AUG-2000; 2000US-0225110.
PR   14-AUG-2000; 2000US-0225156.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225300.
PR   14-AUG-2000; 2000US-0225411.
PR   14-AUG-2000; 2000US-0225453.
PR   14-AUG-2000; 2000US-0225520.
PR   14-AUG-2000; 2000US-0225527.
PR   14-AUG-2000; 2000US-0225533.
PR   14-AUG-2000; 2000US-0225534.
PR   14-AUG-2000; 2000US-0225535.
PR   18-AUG-2000; 2000US-0226274.
PR   22-AUG-2000; 2000US-0226961.
PR   22-AUG-2000; 2000US-0226966.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227866.
PR   30-AUG-2000; 2000US-0229091.
PR   01-SEP-2000; 2000US-0229297.
PR   01-SEP-2000; 2000US-0229314.
PR   01-SEP-2000; 2000US-0229411.
PR   01-SEP-2000; 2000US-0229413.
PR   05-SEP-2000; 2000US-0229664.
PR   05-SEP-2000; 2000US-0229814.
PR   06-SEP-2000; 2000US-0230147.
PR   06-SEP-2000; 2000US-0230169.
PR   08-SEP-2000; 2000US-0231212.
PR   08-SEP-2000; 2000US-0231213.
PR   08-SEP-2000; 2000US-0231344.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0231411.
PR   08-SEP-2000; 2000US-0232086.
PR   08-SEP-2000; 2000US-0232091.
PR   12-SEP-2000; 2000US-0231909.
PR   14-SEP-2000; 2000US-0232307.
PR   14-SEP-2000; 2000US-0232309.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0232809.
PR   14-SEP-2000; 2000US-0232904.
PR   21-SEP-2000; 2000US-0234227.
PR   21-SEP-2000; 2000US-0234271.
PR   25-SEP-2000; 2000US-0234997.
PR   25-SEP-2000; 2000US-0234999.
PR   26-SEP-2000; 2000US-0235481.
PR   27-SEP-2000; 2000US-0235944.
PR   27-SEP-2000; 2000US-0235946.
PR   29-SEP-2000; 2000US-0236327.
PR   29-SEP-2000; 2000US-0236331.
PR   29-SEP-2000; 2000US-0236332.
PR   29-SEP-2000; 2000US-0236333.
PR   29-SEP-2000; 2000US-0236335.
PR   02-OCT-2000; 2000US-0236902.
PR   02-OCT-2000; 2000US-0237017.
PR   02-OCT-2000; 2000US-0237020.
PR   02-OCT-2000; 2000US-0237156.
PR   02-OCT-2000; 2000US-0237175.
PR   13-OCT-2000; 2000US-0239627.
PR   13-OCT-2000; 2000US-0239637.
PR   20-OCT-2000; 2000US-0241810.
PR   20-OCT-2000; 2000US-0241811.
PR   20-OCT-2000; 2000US-0241790.
PR   20-OCT-2000; 2000US-0241794.
PR   20-OCT-2000; 2000US-0241797.
PR   20-OCT-2000; 2000US-0241809.
```

PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0251989.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-581633/65.
DR P-PSDB; AAU87496.
XX
PT New isolated nucleic acid encoding a protein for diagnosing,
PT preventing, treating or ameliorating medical conditions and used as
PT food additives or preservatives
XX
PS Claim 1; SEQ ID No 416; 847pp; English.
XX
CC The invention describes an isolated nucleic acid molecule (I) encoding a
CC novel central nervous system protein. (I) and polypeptides (III) encoded
CC by (I), are used to treat a medical conditions and in diagnosis of a
CC pathological condition. Disorders which are diagnosed or treated include
CC autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
CC disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
CC e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC amniogenesis, nervous system disorders e.g. Alzheimer's disease and
CC amyotrophic lateral sclerosis, infections caused by bacteria
CC e.g. Acquired immunodeficiency virus (AIDS) and fungi, ocular
CC e.g. corneal infection, gastrointestinal disorders e.g. dyspepsia
CC adenocarcinomas and irritable bowel syndrome, reproductive system
CC disorders e.g. testicular feminisation, endocrine disorders e.g. diabetes
CC and pituitary dwarfism, cancers and disorders at the cellular
CC leukaemia, disorders involving neovascularisation e.g. malignancies,
CC respiratory disorders e.g. nonallergic rhinitis, renal disorders
CC acute kidney failure and blood related disorders e.g. myocardial
CC infarction. The polypeptides can also be used to aid wound healing
CC epithelial cell proliferation, to prevent skin aging due to sunlight
CC maintain organs before transplantation, for supporting cell culture
CC primary tissues, to regenerate tissues and in chemotaxis. The
CC polypeptides can also be used as a food additive or preservative
CC increase or decrease storage capabilities, fat content, lipid

Query Match 81.1%; Score 15.1; DB 24; Length
Best Local Similarity 94.1%; Pred. No. 6.6e-02;
Matches 16; Conservative 0; Mismatches 1; Indels

Qy GAAGAAGGAUGAAGGC 0
||||||||||||| |||
Db 262 GAAGGAGGAUGAAGGC 278

RESULT 33
AAF74281
ID AAF74281 standard; DNA; 1647 BP.
XX
AC AAF74281;
XX
DT 04-MAY-2001 (first entry)
XX
DE Liverwort calcium dependent protein kinase clone #1.
XX
KW Calcium dependent protein kinase; CDPK; herbicide resistance;
KW paraquat; diquat; crop production; ds.
XX
OS Marchantia polymorpha.
XX
PN WO200107592-A2.
XX
PD 01-FEB-2001.
XX
PF 26-JUL-2000; 2000WO-GB02876.
XX
PR 27-JUL-1999; 99GB-0017612.
XX
PA (ZENE) ZENECA LTD.
XX
PI Holt CD, White AJ, Michael AJ, Osborn HW;
XX
DR WPI; 2001-168549/17.
XX
PT Producing herbicide resistance plants by inhibiting calcium
PT protein kinase in plants e.g. by providing an intracellular
PT transporter capable of transporting antagonist into
XX
PS Claim 18; Page 42; 50pp; English.
XX
CC The present invention describes a method of producing plants
CC resistant to the herbicides paraquat and diquat, involving
CC the plants a calcium dependent protein kinase (CDPK) and
CC plants which are resistant to the agrochemical of interest
CC useful in the production of crops with herbicide resistance.
XX
SQ Sequence 1647 BP; 447 A; 418 C; 465 G; 306 T; 1 other;

Query Match 81.1%; Score 15.1; DB 22; Length
Best Local Similarity 94.1%; Pred. No.
Matches 16; Conservative 0; Mismatches 1; Indels

Qy GAAGGAGGAUGAAGGC 16

```
             ||||||||| |||||
Db     [illegible] GAAGGAGGATGCACCCC 664


RESULT 34
AAF[illegible]
ID   AAF[illegible] standard; DNA; [illegible] BP.
XX
AC   AAF[illegible];
XX
DT   04 MAY 2001  (first entry)
XX
DE   Liverwort calcium dependent protein kinase clone #[illegible].
XX
KW   Calcium dependent protein kinase; CDPK; herbicide resistance;
KW   paraquat, diquat, crop production, ds.
XX
OS   Marchantia polymorpha.
XX
PN   WO[illegible] A2.
XX
PD   [illegible] FEB 2001.
XX
PF   2[illegible] JUL 2000; 2000WO-GB02870.
XX
PR   27 JUL 1999;   99GB-0017642.
XX
PA   (ZENE ) ZENECA LTD.
XX
PI   H[illegible], White AJ, Michael AJ, Osborn RW;
XX
DR   WPI; 2001-168549/17.
XX
PT   Producing herbicide resistance plants by inhibiting calcium dependent
PT   protein kinase in plants or by providing an intracellular vacuolar
PT   transporter capable of transporting agrochemical into plant vacuole
XX
PS   Claim 18; Page 42; 50pp; English.
XX
CC   The present invention describes a method of producing plants which are
CC   resistant to the herbicides paraquat and diquat, involving inhibiting in
CC   the plants a calcium dependent protein kinase (CDPK) and selecting those
CC   plants which are resistant to the agrochemical of interest. This is
CC   useful in the production of crops with herbicide resistance
XX
SQ   Sequence 1647 BP; 445 A; 348 C; 464 G; [illegible] other;

  Query Match             81.1%;  Score 1[illegible];  DB [illegible];  Length [illegible];
  Best Local Similarity   94.1%;  Pred. No. [illegible];
  Matches   16;  Conservative    0;  Mismatches    [illegible];  Indels    [illegible];  Gaps    [illegible];

Qy          3 GAAGGAGGATGAACCCC 19
              |||||||||| |||||
Db        [illegible] GAAGGAGGATGCACCCC 664


RESULT 35
AAV[illegible]
ID   AAV[illegible] standard; cDNA; [illegible] BP.
XX
AC   AAV[illegible];
XX
DT   2[illegible] NOV 1998  (first entry)
XX
DE   Human HIADX50 (G protein coupled receptor).
XX
KW   G protein coupled receptor; HIADX50; agonist; antagonist; [illegible];
KW   bacterial infection; fungal infection; protozoal infection;
KW   viral infection; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             [illegible]
FT                   /*tag= a
FT                   /product= "human HIADX50"
XX
PN   EP[illegible] A1.
XX
PD   1[illegible] AUG 1998.
XX
PF   18 NOV 1997;   97[illegible].
XX
PR   24 JAN 1997;   97US-[illegible].
XX
PA   (SMIK ) SMITHKLINE BEECHAM CORP.
XX
PI   Bergsma DJ,  Ellis CE;
XX
DR   WPI; 1998-[illegible]/3[illegible].
DR   P-PSDB; AAW[illegible].
XX
PT   New DNA encoding G protein coupled receptor used to diagnose,
PT   prevent and treat e.g. [illegible] infections, pain, cancers, diabetes,
PT   asthma, Parkinson's disease, acute heart failure, hypertension,
PT   osteoporosis, ulcers, allergies and anxiety
XX
PS   Claim 8; Fig 1; 24pp; English.
XX
CC   This is the nucleotide sequence of the novel G protein coupled receptor
CC   (HIADX50) used in the method of the invention.  Agonists and
CC   antagonists for HIADX50 receptors are used to respectively enhance or
CC   inhibit HIADX50 activity.  Alternatively the HIADX50 polynucleotide is
CC   administered in vivo to stimulate receptor activity or an antisense
CC   a nucleic acid molecule that inhibits the expression of the nucleotide
CC   sequence encoding the receptor and/or a polypeptide that competes with
CC   the receptor for its ligand are administered to inhibit receptor
CC   activity.  Diseases or susceptibility to a disease related to
CC   expression or activity of HIADX50 are diagnosed by determining the
CC   presence or absence of a mutation in the nucleotide sequence encoding
CC   HIADX50 in the genome of a subject and/or analysing for the level of
CC   HIADX50 expression.  Identification of compounds which bind to HIADX50
CC   comprises contacting cells with a candidate compound and assessing the
CC   ability of the candidate compound to bind to the cells (by means of
CC   stimulation or diminution of a signal).  The active agents can be used
CC   in the treatment of infections (e.g. bacterial, fungal, protozoan and
CC   viral infections).  Agonists and antagonists can be used to treat
CC   conditions associated with HIADX50 imbalance.
XX
SQ   Sequence [illegible] BP; [illegible] A; [illegible] C; [illegible] G; [illegible] T; [illegible] other;

  Query Match             [illegible];  Score [illegible];  DB [illegible];  Length [illegible];
  Best Local Similarity   [illegible];  Pred. No. [illegible];
  Matches   1[illegible];  Conservative    [illegible];  Mismatches    [illegible];  Indels    [illegible];  Gaps    [illegible];

Qy          1 GGGAAGGAGGATGAACC 17
                ||||| |||||||||
Db        [illegible] GGGAAGAAGGATGAACC [illegible]


RESULT 36
ABK1[illegible]
ID   ABK1[illegible] standard; cDNA; [illegible] BP.
XX
AC   ABK1[illegible];
XX
DT   05 JUN 2002  (first entry)
XX
DE   DNA encoding novel central nervous system protein #[illegible].
XX
KW   Central nervous system; CNS; autoimmune disease; rheumatoid arthritis;
KW   hyperproliferative disorder; neoplasm; cardiovascular disorder;
KW   cardiac atrophy; cerebrovascular disorder; ischaemia; [illegible]
KW   nervous system disorder; Alzheimer's disease; AIDS; ocular disorder;
KW   acquired immunodeficiency; [illegible] dysplasia; gastrointestinal disorder;
KW   adenocarcinoma; reproductive system disorder; testicular [illegible]
```

KW endocrine disorder; diabetes; cancer; leukaemia; neovascularisation;
KW respiratory disorder; renal disorder; kidney failure; blood disorder;
KW myocardial infarction; wound healing; cell proliferation; skin aging;
KW food additive; food preservative; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200155418-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01332.
XX
PR 27-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 14-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 13-JUL-2000; 2000US-0218290.
PR 25-JUL-2000; 2000US-0220963.
PR 25-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227102.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234224.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236527.
PR 29-SEP-2000; 2000US-0236867.
PR 29-SEP-2000; 2000US-0236868.
PR 29-SEP-2000; 2000US-0236869.
PR 29-SEP-2000; 2000US-0236870.
PR 02-OCT-2000; 2000US-0238002.
PR 02-OCT-2000; 2000US-0237837.
PR 02-OCT-2000; 2000US-0237838.
PR 02-OCT-2000; 2000US-0237839.
PR 02-OCT-2000; 2000US-0237840.
PR 13-OCT-2000; 2000US-0239955.
PR 13-OCT-2000; 2000US-0239957.
PR 20-OCT-2000; 2000US-0240900.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241788.
PR 20-OCT-2000; 2000US-0241789.
PR 20-OCT-2000; 2000US-0241825.
PR 01-NOV-2000; 2000US-0244117.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249246.
PR 17-NOV-2000; 2000US-0249247.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250140.
PR 01-DEC-2000; 2000US-0250891.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0251989.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251668.
PR 08-DEC-2000; 2000US-0251669.
PR 08-DEC-2000; 2000US-0251884.

```
PR   0? DEC 2000; 2000US-0251990.
PR   1? DEC 2000; 2000US-0254097.
PR   0? JAN 2001; 2001US-025967?.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-581633/65.
DR   P-PSDB; AAU87179.
XX
PT   New isolated nucleic acid encoding a protein for diagnosing,
PT   preventing, treating or ameliorating medical conditions and used as
PT   food additives or preservatives
XX
PS   Claim 1; SEQ ID No 99; 837pp; English.
XX
CC   The invention describes an isolated nucleic acid molecule (I) encoding a
CC   novel central nervous system protein. (I) and polypeptides (II) encoded
CC   by (I), are used to treat a medical conditions and in diagnosis of a
CC   pathological condition. Disorders which are diagnosed or treated include
CC   autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
CC   disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
CC   e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC   angiogenesis, nervous system disorders e.g. Alzheimer's disease and
CC   amyotrophic lateral sclerosis, infections caused by bacteria, viruses
CC   e.g. Acquired immunodeficiency virus (AIDS) and fungi, ocular disorders
CC   e.g. corneal infection, gastrointestinal disorders e.g. dysphagia,
CC   adenocarcinomas and irritable bowel syndrome, reproductive system
CC   disorders e.g. testicular feminisation, endocrine disorders e.g. diabetes
CC   and pituitary dwarfism, cancers and disorders at the cellular level e.g.
CC   leukaemia, disorders involving neovascularisation e.g. malignancies,
CC   respiratory disorders e.g. nonallergic rhinitis, renal disorders e.g.
CC   acute kidney failure and blood related disorders e.g. myocardial
CC   infarction. The polypeptides can also be used to aid wound healing and
CC   epithelial cell proliferation, to prevent skin aging due to sunburn, to
CC   maintain organs before transplantation, for supporting cell culture of
CC   primary tissues, to regenerate tissues and in chemotaxis. The
CC   polypeptides can also be used as a food additive or preservative to
CC   increase or decrease storage capabilities, fat content, lipid, protein.

  Query Match             81.1%;  Score 15.4;  DB 23;  Length 2?9?;
  Best Local Similarity   94.1%;  Pred. No. 6,?0e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          ? GAAGGAGGATGAAGCC? ??
              |||||||||||||| |||
Db       17?4 GAAGGAGGATGAAGCCC 17?8


RESULT ?7
AAH??? ?
ID   AAH???? standard; cDNA; 2?? BP.
XX
AC   AAH?????;
XX
DT   2? JUN 2001  (first entry)
XX
DE   Human cDNA sequence SEQ ID NO:1????.
XX
KW   Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   EP1???1?-A2.
XX
PD   ?? FEB 2001.
XX
PF   28-JUL-2000; 2000EP-0116126.
XX
PR   2? JUL 1999;   99JP-0248036.
PR   2? AUG 1999;   99JP-0300253.
PR   1? JAN 2000; 2000JP-0118?7?.
PR   0? MAY 2000; 2000JP-0?8???.
PR   ?? JUN 2000; 2000JP-0?????.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Isogai T,  Nishikawa T,  Hayashi K,  Saito K,  Yamamoto J,
PI   Ishii S,  Sugiyama T,  Wakamatsu A,  Nagai K,  Otsuki T;
XX
DR   WPI; 2001-?19??/?1.
XX
PT   Primer sets for synthesizing polynucleotides, particularly the ?
PT   full length cDNAs defined in the specification, and for the detection
PT   and/or diagnosis of the abnormality of the proteins encoded by the
PT   full length cDNAs.
XX
PS   Claim 8; SEQ ID 1????; 2???pp; English.
XX
CC   The present invention describes primer sets for synthesizing ????
CC   full length cDNAs defined in the specification. Where a primer set
CC   comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC   to the complementary strand of a polynucleotide which comprises one of
CC   the 5602 nucleotide sequences defined in the specification, where the
CC   oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC   of an oligonucleotide comprising a sequence complementary to the
CC   complementary strand of a polynucleotide which comprises a 5' end
CC   sequence and an oligonucleotide comprising a sequence complementary to a
CC   polynucleotide which comprises a 3' end sequence, where the
CC   oligonucleotide comprises at least 15 nucleotides and the 5' end and 3'
CC   the 5' end sequence/3' end sequence is selected from those defined in
CC   the specification. The primer sets can be used in antisense therapy and
CC   in gene therapy. The primers are useful for synthesising polynucleotides,
CC   particularly full length cDNAs. The primers are also useful for the
CC   detection and/or diagnosis of the abnormality of the proteins encoded by
CC   the full length cDNAs. The primers allow obtaining of the full length
CC   cDNAs easily without any specialised methods. AAH?????? to AAH?????? and
CC   AAH13633 to AAH1??42 represent human cDNA sequences; AAB9???? to
CC   AAB95893 represent human amino acid sequences; and AAH????? to AAH?????
CC   represent oligonucleotides, all of which are used in the exemplification
CC   of the present invention.
XX
SQ   Sequence 2??? BP; ??? A; ??? C; ??? G; ??? T; 0 other;

  Query Match             ??.?%;  Score ??.?;  DB 2?;  Length 2??;
  Best Local Similarity   ??.?%;  Pred. No. ?,??;
  Matches   1?;  Conservative    0;  Mismatches    ?;  Indels    0;  Gaps    0;

Qy          1 GGGAAGGAGGATGAAGC 1?
              |||||||||| |||||
Db       1784 GGGAAGGAGGAGGAAGC 1800


RESULT 38
AAS9????
ID   AAS9???? standard; cDNA; ???? BP.
XX
AC   AAS9????;
XX
DT   13-FEB-2002  (first entry)
XX
DE   DNA encoding novel human diagnostic protein #2????.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0?????.
```

```
PP   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   P-PSDB; ABG25363.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity
XX
PS   Claim 1; SEQ ID No 25354; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. AAS64197-AAS64364 represent novel human
CC   diagnostic coding sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 3565 BP; 995 A; 867 C; 973 G; 729 T; 1 other;

  Query Match             81.1%;  Score 15.4;  DR 23;  Length 3565;
  Best Local Similarity   94.1%;  Pred. No. 7e-02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 GGGAAGGAGGATGAACC 17
           ||||||||||||| |||||
Db    1951 GGGAAGGAGGAGGAACC 1967


RESULT 39
AB102619/c
ID   AB102619 standard; cDNA; 8054 BP.
XX
AC   AB102619;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Drosophila melanogaster expressed polynucleotide SEQ ID NO 2339.
XX
KW   Drosophila; developmental biology; cell signalling; insecticide;
KW   pharmaceutical; gene; ss.
XX
OS   Drosophila melanogaster.
XX
PN   WO200171042-A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US09231.
XX
PR   24-MAR-2000; 2000US-191637P.
PR   11-JUL-2000; 2000US-0614150.
XX
PA   (PEKE ) PE CORP NY.
XX
PI   Venter JC,  Adams M,  Li PW,  Myers EW;
XX
DR   WPI; 2001-650870/75.
DR   P-PSDB; ABB50615.
XX
PT   New isolated nucleic acid detection reagent for detecting [illegible]
PT   genes from Drosophila and for elucidating cell signalling and [illegible]
PT   interactions
XX
PS   Claim 1; SEQ ID NO 2339; 2PP; English.
XX
CC   The invention relates to an isolated nucleic acid detection reagent
CC   capable of detecting one or more genes from Drosophila. The [illegible]
CC   useful in developmental biology and in elucidating cell signalling and
CC   cell-cell interactions in higher eukaryotes for the development
CC   insecticides, therapeutics and pharmaceutical drugs. The invention
CC   discloses genomic DNA sequences (AB102476-AB102511), expressed DNA
CC   sequences (AB101840-AB101875) and the encoded proteins
CC   (ABB57737-ABB72072).
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 8054 BP; 2250 A; 2287 C; 2117 G; 1600 T; 0 other;

  Query Match             81.1%;  Score 15.4;  DB 23;  Length 8054;
  Best Local Similarity   94.1%;  Pred. No. 7.2e-02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2 GGAAGGAGGATGAACCC 18
           ||| ||||||||||||
Db    4478 GGAAGGAGGATGAACCC 4462


RESULT 40
AAS41943
ID   AAS41943 standard; DNA; 12351 BP.
XX
AC   AAS41943;
XX
DT   17-DEC-2001  (first entry)
XX
DE   Genomic sequence #259 encoding novel human enzyme polypeptide
XX
KW   Human; oxidoreductase; enzyme; transferase; hydrolase; lyase; [illegible]
KW   ligase; hyperproliferative disorder; immunodeficiency disorder;
KW   autoimmune disorder; neurological disorder; metabolic disorder;
KW   inflammatory disorder; cardiovascular disorder; reproductive disorder;
KW   blood-related disorder; infectious disorder; gene therapy; [illegible]
KW   anti-arthritic; nephrotropic; anticoagulant; ds.
XX
OS   Homo sapiens.
XX
PN   WO200155361-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01259.
XX
PR   31-JAN-2000; 2000US-0179060.
PR   04-FEB-2000; 2000US-0180128.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186550.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209462.
PR   28-JUN-2000; 2000US-0214896.
PR   30-JUN-2000; 2000US-0215185.
PR   07-JUL-2000; 2000US-0216647.
```

```
PR   07 JUL 2000; 2000US-0216880.
PR   11 JUL 2000; 2000US-0217487.
PR   11 JUL 2000; 2000US-0217496.
PR   14 JUL 2000; 2000US-0218290.
PR   26 JUL 2000; 2000US-0220963.
PR   26 JUL 2000; 2000US-0220964.
PR   14 AUG 2000; 2000US-0224518.
PR   14 AUG 2000; 2000US-0224519.
PR   14 AUG 2000; 2000US-0225213.
PR   14 AUG 2000; 2000US-0225214.
PR   14 AUG 2000; 2000US-0225266.
PR   14 AUG 2000; 2000US-0225267.
PR   14 AUG 2000; 2000US-0225268.
PR   14 AUG 2000; 2000US-0225270.
PR   14 AUG 2000; 2000US-0225447.
PR   14 AUG 2000; 2000US-0225757.
PR   14 AUG 2000; 2000US-0225758.
PR   14 AUG 2000; 2000US-0225759.
PR   18 AUG 2000; 2000US-0226279.
PR   22 AUG 2000; 2000US-0226681.
PR   22 AUG 2000; 2000US-0226868.
PR   22 AUG 2000; 2000US-0227182.
PR   23 AUG 2000; 2000US-0227009.
PR   [illegible] AUG 2000; 2000US-0228924.
PR   01 SEP 2000; 2000US-0229287.
PR   01 SEP 2000; 2000US-0229343.
PR   01 SEP 2000; 2000US-0229344.
PR   01 SEP 2000; 2000US-0229345.
PR   05 SEP 2000; 2000US-0229509.
PR   05 SEP 2000; 2000US-0229513.
PR   06 SEP 2000; 2000US-0230437.
PR   06 SEP 2000; 2000US-0230438.
PR   08 SEP 2000; 2000US-0231242.
PR   08 SEP 2000; 2000US-0231243.
PR   08 SEP 2000; 2000US-0231244.
PR   08 SEP 2000; 2000US-0231413.
PR   08 SEP 2000; 2000US-0231414.
PR   08 SEP 2000; 2000US-0232080.
PR   08 SEP 2000; 2000US-0232081.
PR   12 SEP 2000; 2000US-0231968.
PR   14 SEP 2000; 2000US-0232397.
PR   14 SEP 2000; 2000US-0232398.
PR   14 SEP 2000; 2000US-0232399.
PR   14 SEP 2000; 2000US-0232400.
PR   14 SEP 2000; 2000US-0232401.
PR   14 SEP 2000; 2000US-0233063.
PR   14 SEP 2000; 2000US-0233064.
PR   14 SEP 2000; 2000US-0233065.
PR   21 SEP 2000; 2000US-0234223.
PR   21 SEP 2000; 2000US-0234274.
PR   25 SEP 2000; 2000US-0234997.
PR   25 SEP 2000; 2000US-0234998.
PR   26 SEP 2000; 2000US-0235484.
PR   27 SEP 2000; 2000US-0235834.
PR   27 SEP 2000; 2000US-0235836.
PR   29 SEP 2000; 2000US-0236327.
PR   29 SEP 2000; 2000US-0236367.
PR   29 SEP 2000; 2000US-0236368.
PR   29 SEP 2000; 2000US-0236369.
PR   29 SEP 2000; 2000US-0236370.
PR   02 OCT 2000; 2000US-0236802.
PR   02 OCT 2000; 2000US-0237037.
PR   02 OCT 2000; 2000US-0237038.
PR   02 OCT 2000; 2000US-0237039.
PR   02 OCT 2000; 2000US-0237040.
PR   13 OCT 2000; 2000US-0239935.
PR   13 OCT 2000; 2000US-0239937.
PR   [illegible] OCT 2000; 2000US-0240960.
PR   [illegible] OCT 2000; 2000US-0241221.
PR   20 OCT 2000; 2000US-0241785.
PR   20 OCT 2000; 2000US-0241786.
PR   20 OCT 2000; 2000US-0241787.
PR   20 OCT 2000; 2000US-0241808.
PR   20 OCT 2000; 2000US-[illegible].
PR   20 OCT 2000; 2000US-[illegible].
PR   01 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-0246474.
PR   08 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-[illegible].
PR   08 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   17 NOV 2000; 2000US-[illegible].
PR   01 DEC 2000; 2000US-[illegible].
PR   01 DEC 2000; 2000US-[illegible].
PR   05 DEC 2000; 2000US-[illegible].
PR   05 DEC 2000; 2000US-[illegible].
PR   05 DEC 2000; 2000US-[illegible].
PR   06 DEC 2000; 2000US-[illegible].
PR   08 DEC 2000; 2000US-[illegible].
PR   08 DEC 2000; 2000US-[illegible].
PR   08 DEC 2000; 2000US-[illegible].
PR   08 DEC 2000; 2000US-[illegible].
PR   08 DEC 2000; 2000US-[illegible].
PR   11 DEC 2000; 2000US-[illegible].
PR   05 JAN 2001; 2001US-[illegible].
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA, [illegible], Ruben SM;
XX
DR   WPI; 2001-[illegible].
XX
PT   Novel polypeptides and polynucleotides useful for diagnosing,
PT   preventing, treating neural, immune system, muscular, reproductive,
PT   pulmonary, cardiovascular, renal, proliferative disorders and infectious
PT   diseases -
XX
PS   Disclosure; SEQ ID NO [illegible]; [illegible]pp; English.
XX
CC   The present invention relates to the identification of novel human
CC   polypeptides (AAB2[illegible]-AAB2[illegible]1), and the cDNA and genomic sequences
CC   encoding them. The enzyme polypeptides of the invention are members of the
CC   functional classes of oxidoreductases, transferases, hydrolases, [illegible]
CC   isomerases or ligases. The sequences of the invention are useful in the
CC   diagnosis, treatment, prevention and/or prognosis of a wide range of
CC   disorders including hyperproliferative disorders (e.g. cancer),
CC   immunodeficiency disorders (e.g. AIDS) autoimmune disorders
```

CC (e.g. arthritis), neurological disorders (e.g. Alzheimer's disease),
CC metabolic disorders (e.g. phenylketonuria), inflammatory disorders
CC (e.g. asthma), cardiovascular disorders (e.g. atherosclerosis),
CC blood-related disorders (e.g. haemophilia), reproductive disorders
CC (e.g. infertility) and infectious disorders (e.g. influenza). The
CC polynucleotides of the invention can also be used in gene therapy.
CC AAS41685-AAS42192 represent DNA sequences encoding for the novel human
CC enzyme polypeptides of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12851 BP; 3489 A; 2688 C; 2702 G; 3472 T; 0 other;

Query Match 81.1%; Score 15.4; DB 22; Length 12851;
Best Local Similarity 94.1%; Prod. No. 7.4e-02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 8 GAAGGAGGATGAAGCCC 24
||||||||||||||||| |||
Db 12858 GAAGGAGGATGAAGCCC 12801

RESULT 41
AAS41942
ID AAS41942 standard; DNA; 12410 BP.
XX
AC AAS41942;
XX
DT 17-DEC-2001 (first entry)
XX
DE Genomic sequence #258 encoding novel human enzyme polypeptide.
XX
KW Human; oxidoreductase enzyme; transferase; hydrolase; lyase; isomerase;
KW ligase; hyperproliferative disorder; immunodeficiency disorder;
KW autoimmune disorder; neurological disorder; metabolic disorder;
KW inflammatory disorder; cardiovascular disorder; reproductive disorder;
KW blood-related disorder; infectious disorder; gene therapy; cytostatic;
KW anti arthritic; nephrotropic; anticoagulant; ds.
XX
OS Homo sapiens.
XX
PN WO200155301-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01239.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186850.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0231437.
PR 06-SEP-2000; 2000US-0230439.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231998.
PR 14-SEP-2000; 2000US-0232497.
PR 14-SEP-2000; 2000US-0232498.
PR 14-SEP-2000; 2000US-0232499.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235884.
PR 27-SEP-2000; 2000US-0235886.
PR 29-SEP-2000; 2000US-0236427.
PR 29-SEP-2000; 2000US-0236487.
PR 29-SEP-2000; 2000US-0236488.
PR 29-SEP-2000; 2000US-0236489.
PR 29-SEP-2000; 2000US-0236490.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0236837.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239955.
PR 13-OCT-2000; 2000US-0239957.
PR 20-OCT-2000; 2000US-0240660.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.

```
PR   08 NOV 2000; 2000US-0246528.
PR   08 NOV 2000; 2000US-02465[illegible].
PR   08 NOV 2000; 2000US-0246609.
PR   08 NOV 2000; 2000US-0246610.
PR   08 NOV 2000; 2000US-0246611.
PR   08 NOV 2000; 2000US-0246613.
PR   17 NOV 2000; 2000US-0249207.
PR   17 NOV 2000; 2000US-0249208.
PR   17 NOV 2000; 2000US-0249209.
PR   17 NOV 2000; 2000US-0249210.
PR   17 NOV 2000; 2000US-0249211.
PR   17 NOV 2000; 2000US-0249212.
PR   17 NOV 2000; 2000US-0249213.
PR   17 NOV 2000; 2000US-0249214.
PR   17 NOV 2000; 2000US-0249215.
PR   17 NOV 2000; 2000US-0249216.
PR   17 NOV 2000; 2000US-0249217.
PR   17 NOV 2000; 2000US-0249218.
PR   17 NOV 2000; 2000US-0249244.
PR   17 NOV 2000; 2000US-0249245.
PR   17 NOV 2000; 2000US-0249264.
PR   17 NOV 2000; 2000US-0249265.
PR   17 NOV 2000; 2000US-0249297.
PR   17 NOV 2000; 2000US-0249299.
PR   17 NOV 2000; 2000US-0249300.
PR   01 DEC 2000; 2000US-0250160.
PR   01 DEC 2000; 2000US-0250391.
PR   [illegible] DEC 2000; 2000US-0251030.
PR   [illegible] DEC 2000; 2000US-0251088.
PR   [illegible] DEC 2000; 2000US-0256713.
PR   [illegible] DEC 2000; 2000US-0251479.
PR   08 DEC 2000; 2000US-0251856.
PR   08 DEC 2000; 2000US-0251868.
PR   08 DEC 2000; 2000US-0251869.
PR   08 DEC 2000; 2000US-0251989.
PR   08 DEC 2000; 2000US-0251990.
PR   12 DEC 2000; 2000US-0254097.
PR   05 JAN 2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-465566/50.
XX
PT   Novel polypeptides and polynucleotides useful for diagnosing,
PT   preventing, treating neural, immune system, muscular, reproductive,
PT   pulmonary, cardiovascular, renal, proliferative disorders and cancerous
PT   diseases
XX
PS   Disclosure; SEQ ID No 2068; 1186pp; English.
XX
CC   The present invention relates to the isolation of novel human enzyme
CC   polypeptides (AAU22915-AAU23814), and the cDNA and genomic sequences
CC   encoding them. The enzyme polypeptides of the invention may comprise the
CC   functional classes of oxidoreductases, transferases, hydrolases, lyases,
CC   isomerases or ligases. The sequences of the invention are useful in the
CC   diagnosis, treatment, prevention and/or prognosis of a wide range of
CC   disorders including hyperproliferative disorders (e.g. cancer),
CC   immunodeficiency disorders (e.g. AIDS) autoimmune disorders
CC   (e.g. arthritis), neurological disorders (e.g. Alzheimer's disease),
CC   metabolic disorders (e.g. phenylketonuria), inflammatory disorders
CC   (e.g. asthma), cardiovascular disorders (e.g. atherosclerosis),
CC   blood related disorders (e.g. haemophilia), reproductive disorders
CC   (e.g. infertility) and infectious disorders (e.g. influenza). The
CC   polynucleotides of the invention can also be used in gene therapy.
CC   AAS41085-AAS42192 represent DNA sequences encoding for the novel human
CC   enzyme polypeptides of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12410 BP; 3511 A; 2656 C; 2718 G; 3485 T; [illegible]

  Query Match             [illegible]
  Best Local Similarity   [illegible]
  Matches   [illegible];  Conservative   [illegible];  Mismatches   [illegible];  Indels   [illegible];  Gaps   [illegible];

Qy        [illegible] GAAGGAGGATGAA[illegible]
              ||||||||||||| |||
Db   [illegible] GAAGGAGGATGAA[illegible]


RESULT 42
AAS41941
ID   AAS41941 standard; DNA; 12[illegible] BP.
XX
AC   AAS41941;
XX
DT   17 DEC 2001  (first entry)
XX
DE   Genomic sequence #[illegible] encoding a novel human enzyme polypeptide.
XX
KW   Human; oxidoreductase; enzyme; transferase; hydrolase; lyase; [illegible]
KW   ligase; hyperproliferative disorder; immunodeficiency; [illegible]
KW   autoimmune disorder; neurological disorder; metabolic [illegible]
KW   inflammatory disorder; cardiovascular disorder; reproductive [illegible]
KW   blood related disorder; infectious disorder; gene therapy; [illegible]
KW   antiarthritic; nephrotropic; antiasthmatic; [illegible]
XX
OS   Homo sapiens.
XX
PN   WO200[illegible]-A2.
XX
PD   02 AUG 2001.
XX
PF   17 JAN 2001; 2001WO-US01[illegible].
XX
PR   31 JAN 2000; 2000US-0179065.
PR   04 FEB 2000; 2000US-0180628.
PR   24 FEB 2000; 2000US-0184664.
PR   02 MAR 2000; 2000US-0186[illegible].
PR   16 MAR 2000; 2000US-0189874.
PR   17 MAR 2000; 2000US-0190076.
PR   18 APR 2000; 2000US-0198123.
PR   19 MAY 2000; 2000US-0205515.
PR   07 JUN 2000; 2000US-0209467.
PR   28 JUN 2000; 2000US-0214886.
PR   30 JUN 2000; 2000US-0215135.
PR   07 JUL 2000; 2000US-0216647.
PR   07 JUL 2000; 2000US-02168[illegible].
PR   11 JUL 2000; 2000US-0217487.
PR   11 JUL 2000; 2000US-0217496.
PR   14 JUL 2000; 2000US-0218290.
PR   26 JUL 2000; 2000US-0220963.
PR   26 JUL 2000; 2000US-0220964.
PR   14 AUG 2000; 2000US-0224518.
PR   14 AUG 2000; 2000US-0224519.
PR   14 AUG 2000; 2000US-0225[illegible].
PR   14 AUG 2000; 2000US-0225[illegible].
PR   14 AUG 2000; 2000US-0225[illegible].
PR   14 AUG 2000; 2000US-0225[illegible].
PR   14 AUG 2000; 2000US-0225[illegible].
PR   14 AUG 2000; 2000US-0225[illegible].
PR   14 AUG 2000; 2000US-0225447.
PR   14 AUG 2000; 2000US-0225[illegible].
PR   14 AUG 2000; 2000US-0225[illegible].
PR   14 AUG 2000; 2000US-0225[illegible].
PR   18 AUG 2000; 2000US-0226[illegible].
PR   22 AUG 2000; 2000US-0226[illegible].
PR   22 AUG 2000; 2000US-0226868.
PR   22 AUG 2000; 2000US-0227182.
PR   23 AUG 2000; 2000US-0227[illegible].
PR   30 AUG 2000; 2000US-0229[illegible].
PR   01 SEP 2000; 2000US-0229287.
PR   01 SEP 2000; 2000US-0229343.
```

PR 01-SEP-2000; 2000US-0229444.
PR 01-SEP-2000; 2000US-0229445.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237047.
PR 02-OCT-2000; 2000US-0237048.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 23-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 09-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 09-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249243.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249254.
PR 17-NOV-2000; 2000US-0249255.
PR 17-NOV-2000; 2000US-0249257.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250591.
PR 05-DEC-2000; 2000US-0251086.
PR 05-DEC-2000; 2000US-0251089.
PR 05-DEC-2000; 2000US-0250711.
PR 06-DEC-2000; 2000US-0251179.
PR 08-DEC-2000; 2000US-0253856.
PR 08-DEC-2000; 2000US-0253868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251884.
PR 08-DEC-2000; 2000US-0251995.
PR 11-DEC-2000; 2000US-0254007.
PR 05-JAN-2001; 2001US-0259729.
XX
PA (HUMA) HUMAN GENOME SCI INC.
XX
PI Rosen CA; Barash SC; Ruben SM;
XX
DR WPI; 2001-465566/50.
XX
PT Novel polypeptides and polynucleotides useful for diagnostic,
PT preventive, treatment, neural, immune system, muscular, reproductive,
PT pulmonary, cardiovascular, renal, proliferative disorders and
PT diseases
XX
PS Disclosure; SEQ ID NO 2067; 136pp; English.
XX
CC The present invention relates to the isolation of novel human
CC polypeptides (AAU22915-AAU22914), and the cDNA and genomic sequences
CC encoding them. The enzyme polypeptides of the invention may exhibit
CC functional classes of oxidoreductases, transferases, hydrolases, lyases
CC isomerases or ligases. The sequences of the invention are useful in the
CC diagnosis, treatment, prevention and/or prognosis of a wide range
CC disorders including hyperproliferative disorders (e.g. cancer),
CC immunodeficiency disorders (e.g. AIDS) autoimmune disorders
CC (e.g. arthritis), neurological disorders (e.g. Alzheimer's disease),
CC metabolic disorders (e.g. phenylketonuria), inflammatory disorders
CC (e.g. asthma), cardiovascular disorders (e.g. atherosclerosis),
CC blood-related disorders (e.g. haemophilia), reproductive disorders
CC (e.g. infertility) and infectious disorders (e.g. influenza). The
CC polynucleotides of the invention can also be used in gene therapy. The
CC AAS41585 AAS41594 represent DNA sequences encoding the
CC enzyme polypeptides of the invention.
CC Note: The sequence data for this patent did not form part
CC specification, but was obtained in electronic format directly
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 1212 BP; 300 A; 299 C; 232 G; 384 T; 0 other;

Query Match 81.1%; Score 1545; DB 22; Length 1212;
Best Local Similarity 94.1%; Pred. No. 2.4e-102;
Matches 1620; Conservative 0; Mismatches 81; Indels 0; Gaps 0;

Qy 8 GAAGGAGGAGGAAGGG 23
||||||||||||||||
Db 10645 GAAGGAGGAGGAAGGG 10660

RESULT 43
ABL02618
ID ABL02618 standard; cDNA; 1361 BP.

```
XX
AC   ABL[illegible];
XX
DT   2[illegible] MAR 2002  (first entry)
XX
DE   Drosophila melanogaster expressed polynucleotide [illegible].
XX
KW   Drosophila; developmental biology; cell signalling; insecticide;
KW   pharmaceutical; gene; ss.
XX
OS   Drosophila melanogaster.
XX
PN   W[illegible]171042 A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US09231.
XX
PR   23-MAR-2000; 2000US-191637P.
PR   1[illegible]-JUL-2000; 2000US-0614150.
XX
PA   (PEKE-) PE CORP NY.
XX
PI   Venter JC, Adams M, Li PWD, Myers EW;
XX
DR   WPI; 2001-656860/75.
DR   P-PSDB; ABB58515.
XX
PT   New isolated nucleic acid detection reagent for detecting 1000 or more
PT   genes from Drosophila and for elucidating cell signalling and cell-cell
PT   interactions
XX
PS   Claim 1; SEQ ID NO 2[illegible]; 2[illegible]pp; Sequence Listing; English.
XX
CC   The invention relates to an isolated nucleic acid detection reagent
CC   capable of detecting 1000 or more genes from Drosophila. The invention is
CC   useful in developmental biology and in elucidating cell signalling and
CC   cell-cell interactions in higher eukaryotes for the development of
CC   insecticides, therapeutics and pharmaceutical drugs. The invention
CC   discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC   sequences (ABL01840-ABL16175) and the encoded proteins
CC   (ABB[illegible]-ABB72072).
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 14361 BP; 3565 A; 3334 C; 3507 G; [illegible] T; [illegible] other;

  Query Match             81.1%;  Score 15.4;  DB 23;  Length 14361;
  Best Local Similarity   94.1%;  Pred. No. 7.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          2 [illegible]GAAGGAGGATGAACC[illegible] 18
              [illegible]|||||||||||||
Db       4977 [illegible]GAGGAGGATGAACC[illegible] 4993


RESULT 44
AAL[illegible]
ID   AAL[illegible] standard; DNA; 1674[illegible] BP.
XX
AC   AAL[illegible];
XX
DT   [illegible] JAN 2002  (first entry)
XX
DE   Human musculoskeletal system related polynucleotide SEQ ID NO [illegible].
XX
KW   Cytostatic; immunosuppressive; neotropic; nootropic; [illegible]; antiviral;
KW   antiallergic; hepatotropic; antidiabetic; antiinflammatory; [illegible];
KW   vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW   cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW   neurological disease; infection; human; secreted protein;
KW   musculoskeletal system; ds.
XX
OS   Homo sapiens.
XX
PN   WO200155[illegible] A[illegible].
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-[illegible].
XX
PR   [illegible]-JAN-2000; 2000US-[illegible].
PR   04-FEB-2000; 2000US-[illegible].
PR   24-FEB-2000; 2000US-0184[illegible].
PR   02-MAR-2000; 2000US-[illegible].
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-019007[illegible].
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-[illegible].
PR   07-JUL-2000; 2000US-[illegible].
PR   07-JUL-2000; 2000US-021[illegible].
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-022[illegible].
PR   26-JUL-2000; 2000US-022[illegible].
PR   14-AUG-2000; 2000US-[illegible].
PR   14-AUG-2000; 2000US-[illegible].
PR   14-AUG-2000; 2000US-[illegible].
PR   14-AUG-2000; 2000US-[illegible].
PR   14-AUG-2000; 2000US-[illegible].
PR   14-AUG-2000; 2000US-[illegible].
PR   14-AUG-2000; 2000US-[illegible].
PR   14-AUG-2000; 2000US-[illegible].
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-[illegible].
PR   14-AUG-2000; 2000US-[illegible].
PR   14-AUG-2000; 2000US-[illegible].
PR   18-AUG-2000; 2000US-[illegible].
PR   22-AUG-2000; 2000US-[illegible].
PR   22-AUG-2000; 2000US-[illegible].
PR   22-AUG-2000; 2000US-[illegible].
PR   23-AUG-2000; 2000US-[illegible].
PR   30-AUG-2000; 2000US-[illegible].
PR   01-SEP-2000; 2000US-[illegible].
PR   01-SEP-2000; 2000US-[illegible].
PR   01-SEP-2000; 2000US-[illegible].
PR   01-SEP-2000; 2000US-[illegible].
PR   05-SEP-2000; 2000US-[illegible].
PR   05-SEP-2000; 2000US-[illegible].
PR   06-SEP-2000; 2000US-[illegible].
PR   06-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   08-SEP-2000; 2000US-[illegible].
PR   12-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   14-SEP-2000; 2000US-[illegible].
PR   21-SEP-2000; 2000US-[illegible].
PR   21-SEP-2000; 2000US-[illegible].
PR   25-SEP-2000; 2000US-[illegible].
PR   25-SEP-2000; 2000US-[illegible].
```

```
PR   26-SEP-2000; 2000US-0235484.
PR   27-SEP-2000; 2000US-0235831.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236327.
PR   29-SEP-2000; 2000US-0236367.
PR   29-SEP-2000; 2000US-0236368.
PR   29-SEP-2000; 2000US-0236369.
PR   29-SEP-2000; 2000US-0236370.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237040.
PR   13-OCT-2000; 2000US-0239935.
PR   13-OCT-2000; 2000US-0239937.
PR   20-OCT-2000; 2000US-0240960.
PR   20-OCT-2000; 2000US-0241221.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-0246609.
PR   08-NOV-2000; 2000US-0246610.
PR   08-NOV-2000; 2000US-0246611.
PR   08-NOV-2000; 2000US-0246613.
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
PR   17-NOV-2000; 2000US-0249215.
PR   17-NOV-2000; 2000US-0249216.
PR   17-NOV-2000; 2000US-0249217.
PR   17-NOV-2000; 2000US-0249218.
PR   17-NOV-2000; 2000US-0249244.
PR   17-NOV-2000; 2000US-0249245.
PR   17-NOV-2000; 2000US-0249264.
PR   17-NOV-2000; 2000US-0249265.
PR   17-NOV-2000; 2000US-0249297.
PR   17-NOV-2000; 2000US-0249299.
PR   17-NOV-2000; 2000US-0249300.
PR   01-DEC-2000; 2000US-0250160.
PR   01-DEC-2000; 2000US-0250391.
PR   05-DEC-2000; 2000US-0251030.
PR   05-DEC-2000; 2000US-0251988.
PR   05-DEC-2000; 2000US-0256719.
PR   06-DEC-2000; 2000US-0251479.
PR   08-DEC-2000; 2000US-0251856.
PR   08-DEC-2000; 2000US-0251868.
PR   08-DEC-2000; 2000US-0251869.
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-451957/48.
XX
PT   Isolated polypeptide for treating, preventing and/ or prognosing
PT   disorders related to the musculoskeletal system including
PT   musculoskeletal cancers and also for testing and detection e.g.
PT   diagnosis -
XX
PS   Example 2; SEQ ID No 3354; 78pp; Sequence Listing; English.
XX
CC   The invention relates to novel genes (AAL34664-AAL37666) and proteins
CC   (AAB95067-AAB68159) associated with the musculoskeletal system, useful
CC   for preventing, treating or ameliorating medical conditions e.g. by
CC   protein or gene therapy. The genes are isolated from a range of human
CC   tissues disclosed in the specification. The nucleic acids, proteins
CC   antibodies and (ant)agonists are useful in the diagnosis, treatment
CC   and prevention of: (a) cancer, e.g. breast and ovarian cancer and
CC   other cancers of the adrenal gland, bone, bone marrow, breast,
CC   gastrointestinal tract, liver, lung, or urogenital; (b) immune
CC   disorders e.g. Addison's disease, allergies, autoimmune haem...
CC   anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
CC   multiple sclerosis, rheumatoid arthritis and ulcerative colitis;
CC   (c) cardiovascular disorders such as myocardial ischaemias; (d) wound
CC   healing; (e) neurological diseases e.g. cerebral anoxia and epilepsy;
CC   and (f) infectious diseases such as viral, bacterial, fungal and
CC   parasitic infections.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format ...
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 16747 BP; 4203 A; 3717 C; 3840 G; 3787 T; 1200 other;

  Query Match             8.1%;  Score 15.4;  DB 22;  Length 16747;
  Best Local Similarity   94.1%;  Pred. No. 7.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 GGGAAGGAGGAGGAACC 17
                |||||||||| |||||
Db        384 GGGAAGGAGGAGGAACC 400


RESULT 49
AAK80326
ID   AAK80326 standard; DNA; 16747 BP.
XX
AC   AAK80326;
XX
DT   07 NOV 2001  (first entry)
XX
DE   Human immune/haematopoietic antigen genomic sequence SEQ ID NO ...
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; ...
KW   cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS   Homo sapiens.
XX
PN   WO200157182-A2.
XX
PD   09-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01354.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
```

```
PR   2[illegible] JUN 2000; 2000US-0209467.
PR   2[illegible] JUN 2000; 2000US-0214886.
PR   [illegible] JUN 2000; 2000US-021[illegible].
PR   0[illegible] JUL 2000; 2000US-0216647.
PR   07 JUL 2000; 2000US-0216880.
PR   11 JUL 2000; 2000US-0217487.
PR   11 JUL 2000; 2000US-0217496.
PR   14 JUL 2000; 2000US-0218290.
PR   2[illegible] JUL 2000; 2000US-0220963.
PR   2[illegible] JUL 2000; 2000US-0220964.
PR   14 AUG 2000; 2000US-0224518.
PR   14 AUG 2000; 2000US-0224519.
PR   14 AUG 2000; 2000US-0225213.
PR   14 AUG 2000; 2000US-0225214.
PR   14 AUG 2000; 2000US-0225266.
PR   14 AUG 2000; 2000US-0225267.
PR   14 AUG 2000; 2000US-0225268.
PR   14 AUG 2000; 2000US-0225270.
PR   14 AUG 2000; 2000US-0225447.
PR   14 AUG 2000; 2000US-022575[illegible].
PR   14 AUG 2000; 2000US-0225758.
PR   14 AUG 2000; 2000US-0225759.
PR   1[illegible] AUG 2000; 2000US-0226279.
PR   2[illegible] AUG 2000; 2000US-0226681.
PR   2[illegible] AUG 2000; 2000US-0226868.
PR   2[illegible] AUG 2000; 2000US-0227182.
PR   2[illegible] AUG 2000; 2000US-0227009.
PR   [illegible] AUG 2000; 2000US-0228924.
PR   0[illegible] SEP 2000; 2000US-0229287.
PR   01 SEP 2000; 2000US-0229343.
PR   01 SEP 2000; 2000US-0229344.
PR   [illegible] SEP 2000; 2000US-0229345.
PR   [illegible] SEP 2000; 2000US-0229[illegible].
PR   0[illegible] SEP 2000; 2000US-0229513.
PR   06 SEP 2000; 2000US-0230437.
PR   0[illegible] SEP 2000; 2000US-0230438.
PR   08 SEP 2000; 2000US-0231242.
PR   08 SEP 2000; 2000US-0231243.
PR   08 SEP 2000; 2000US-0231244.
PR   08 SEP 2000; 2000US-0231413.
PR   08 SEP 2000; 2000US-0231414.
PR   08 SEP 2000; 2000US-0232080.
PR   08 SEP 2000; 2000US-0232081.
PR   1[illegible] SEP 2000; 2000US-0231968.
PR   14 SEP 2000; 2000US-0232397.
PR   14 SEP 2000; 2000US-0232398.
PR   14 SEP 2000; 2000US-0232399.
PR   14 SEP 2000; 2000US-0232400.
PR   14 SEP 2000; 2000US-0232401.
PR   14 SEP 2000; 2000US-0233063.
PR   14 SEP 2000; 2000US-0233064.
PR   14 SEP 2000; 2000US-0233065.
PR   2[illegible] SEP 2000; 2000US-0234223.
PR   21 SEP 2000; 2000US-0234271.
PR   2[illegible] SEP 2000; 2000US-0234[illegible].
PR   2[illegible] SEP 2000; 2000US-0234998.
PR   2[illegible] SEP 2000; 2000US-0235484.
PR   2[illegible] SEP 2000; 2000US-0235834.
PR   2[illegible] SEP 2000; 2000US-0235[illegible].
PR   29 SEP 2000; 2000US-0236327.
PR   29 SEP 2000; 2000US-0236367.
PR   29 SEP 2000; 2000US-0236368.
PR   29 SEP 2000; 2000US-0236369.
PR   29 SEP 2000; 2000US-0236370.
PR   0[illegible] OCT 2000; 2000US-0236862.
PR   02 OCT 2000; 2000US-0237037.
PR   02 OCT 2000; 2000US-0237038.
PR   02 OCT 2000; 2000US-0237039.
PR   02 OCT 2000; 2000US-0237040.
PR   1[illegible] OCT 2000; 2000US-0239935.
PR   1[illegible] OCT 2000; 2000US-0239937.
PR   20 OCT 2000; 2000US-0240960.
PR   2[illegible] OCT 2000; 2000US-0241221.
PR   20 OCT 2000; [illegible]
PR   20 OCT 2000; [illegible]
PR   20 OCT 2000; 2000US-0241[illegible].
PR   20 OCT 2000; 2000US-0241808
PR   20 OCT 2000; [illegible]
PR   20 OCT 2000; [illegible]
PR   01 NOV 2000; [illegible]
PR   08 NOV 2000; 2000US-0246171.
PR   08 NOV 2000; [illegible]
PR   08 NOV 2000; [illegible]
PR   08 NOV 2000; [illegible]
PR   08 NOV 2000; [illegible]
PR   08 NOV 2000; [illegible]
PR   08 NOV 2000; [illegible]
PR   08 NOV 2000; [illegible]
PR   08 NOV 2000; [illegible]
PR   08 NOV 2000; [illegible]
PR   08 NOV 2000; [illegible]
PR   08 NOV 2000; [illegible]
PR   08 NOV 2000; [illegible]
PR   08 NOV 2000; [illegible]
PR   08 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   17 NOV 2000; [illegible]
PR   01 DEC 2000; [illegible]
PR   01 DEC 2000; [illegible]
PR   05 DEC 2000; [illegible]
PR   05 DEC 2000; 2000US-0251008.
PR   0[illegible] DEC 2000; [illegible]
PR   06 DEC 2000; [illegible]
PR   08 DEC 2000; [illegible]
PR   08 DEC 2000; [illegible]
PR   08 DEC 2000; [illegible]
PR   08 DEC 2000; [illegible]
PR   08 DEC 2000; [illegible]
PR   11 DEC 2000; [illegible]
PR   05 JAN 2001; [illegible]
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA, Barash SC, Ruben SM;
XX
DR   WPI; 2001-[illegible].
XX
PT   Nucleic acids encoding human immune/haematopoietic antigen [illegible]
PT   useful for preventing, diagnosing and/or treating cancer and
PT   metastasis
XX
PS   Disclosure; SEQ ID NO [illegible]; [illegible]pp; Sequence Listing; English.
XX
CC   AAK[illegible] to AAK[illegible] encode the human immune/haematopoietic antigen (I)
CC   amino acid sequences given in AAM[illegible] to AAM[illegible]. (I) [illegible]
CC   activity, and can be used in gene therapy and vaccine production. (I)
CC   proteins and polynucleotides may be used in the prevention, [illegible] and
CC   treatment of disorders associated with inappropriate (I) expression [illegible]
```

```
CC   example, they may be used to treat disorders associated with decreased
CC   expression by rectifying mutations or deletions in a patient's genome
CC   that affect the activity of (i) by expressing inactive proteins or to
CC   supplement the patients own production of (i). Additionally, (i)
CC   polynucleotides may be used to produce the secreted (i), by inserting
CC   the nucleic acids into a host cell and culturing the cell to express the
CC   protein. (i) proteins and polynucleotides may be used to prevent,
CC   diagnose and treat immune/haematopoietic-related diseases, especially
CC   cancers and cancer metastases of haematopoietic derived cells. AAK64703
CC   to AAK87694 represent human immune/haematopoietic antigen genomic
CC   sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC   represent sequences used in the exemplification of the present invention.
XX
SQ   Sequence 16747 BP; 4203 A; 3717 C; 3840 G; 4787 T; 1200 other;

  Query Match             81.1%;  Score 15.4;  DB 22;  Length 16747;
  Best Local Similarity   94.1%;  Pred. No. 7.5e-02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        1 GGGAAGGAGGATGAACC 17
            ||||||||||| |||||
Db      384 GGGAAGGAGGAGGAACC 400


RESULT 46
AAK86604
ID   AAK86604 standard; DNA; 16747 BP.
XX
AC   AAK86604;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Human immune/haematopoietic antigen genomic sequence SEQ ID NO:41416.
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW   cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS   Homo sapiens.
XX
PN   WO200157182-A2.
XX
PD   09-AUG-2001.
XX
PF   07-JAN-2001; 2001WO-US01454.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186450.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215145.
PR   07-JUL-2000; 2000US-0216547.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220964.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226274.
PR   22-AUG-2000; 2000US-0226581.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229345.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229599.
PR   05-SEP-2000; 2000US-0229615.
PR   06-SEP-2000; 2000US-0230137.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231245.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231418.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0232000.
PR   08-SEP-2000; 2000US-0232001.
PR   12-SEP-2000; 2000US-0231668.
PR   14-SEP-2000; 2000US-0232397.
PR   14-SEP-2000; 2000US-0232398.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0233063.
PR   14-SEP-2000; 2000US-0233064.
PR   14-SEP-2000; 2000US-0233065.
PR   21-SEP-2000; 2000US-0234223.
PR   21-SEP-2000; 2000US-0234274.
PR   25-SEP-2000; 2000US-0234997.
PR   25-SEP-2000; 2000US-0234998.
PR   26-SEP-2000; 2000US-0235484.
PR   27-SEP-2000; 2000US-0235834.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236527.
PR   29-SEP-2000; 2000US-0236567.
PR   29-SEP-2000; 2000US-0236568.
PR   29-SEP-2000; 2000US-0236569.
PR   29-SEP-2000; 2000US-0236570.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237040.
PR   13-OCT-2000; 2000US-0239035.
PR   13-OCT-2000; 2000US-0239037.
PR   20-OCT-2000; 2000US-0241221.
PR   20-OCT-2000; 2000US-0241222.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241825.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246552.
PR   09-NOV-2000; 2000US-0246604.
```

```
PR    08 NOV 2000; 2000US-0246610.
PR    08 NOV 2000; 2000US-0246611.
PR    08 NOV 2000; 2000US-0246613.
PR    17 NOV 2000; 2000US-0249207.
PR    17 NOV 2000; 2000US-0249208.
PR    17 NOV 2000; 2000US-0249209.
PR    17 NOV 2000; 2000US-0249210.
PR    17 NOV 2000; 2000US-0249211.
PR    17 NOV 2000; 2000US-0249212.
PR    17 NOV 2000; 2000US-0249213.
PR    17 NOV 2000; 2000US-0249214.
PR    17 NOV 2000; 2000US-0249215.
PR    17 NOV 2000; 2000US-0249216.
PR    17 NOV 2000; 2000US-0249217.
PR    17 NOV 2000; 2000US-0249218.
PR    17 NOV 2000; 2000US-0249244.
PR    17 NOV 2000; 2000US-0249245.
PR    17 NOV 2000; 2000US-0249264.
PR    17 NOV 2000; 2000US-0249265.
PR    17 NOV 2000; 2000US-0249297.
PR    17 NOV 2000; 2000US-0249299.
PR    17 NOV 2000; 2000US-0249300.
PR    01 DEC 2000; 2000US-0250160.
PR    01 DEC 2000; 2000US-0250391.
PR    05 DEC 2000; 2000US-0251030.
PR    05 DEC 2000; 2000US-0251988.
PR    05 DEC 2000; 2000US-0256719.
PR    06 DEC 2000; 2000US-0251479.
PR    08 DEC 2000; 2000US-0251856.
PR    08 DEC 2000; 2000US-0251868.
PR    08 DEC 2000; 2000US-0251869.
PR    08 DEC 2000; 2000US-0251989.
PR    08 DEC 2000; 2000US-0251990.
PR    11 DEC 2000; 2000US-0254097.
PR    05 JAN 2001; 2001US-0259678.
XX
PA    (HUMA-) HUMAN GENOME SCI INC.
XX
PI    Rosen CA,  Barash SC,  Ruben SM;
XX
DR    WPI; 2001-483426/52.
XX
PT    Nucleic acids encoding human immune/hematopoietic antigen polypeptides
PT    useful for preventing, diagnosing and/or treating cancers and
PT    metastasis
XX
PS    Claim 1; SEQ ID NO 41416; [illegible] Sequence Listing; English.
XX
CC    AAK[illegible] to AAK64702 encode the human immune/haematopoietic antigen (I)
CC    amino acid sequences given in AAM82170 to AAM[illegible]. (I) have cytostatic
CC    activity, and can be used in gene therapy and vaccine production. (I)
CC    proteins and polynucleotides may be used in the prevention, diagnosis and
CC    treatment of diseases associated with inappropriate (I) expression. For
CC    example, they may be used to treat disorders associated with decreased
CC    expression by rectifying mutations or deletions in a patient's genome
CC    that affect the activity of (I) by expressing inactive proteins or to
CC    supplement the patients own production of (I). Additionally, (I)
CC    polynucleotides may be used to produce the secreted (I), by inserting
CC    the nucleic acids into a host cell and culturing the cell to express the
CC    protein. (I) proteins and polynucleotides may be used to prevent,
CC    diagnose and treat immune/haematopoietic related diseases, especially
CC    cancers and cancer metastases of haematopoietic derived cells. AAK[illegible]
CC    to AAK[illegible] represent human immune/haematopoietic antigen genomic
CC    sequences from the present invention. AAK[illegible] to AAK[illegible] and AAM[illegible]
CC    represent sequences used in the exemplification of the present invention.
XX
SQ    Sequence 16747 BP; 4203 A; 3717 C; 3840 G; [illegible] T; [illegible] other;

  Query Match             81.1%;  Score 15.4;  DB 22;  Length 16747;
  Best Local Similarity   94.1%;  Pred. No. [illegible];
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 GGGAAGGAGGATGAACC 17
                |||||||:|||||||||
Db        984 GGGAAGGAGGAGGAACC 1000


RESULT 47
AAK[illegible]
ID    AAK[illegible] standard; DNA; [illegible] BP.
XX
AC    AAK[illegible];
XX
DT    0[illegible] NOV 2001  (first entry)
XX
DE    Human digestive system antigen genomic sequence SEQ ID NO:[illegible].
XX
KW    Human; digestive system antigen; gene therapy; cancer; appendicitis;
KW    ulcerative colitis; infection; Hirschsprung's disease; Chagas' disease;
KW    digestive system disorder; Meckel's diverticulum; ss.
XX
OS    Homo sapiens.
XX
PN    WO[illegible]-A1.
XX
PD    02 AUG 2001.
XX
PF    17 JAN 2001; 2001WO-US01[illegible].
XX
PR    31 JAN 2000; 2000US-[illegible].
PR    1[illegible] FEB 2000; 2000US-[illegible].
PR    24 FEB 2000; 2000US-[illegible].
PR    02 MAR 2000; 2000US-[illegible].
PR    16 MAR 2000; 2000US-018[illegible].
PR    17 MAR 2000; 2000US-[illegible].
PR    18 APR 2000; 2000US-[illegible].
PR    19 MAY 2000; 2000US-[illegible].
PR    07 JUN 2000; 2000US-[illegible].
PR    28 JUN 2000; 2000US-[illegible].
PR    30 JUN 2000; 2000US-[illegible].
PR    07 JUL 2000; 2000US-[illegible].
PR    07 JUL 2000; 2000US-[illegible].
PR    11 JUL 2000; 2000US-[illegible].
PR    11 JUL 2000; 2000US-[illegible].
PR    14 JUL 2000; 2000US-[illegible].
PR    26 JUL 2000; 2000US-[illegible].
PR    26 JUL 2000; 2000US-[illegible].
PR    14 AUG 2000; 2000US-[illegible].
PR    14 AUG 2000; 2000US-[illegible].
PR    14 AUG 2000; 2000US-[illegible].
PR    14 AUG 2000; 2000US-[illegible].
PR    14 AUG 2000; 2000US-[illegible].
PR    14 AUG 2000; 2000US-[illegible].
PR    14 AUG 2000; 2000US-[illegible].
PR    14 AUG 2000; 2000US-[illegible].
PR    14 AUG 2000; 2000US-[illegible].
PR    14 AUG 2000; 2000US-[illegible].
PR    14 AUG 2000; 2000US-[illegible].
PR    14 AUG 2000; 2000US-[illegible].
PR    18 AUG 2000; 2000US-[illegible].
PR    22 AUG 2000; 2000US-[illegible].
PR    22 AUG 2000; 2000US-[illegible].
PR    22 AUG 2000; 2000US-[illegible].
PR    23 AUG 2000; 2000US-[illegible].
PR    30 AUG 2000; 2000US-[illegible].
PR    01 SEP 2000; 2000US-[illegible].
PR    01 SEP 2000; 2000US-[illegible].
PR    01 SEP 2000; 2000US-[illegible].
PR    01 SEP 2000; 2000US-[illegible].
PR    05 SEP 2000; 2000US-[illegible].
PR    05 SEP 2000; 2000US-[illegible].
PR    06 SEP 2000; 2000US-[illegible].
PR    06 SEP 2000; 2000US-[illegible].
PR    08 SEP 2000; 2000US-[illegible].
PR    08 SEP 2000; 2000US-[illegible].
PR    08 SEP 2000; 2000US-[illegible].
```

PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0241968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234999.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235846.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249267.
PR 17-NOV-2000; 2000US-0249268.
PR 17-NOV-2000; 2000US-0249269.
PR 01-DEC-2000; 2000US-0250166.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251650.
PR 05-DEC-2000; 2000US-0251888.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0255479.
PR 08-DEC-2000; 2000US-0251866.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (GEMA) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-562688/55.
XX
PT Polynucleotides encoding digestive system antigens, useful in t
PT diagnosing, treating, preventing and/or prognosing disorders of
PT digestive system, particularly cancer and cancer metastases
XX
PS Disclosure; SEQ ID NO 4288; 986pp; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human digestive system antigens. These can be used in the
CC diagnosis, treatment and prevention of digestive system disorders,
CC including cancer, Meckel's diverticulum, bacterial or parasitic
CC infections, appendicitis, Hirschsprung's disease, chronic or acute
CC ulcerative colitis. The present sequence is a genomic DNA fragment
CC encoding a digestive system antigen of the invention.
XX
SQ Sequence 1747 BP; 424 A; 717 C; 384 G; 387 T; 125 other;

Query Match 91.1%; Score 15.4; DB 22; Length 1747;
Best Local Similarity 94.1%; Pred. No. 7.5e-002;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 GGGAAGGAGAGAGAAG 17
||||||||||||||||
Db 344 GGGAAGGAGAGAGAAG 360

RESULT 48
AAS99915
ID AAS99915 standard; DNA; 1218 BP.
XX
AC AAS99915;
XX
DT 17-DEC-2001 (first entry)
XX
DE Genomic sequence #334 encoding human colon associated polypeptide
XX
KW Human; colon cancer; congenital abnormality; infection; ss.
KW inflammatory bowel disease; IBD; neoplastic disorder; dese
KW intestinal inflammatory disorder; malabsorption syndrome; ss.
KW sigmoid disease; antibacterial; antiviral; antiinflammatory;
KW cytostatic; ds.
XX
OS Homo sapiens.
XX
PN WO200155302-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01211.
XX
PR 31-JAN-2000; 2000US-179065.

```
PS   Disclosure; SEQ ID No 812; 562pp; English.
XX
CC   The present invention relates to the isolation of novel human colon
CC   associated polypeptides (AAU22478-AAU27613) and the cDNA and genomic
CC   sequences encoding for them. The sequences of the invention are useful
CC   in the diagnosis, treatment, prevention and/or prognosis of disorders
CC   of the colon including colon cancer, congenital abnormalities
CC   (e.g. atresia and stenosis), bacterial and viral infections,
CC   inflammatory bowel disease (IBD), neoplastic cell disorders
CC   (e.g. polyps and adenomas, intestinal inflammatory disorders, colitis,
CC   colonic inflammation, diarrhoea and dysentery, malabsorption syndromes
CC   (e.g. lactose intolerance), intestinal obstruction and sigmoid diseases.
CC   The polynucleotides sequences of the invention can also be used in gene
CC   therapy. AAS39582-AAS40060 represent DNA sequences encoding for the
CC   novel human colon associated polypeptides of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 31718 BP; 7951 A; 7687 C; 8287 G; 7793 T; 0 other;

  Query Match             81.1%;  Score 15.4;  DB 22;  Length 31718;
  Best Local Similarity   94.1%;  Pred. No. 7.7e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 GGGAAGGAGGATGAACC 17
              |||| ||||||||||||
Db      19444 GGGAGGGAGGATGAACC 19460

RESULT 49
AAS39916
ID   AAS39916 standard; DNA; 31718 BP.
XX
AC   AAS39916;
XX
DT   17-DEC-2001  (first entry)
XX
DE   Genomic sequence #335 encoding human colon associated polypeptide.
XX
KW   Human; colon cancer; congenital abnormality; infection; colitis;
KW   inflammatory bowel disease; IBD; neoplastic disorder; gene therapy;
KW   intestinal inflammatory disorder; malabsorption syndrome; gastric;
KW   sigmoid disease; antibacterial; antiviral; antiinflammatory;
KW   cytostatic; ds.
XX
OS   Homo sapiens.
XX
PN   WO200155302-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01240.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231243.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231413.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0232080.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231968.
PR   14-SEP-2000; 2000US-0232397.
PR   14-SEP-2000; 2000US-0232398.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0233063.
PR   14-SEP-2000; 2000US-0233064.
PR   14-SEP-2000; 2000US-0233065.
PR   21-SEP-2000; 2000US-0234223.
PR   21-SEP-2000; 2000US-0234274.
PR   25-SEP-2000; 2000US-0234997.
PR   25-SEP-2000; 2000US-0234998.
PR   26-SEP-2000; 2000US-0235484.
PR   27-SEP-2000; 2000US-0235834.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236327.
PR   29-SEP-2000; 2000US-0236367.
PR   29-SEP-2000; 2000US-0236368.
PR   29-SEP-2000; 2000US-0236369.
PR   29-SEP-2000; 2000US-0236370.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237040.
PR   13-OCT-2000; 2000US-0239935.
PR   13-OCT-2000; 2000US-0239937.
PR   20-OCT-2000; 2000US-0240960.
PR   20-OCT-2000; 2000US-0241221.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
```

```
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-0246609.
PR   08-NOV-2000; 2000US-0246610.
PR   08-NOV-2000; 2000US-0246611.
PR   08-NOV-2000; 2000US-0246613.
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
PR   17-NOV-2000; 2000US-0249215.
PR   17-NOV-2000; 2000US-0249216.
PR   17-NOV-2000; 2000US-0249217.
PR   17-NOV-2000; 2000US-0249218.
PR   17-NOV-2000; 2000US-0249244.
PR   17-NOV-2000; 2000US-0249245.
PR   17-NOV-2000; 2000US-0249264.
PR   17-NOV-2000; 2000US-0249265.
PR   17-NOV-2000; 2000US-0249297.
PR   17-NOV-2000; 2000US-0249299.
PR   17-NOV-2000; 2000US-0249300.
PR   01-DEC-2000; 2000US-0250160.
PR   01-DEC-2000; 2000US-0250391.
PR   05-DEC-2000; 2000US-0251030.
PR   05-DEC-2000; 2000US-0251988.
PR   05-DEC-2000; 2000US-0256719.
PR   06-DEC-2000; 2000US-0251479.
PR   08-DEC-2000; 2000US-0251856.
PR   08-DEC-2000; 2000US-0251868.
PR   08-DEC-2000; 2000US-0251869.
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-465567/50.
XX
PT   Isolated polypeptide for treating, preventing and/or prognosing
PT   disorders related to the colon including colon cancers and also for
PT   testing and detection e.g. diagnosis
XX
PS   Disclosure; SEQ ID No 813; 562pp; English.
XX
CC   The present invention relates to the isolated novel human colon
CC   associated polypeptides (AAU22468-AAU22701), and the cDNA and genomic
CC   sequences encoding for them. The sequences of the invention are useful
CC   in the diagnosis, treatment, prevention and/or prognosis of disorders
CC   of the colon including colon cancer, congenital abnormalities
CC   (e.g. atresia and stenosis), bacterial and viral infections,
CC   inflammatory bowel disease (IBD), neoplastic cell disorders
CC   (e.g. polyps and adenomas, intestinal inflammatory disorders, colitis,
CC   enteric inflammation, diarrhoea and dysentery, malabsorption syndromes
CC   (e.g. lactose intolerance), intestinal obstruction and sigmoid diseases.
CC   The polynucleotides sequences of the invention can also be used in gene
CC   therapy. AAS39582-AAS40060 represent DNA sequences encoding for the
CC   novel human colon associated polypeptides of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence [illegible] BP; [illegible]

  Query Match              81.1%;  Score 15.1;  DB 22;  Length [illegible];
  Best Local Similarity    [illegible];  Pred. No. [illegible];
  Matches   16;  Conservative    0;  Mismatches    [illegible];  Indels    [illegible];  Gaps    [illegible];

Qy          1 [illegible]AA[illegible]A[illegible]AA[illegible] [illegible]
              |||| ||||||||||||
Db   [illegible] [illegible] [illegible]


RESULT 50
AAL06415
ID   AAL06415 standard; DNA; [illegible] BP.
XX
AC   AAL06415;
XX
DT   21-NOV-2001  (first entry)
XX
DE   Human reproductive system related antigen DNA SEQ ID NO: [illegible]
XX
KW   Human; reproductive system related antigen; reproductive [illegible]
KW   cancer; gene therapy; [illegible]
XX
OS   Homo sapiens.
XX
PN   WO200155[illegible]-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US[illegible].
XX
PR   31-JAN-2000; 2000US-017[illegible].
PR   04-FEB-2000; 2000US-018[illegible].
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-018[illegible].
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-019[illegible].
PR   19-MAY-2000; 2000US-020[illegible].
PR   07-JUN-2000; 2000US-020[illegible].
PR   28-JUN-2000; 2000US-021[illegible].
PR   30-JUN-2000; 2000US-021[illegible].
PR   07-JUL-2000; 2000US-021[illegible].
PR   07-JUL-2000; 2000US-0216[illegible].
PR   11-JUL-2000; 2000US-021[illegible].
PR   11-JUL-2000; 2000US-021[illegible].
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-022[illegible].
PR   26-JUL-2000; 2000US-022[illegible].
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-022[illegible].
PR   14-AUG-2000; 2000US-022[illegible].
PR   14-AUG-2000; 2000US-022[illegible].
PR   14-AUG-2000; 2000US-022[illegible].
PR   14-AUG-2000; 2000US-022[illegible].
PR   14-AUG-2000; 2000US-022[illegible].
PR   14-AUG-2000; 2000US-022[illegible].
PR   14-AUG-2000; 2000US-022[illegible].
PR   14-AUG-2000; 2000US-022[illegible].
PR   14-AUG-2000; 2000US-022[illegible].
PR   14-AUG-2000; 2000US-022[illegible].
PR   18-AUG-2000; 2000US-022[illegible].
PR   22-AUG-2000; 2000US-022[illegible].
PR   22-AUG-2000; 2000US-022[illegible].
PR   22-AUG-2000; 2000US-022[illegible].
PR   23-AUG-2000; 2000US-022[illegible].
PR   30-AUG-2000; 2000US-022[illegible].
PR   01-SEP-2000; 2000US-022[illegible].
PR   01-SEP-2000; 2000US-022[illegible].
PR   01-SEP-2000; 2000US-022[illegible].
PR   01-SEP-2000; 2000US-022[illegible].
```

PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 13-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 26-OCT-2000; 2000US-0241221.
PR 26-OCT-2000; 2000US-0241785.
PR 26-OCT-2000; 2000US-0241786.
PR 26-OCT-2000; 2000US-0241787.
PR 26-OCT-2000; 2000US-0241808.
PR 26-OCT-2000; 2000US-0241809.
PR 26-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249292.
PR 17-NOV-2000; 2000US-0249293.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250100.
PR 01-DEC-2000; 2000US-0250591.
PR 05-DEC-2000; 2000US-0251080.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0253479.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251884.
PR 08-DEC-2000; 2000US-0251900.
PR 11-DEC-2000; 2000US-0254307.
PR 05-JAN-2001; 2001US-0259078.
XX
PA (HUMA) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-466523/50.
XX
PT Isolated nucleic acid molecule encoding a reproductive system associated
PT protein used in prevention, treatment or amelioration of medical conditions
XX
PS Disclosure; SEQ ID NO 9165; 127pp; English.
XX
CC The present invention provides the protein and coding sequences for a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders
CC including cancer. The present sequence is a genomic sequence of a human
CC protein of the invention.
XX
SQ Sequence 41718 BP; 7951 A; 7487 C; 8287 G; 7793 T; 0 other;

Query Match 81.1%; Score 15.4; DB 22; Length 41718;
Best Local Similarity 94.1%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 GGGAAGGAGGAIGAAGG 17
||||.||||||||||
Db 19444 GGGAGGGAGGATGAAGG 19460

Search completed: May 25, 2003, 0:45:37
Job time : 386.5 secs